US12474353B2 - Methods and materials for assessing and treating obesity - Google Patents

Methods and materials for assessing and treating obesity

Info

Publication number
US12474353B2
US12474353B2 US18/221,036 US202318221036A US12474353B2 US 12474353 B2 US12474353 B2 US 12474353B2 US 202318221036 A US202318221036 A US 202318221036A US 12474353 B2 US12474353 B2 US 12474353B2
Authority
US
United States
Prior art keywords
obesity
mammal
sample
group
intervention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
US18/221,036
Other versions
US20230358765A1 (en
Inventor
Andres J. Acosta
Michael L. Camilleri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mayo Clinic in Florida
Original Assignee
Mayo Clinic in Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Clinic in Florida filed Critical Mayo Clinic in Florida
Priority to US18/221,036 priority Critical patent/US12474353B2/en
Publication of US20230358765A1 publication Critical patent/US20230358765A1/en
Application granted granted Critical
Publication of US12474353B2 publication Critical patent/US12474353B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Definitions

  • This document relates to methods and materials for assessing and/or treating obesity in mammals (e.g., humans). For example, this document provides methods and materials for determining an obesity analyte signature of a mammal. For example, this document provides methods and materials for determining an obesity phenotype of a mammal. For example, this document provides methods and materials for using one or more interventions (e.g., one or more pharmacological interventions) to treat obesity and/or obesity-related comorbidities in a mammal (e.g., a human) identified as being likely to respond to a particular intervention (e.g., a pharmacological intervention).
  • interventions e.g., one or more pharmacological interventions
  • Estimated costs to the healthcare system are more than $550 billion annually.
  • Increased severity of obesity correlates with a higher prevalence of the associated co-morbidities.
  • obesity increases the risk of premature mortality (Hensrud et al., 2006 Mayo Clinic Proceedings 81(10 Suppl):S5-10).
  • Obesity affects almost every organ system in the body and increases the risk of numerous diseases including type 2 diabetes mellitus, hypertension, dyslipidemia, cardiovascular disease, and cancer. It is estimated that a man in his twenties with a BMI over 45 will have a 22% reduction (13 years) in life expectancy.
  • this document provides methods and materials for assessing and/or treating obesity in mammals (e.g., humans).
  • this document provides methods and materials for identifying an obese mammal as being responsive to a pharmacological intervention (e.g., by identifying the mammal as having a pharmacotherapy responsive obesity analyte signature), and administering one or more interventions (e.g., pharmacological interventions) to treat the mammal.
  • a sample obtained from an obese mammal can be assessed to determine if the obese mammal is likely to be responsive to pharmacological intervention based; at least in part; on an obesity phenotype, which is based, at least in part, on an obesity analyte signature in the sample.
  • each obesity phenotype is likely to be responsive to one or more particular interventions (e.g., pharmacological intervention, surgical intervention, weight loss device, diet intervention, behavior intervention, and/or microbiome intervention).
  • interventions e.g., pharmacological intervention, surgical intervention, weight loss device, diet intervention, behavior intervention, and/or microbiome intervention.
  • one aspect of this document features a method for treating obesity in a mammal.
  • the method includes, or consists essentially of, identifying the mammal as having an intervention responsive obesity analyte signature in a sample obtained from the mammal; and administering an intervention to the mammal.
  • the sample can be a blood sample, a saliva sample, a urine sample, a breath sample, or a stool sample.
  • the sample can be a breath sample.
  • the method sample can be a stool sample.
  • the mammal can be a human.
  • the obesity analyte signature can include 1-methylhistine, serotonin, glutamine, gamma-amino-n-butyric-acid, isocaproic, allo-isoleucine, hydroxyproline, beta-aminoisobutyric-acid, al anine, hexanoic, tyrosine, phenylalanine, ghrelin, and peptide tyrosine tyrosine (PYY).
  • the intervention can be effective to reduce the total body weight of said mammal by at least 4%.
  • the intervention can be effective to reduce the total body weight of said mammal by from about 3 kg to about 100 kg.
  • the intervention can be effective to reduce the waist circumference of said mammal by from about 1 inches to about 10 inches.
  • the identifying step also can include obtaining results from a Hospital Anxiety and Depression Scale (HADS) questionnaire and/or a Three Factor Eating questionnaire (TFEQ).
  • HADS Hospital Anxiety and Depression Scale
  • TFEQ Three Factor Eating questionnaire
  • the obesity analyte signature can include a presence of serotonin, glutamine, isocaproic, allo-isoleucine, hydroxyproline, beta-aminoisobutyric-acid, alanine, hexanoic, tyrosine, and PYY, and an absence of (e.g., lacks the presence of) 1-methylhistine, gamma-amino-n-butyric-acid, phenylalanine, ghrelin; the HADS questionnaire result does not indicate an anxiety subscale; and the mammal can be responsive to intervention with phentermine-topiramate pharmacotherapy and/or lorcaserin pharmacotherapy.
  • the obesity analyte signature can include a presence of 1-methylhistine, allo-isoleucine, hydroxyproline, beta-aminoisobutyric-acid, alanine, and phenylalanine, and an absence of serotonin, glutamine, gamma-amino-n-butyric-acid, isocaproic, hexanoic, tyrosine, ghrelin, and PYY; the HADS questionnaire result not indicate an anxiety subscale; and the mammal can be responsive to intervention with liraglutide pharmacotherapy.
  • the obesity analyte signature can include a presence of serotonin, and an absence of 1-methylhistine, glutamine, gamma-amino-n-butyric-acid, isocaproic, allo-isoleucine, hydroxyproline, beta-aminoisobutyric-acid, alanine, hexanoic, tyrosine, phenylalanine, ghrelin, and PYY; the HADS questionnaire result indicates an anxiety subscale; and the mammal can be responsive to intervention with naltrexone-bupropion pharmacotherapy.
  • the obesity analyte signature can include a presence of 1-methylhistine, glutamine, gamma-amino-n-butyric-acid, isocaproic, allo-isoleucine, beta-aminoisobutyric-acid, alanine, hexanoic, tyrosine, phenylalanine, PYY, and an absence of serotonin, hydroxyproline, and ghrelin; the HADS questionnaire result indicates an anxiety subscale; and the mammal can be responsive to intervention with naltrexone-bupropion pharmacotherapy.
  • the obesity analyte signature can include a presence of 1-methylhistine, serotonin, glutamine, gamma-amino-n-butyric-acid, isocaproic, allo-isoleucine, alanine, tyrosine, ghrelin, PYY, and an absence of hydroxyproline, beta-aminoisobutyric-acid, hexanoic, and phenylalanine; the HADS questionnaire result indicates an anxiety subscale; and the mammal can be responsive to intervention with phentermine pharmacotherapy.
  • the obesity analyte signature can include HTR2C, GNB3, FTO, iso-caproic acid, beta-aminoisobutyricacid, butyric, allo-isoleucine, tryptophan, and glutamine.
  • the identifying step also can include obtaining results from a HADS questionnaire.
  • the obesity analyte signature can include the presence of a single nucleotide polymorphism (SNP) in HTR2C, POMC, NPY, AGRP, MC4R, GNB3, SERT, and/or BDNF; the HADS questionnaire result does not indicate an anxiety subscale; and the mammal can be responsive to intervention with phentermine-topiramate pharmacotherapy and/or lorcaserin pharmacotherapy.
  • SNP single nucleotide polymorphism
  • the SNP can be rs1414334.
  • the obesity analyte signature can include the presence of a SNP in PYY, GLP-1, MC4R, GPBAR1, TCF7L2, ADRA2A,PCSK, and/or TMEM18; the HADS questionnaire result not indicate an anxiety subscale; and the mammal can be responsive to intervention with liraglutide pharmacotherapy.
  • the SNP can be rs7903146.
  • the obesity analyte signature can include presence of a SNP in SLC6A4/SERT, and/or DRD2; the HADS questionnaire result indicates an anxiety subscale; and the mammal can be responsive to intervention with naltrexone-bupropion pharmacotherapy.
  • the SNP can be rs4795541.
  • the obesity analyte signature can include the presence of a SNP in TCF7L2, UCP3, and/or ADRA2A; the HADS questionnaire result indicates an anxiety subscale; and the mammal can be responsive to intervention with naltrexone-bupropion pharmacotherapy.
  • the SNP can be rs1626521.
  • the obesity analyte signature can include the presence of a SNP in FTO, LEP, LEPR, UCP1, UCP2, UCP3, ADRA2, KLF14, NPC1, LYPLAL1, ADRB2, ADRB3, and/or BBS1; the HADS questionnaire result indicates an anxiety subscale; and the mammal can be responsive to intervention with phentermine pharmacotherapy.
  • the SNP can be rs2075577.
  • this document features a method for treating obesity in a mammal.
  • the method includes, or consists essentially of, administering an intervention to a mammal that was identified as having an intervention responsive obesity analyte signature.
  • the mammal can be a human.
  • the obesity analyte signature can include 1-methylhistine, serotonin, glutamine, gamma-amino-n-butyric-acid, isocaproic, allo-isoleucine, hydroxyproline, beta-aminoisobutyric-acid, alanine, hexanoic, tyrosine, phenylalanine, ghrelin, and peptide tyrosine tyrosine (PYY).
  • the intervention can be effective to reduce the total body weight of said mammal by at least 4%.
  • the intervention can be effective to reduce the total body weight of said mammal by from about 3 kg to about 100 kg.
  • the intervention can be effective to reduce the waist circumference of said mammal by from about 1 inches to about 10 inches.
  • the identifying step also can include obtaining results from a Hospital Anxiety and Depression Scale (HADS) questionnaire.
  • HADS Hospital Anxiety and Depression Scale
  • the obesity analyte signature can include a presence of serotonin, glutamine, isocaproic, allo-isoleucine, hydroxyproline, beta-aminoisobutyric-acid, alanine, hexanoic, tyrosine, and PYY, and an absence of (e.g., lacks the presence of) 1-methylhistine, gamma-amino-n-butyric-acid, phenylalanine, ghrelin; the HADS questionnaire result does not indicate an anxiety subscale; and the mammal can be responsive to intervention with phentermine-topiramate pharmacotherapy and/or lorcaserin pharmacotherapy.
  • the obesity analyte signature can include a presence of 1-methylhistine, allo-isoleucine, hydroxyproline, beta-aminoisobutyric-acid, alanine, and phenylalanine, and an absence of serotonin, glutamine, gamma-amino-n-butyric-acid, isocaproic, hexanoic, tyrosine, ghrelin, and PYY; the HADS questionnaire result not indicate an anxiety subscale; and the mammal can be responsive to intervention with liraglutide pharmacotherapy.
  • the obesity analyte signature can include a presence of serotonin, and an absence of 1-methylhistine, glutamine, gamma-amino-n-butyric-acid, isocaproic, allo-isoleucine, hydroxyproline, beta-aminoisobutyric-acid, alanine, hexanoic, tyrosine, phenylalanine, ghrelin, and PYY; the HADS questionnaire result indicates an anxiety subscale; and the mammal can be responsive to intervention with naltrexone-bupropion pharmacotherapy.
  • the obesity analyte signature can include a presence of 1-methylhistine, glutamine, gamma-amino-n-butyric-acid, isocaproic, allo-isoleucine, beta-aminoisobutyric-acid, alanine, hexanoic, tyrosine, phenylalanine, PYY, and an absence of serotonin, hydroxyproline, and ghrelin; the HADS questionnaire result indicates an anxiety subscale; and the mammal can be responsive to intervention with naltrexone-bupropion pharmacotherapy.
  • the obesity analyte signature can include a presence of 1-methylhistine, serotonin, glutamine, gamma-amino-n-butyric-acid, isocaproic, allo-isoleucine, alanine, tyrosine, ghrelin, PYY, and an absence of hydroxyproline, beta-aminoisobutyric-acid, hexanoic, and phenylalanine; the HADS questionnaire result indicates an anxiety subscale; and the mammal can be responsive to intervention with phentermine pharmacotherapy.
  • this document features a method for identifying an obese mammal as being responsive to treatment with an intervention.
  • the method includes, or consists essentially of, determining an obesity analyte signature in a sample obtained from a mammal, where the obesity analyte signature can include 1-methylhistine, serotonin, glutamine, gamma-amino-n-butyric-acid, isocaproic, allo-isoleucine, hydroxyproline, beta-aminoisobutyric-acid, alanine, hexanoic, tyrosine, phenylalanine, ghrelin, and PYY; and classifying the mammal as having an intervention responsive obesity analyte signature based upon the presence and absence of analytes in the obesity analyte signature.
  • the mammal can be a human.
  • the sample can be a blood sample, a saliva sample, a urine sample, a breath sample, or a stool sample.
  • the sample can be a breath sample.
  • the method sample can be a stool sample.
  • the method also can include obtaining results from a HADS questionnaire.
  • the obesity analyte signature can include a presence of serotonin, glutamine, isocaproic, allo-isoleucine, hydroxyproline, beta-aminoisobutyric-acid, alanine, hexanoic, tyrosine, and PYY, and an absence of (e.g., lacks the presence of) 1-methylhistine, gamma-amino-n-butyric-acid, phenylalanine, ghrelin; the HADS questionnaire result does not indicate an anxiety subscale; and the mammal can be responsive to intervention with phentermine-topiramate pharmacotherapy and/or lorcaserin pharmacotherapy.
  • the obesity analyte signature can include a presence of 1-methylhistine, allo-isoleucine, hydroxyproline, beta-aminoisobutyric-acid, alanine, and phenylalanine, and an absence of serotonin, glutamine, gamma-amino-n-butyric-acid, isocaproic, hexanoic, tyrosine, ghrelin, and PYY; the HADS questionnaire result not indicate an anxiety subscale; and the mammal can be responsive to intervention with liraglutide pharmacotherapy.
  • the obesity analyte signature can include a presence of serotonin, and an absence of 1-methylhistine, glutamine, gamma-amino-n-butyric-acid, isocaproic, allo-isoleucine, hydroxyproline, beta-aminoisobutyric-acid, alanine, hexanoic, tyrosine, phenylalanine, ghrelin, and PYY; the HADS questionnaire result indicates an anxiety subscale; and the mammal can be responsive to intervention with naltrexone-bupropion pharmacotherapy.
  • the obesity analyte signature can include a presence of 1-methylhistine, glutamine, gamma-amino-n-butyric-acid, isocaproic, allo-isoleucine, beta-aminoisobutyric-acid, alanine, hexanoic, tyrosine, phenylalanine, PYY, and an absence of serotonin, hydroxyproline, and ghrelin; the HADS questionnaire result indicates an anxiety subscale; and the mammal can be responsive to intervention with naltrexone-bupropion pharmacotherapy.
  • the obesity analyte signature can include a presence of 1-methylhistine, serotonin, glutamine, gamma-amino-n-butyric-acid, isocaproic, allo-isoleucine, alanine, tyrosine, ghrelin, PYY, and an absence of hydroxyproline, beta-aminoisobutyric-acid, hexanoic, and phenylalanine; the HADS questionnaire result indicates an anxiety subscale; and the mammal can be responsive to intervention with phentermine pharmacotherapy.
  • this document features a identifying an obese mammal as being responsive to treatment with an intervention.
  • the method includes, or consists essentially of, determining an obesity analyte signature in a sample obtained from an obese mammal, where the obesity analyte signature includes HTR2C, GNB3, FTO, iso-caproic acid, beta-aminoisobutyricacid, butyric, allo-isoleucine, tryptophan, and glutamine; obtaining results from a HADS questionnaire; and classifying the mammal as having a intervention responsive obesity analyte signature based upon the presence and absence of analytes in the obesity analyte signature.
  • the mammal can be a human.
  • the sample can be a blood sample, a saliva sample, a urine sample, a breath sample, or a stool sample. In some cases, the sample can be a breath sample. In some cases, the sample can be a stool sample.
  • the obesity analyte signature can include the presence of a SNP in HTR2C, POMC, NPY, AGRP, MC4R, GNB3, SERT, and/or BDNF; the HADS questionnaire result can not indicate an anxiety subscale; and the mammal can be classified as being responsive to intervention with phentermine-topiramate pharmacotherapy and/or lorcaserin pharmacotherapy.
  • the SNP can be rs1414334.
  • the obesity analyte signature can include the presence of a SNP in PYY, GLP-1, MC4R, GPBAR1, TCF7L2, ADRA2A,PCSK, and/or TMEM18; the HADS questionnaire result can not indicate an anxiety subscale; and the mammal can be classified as being responsive to intervention with liraglutide pharmacotherapy.
  • the SNP can be rs7903146.
  • the obesity analyte signature can include the presence of a SNP in SLC6A4/SERT, and/or DRD2; the HADS questionnaire result can indicate an anxiety subscale; and the mammal can be classified as being responsive to intervention with naltrexone-bupropion pharmacotherapy.
  • the SNP can be rs4795541.
  • the obesity analyte signature can include the presence of a SNP in TCF7L2, UCP3, and/or ADRA2A; the HADS questionnaire result can indicate an anxiety subscale; and the mammal can be classified as being responsive to intervention with naltrexone-bupropion pharmacotherapy.
  • the SNP can be rs1626521.
  • the obesity analyte signature can include the presence of a SNP in FTO, LEP, LEPR, UCP1, UCP2, UCP3, ADRA2, KLF14, NPC1, LYPLAL1, ADRB2, ADRB3, and/or BBS1; the HADS questionnaire result can indicate an anxiety subscale; and the mammal can be classified as being responsive to intervention with phentermine pharmacotherapy.
  • the SNP can be rs2075577.
  • FIGS. 1 A- 1 E shows classifications of obesity.
  • FIGS. 2 A and 2 B show biomarker discovery.
  • PCA principal component analysis
  • FIG. 3 is a receiver operating characteristic (ROC) curve showing the sensitivity and specificity of determining an obesity phenotype based on metabolic signature.
  • ROC receiver operating characteristic
  • FIG. 4 is a ROC curve using Bayesian covariate predictors for low satiation, behavioral eating, and low resting energy expenditure.
  • FIG. 5 is a ROC curve showing the sensitivity and specificity of determining an obesity phenotype based on metabolic signature.
  • FIG. 6 shows food intake meal paradigms measuring ‘maximal’ fullness (MTV), ‘usual’ fullness (VTF) in a nutrient drink test and ‘usual’ fullness to mixed meal (solids) in an ad libitum buffet meal.
  • FIGS. 7 A- 7 D shows abnormal satiety deeper phenotypes.
  • FIGS. 8 A- 8 B show hedonic group deeper phenotypes. A) Anxiety, depression and self-esteem levels and B) fasting serum tryptophan levels in patients with hedonic obesity compared to normal.
  • FIGS. 9 A- 9 D show slow metabolism deeper phenotypes.
  • Metabolites describes are Alanine, isocaproic acid, phosphoetahnol amine, phenylalanine, tyrosine, alpha-amino-N-butyric acid, sarcasine, and 1-methylhistidine.
  • FIG. 10 is a bar graph showing body weight change in response to treatment with placebo or a combination of phentermine and topiramate (PhenTop) and kcal intake at prior ad-libitum meal (satiation test).
  • FIG. 11 is a bar graph showing body weight change in response to treatment with placebo or exenatide in patients with a particular obesity phenotype.
  • FIGS. 12 A- 12 C are a flow charts showing exemplary treatment interventions for obesity groups identified based, at least in part, on a patient's obesity analyte signature.
  • FIG. 13 is a bar graph showing total body weight loss (TBWL) in response to individualized intervention based on pre-selecting the specific individual patient's obesity analyte signature.
  • TBWL total body weight loss
  • FIG. 14 is a line graph showing TBWL in response to individualized intervention over time.
  • This document provides methods and materials for assessing and/or treating obesity in mammals (e.g., humans). In some cases, this document provides methods and materials for identifying an obese mammal as being responsive to a pharmacological intervention, and administering one or more pharmacological interventions to treat the mammal. For example, a sample obtained from an obese mammal can be assessed to determine if the obese mammal is likely to be responsive to intervention (e.g., pharmacological intervention, surgical intervention, weight loss device, diet intervention, behavior intervention, and/or microbiome intervention) based, at least in part, on an obesity phenotype, which is based, at least in part, on an obesity analyte signature in the sample.
  • intervention e.g., pharmacological intervention, surgical intervention, weight loss device, diet intervention, behavior intervention, and/or microbiome intervention
  • An obesity analyte signature can include the presence, absence, or level (e.g., concentration) of two or more (e.g., three, four, five, six, seven, eight, nine, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more) obesity analytes (e.g., biomarkers associated with obesity).
  • an obesity analyte signature can include 14 obesity analytes.
  • a pharmacotherapy responsive obesity analyte signature can be based, at least in part, on the presence, absence, or level of 14 obesity analytes.
  • an obesity analyte signature can include 9 obesity analytes.
  • a pharmacotherapy responsive obesity analyte signature can be based, at least in part, on the presence, absence, or level of 9 obesity analytes.
  • the methods and materials described herein can be used to predict further weight loss response (e.g., during the course of an obesity treatment).
  • the methods and materials described herein can be used to prevent plateaus (e.g., during the course of an obesity treatment).
  • the methods and materials described herein can be used to enhance weight loss maintenance (e.g., during the course of an obesity treatment).
  • the methods and materials described herein can be used to treat patients unable to lose and maintain weight with diet and exercise alone.
  • a distinct obesity analyte signature can be present in each of six main obesity phenotypes: Group 1) low satiation, Group 2) low satiety (e.g., rapid return to hunger), Group 3) behavioral eating (e.g., as identified by questionnaire), Group 4) large fasting gastric volume, Group 5) mixed, and Group 6) low resting energy expenditure group.
  • the obesity analyte signature in sample obtained from an obese mammal can be used to predict intervention responsiveness.
  • obesity phenotype groups can be simplified as: 1) high energy intake, 2) behavioral/emotional eating, and 3) low energy expenditure; or can be simplified as 1) low satiation (fullness), 2) low satiety (return to hunger), 3) behavioral/emotional eating, 4) low energy expenditure, 5) mixed, and 6) other.
  • the mammal can also have one or more obesity-related (e.g., weight-related) co-morbidities.
  • weight-related co-morbidities include, without limitation, hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, gastroesophageal reflux disease, weight baring joint arthritis, cancer, non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, depression, anxiety, and atherosclerosis (coronary artery disease and/or cerebrovascular disease).
  • the methods and materials described herein can be used to treat one or more obesity-related co-morbidities.
  • the treatment can be effective to reduce the weight, reduce the waist circumference, slow or prevent weight gain of the mammal, improve the hemoglobin A1c, and/or improve the fasting glucose.
  • treatment described herein can be effective to reduce the weight (e.g., the total body weight) of an obese mammal by at least 3% (e.g., at least 5%, at least 8%, at least 10%, at least 12%, at least 15%, at least 18%, at least 20%, at least 22%, at least 25%, at least 28%, at least 30%, at least 33%, at least 36%, at least 39%, or at least 40%).
  • treatment described herein can be effective to reduce the weight (e.g., the total body weight) of an obese mammal by from about 3% to about 40% (e.g., from about 3% to about 35%, from about 3% to about 30%, from about 3% to about 25%, from about 3% to about 20%, from about 3% to about 15%, from about 3% to about 10%, from about 3% to about 5%, from about 5% to about 40%, from about 10% to about 40%, from about 15% to about 40%, from about 20% to about 40%, from about 25% to about 40%, from about 35% to about 40%, from about 5% to about 35%, from about 10% to about 30%, from about 15% to about 25%, or from about 18% to about 22%).
  • weight e.g., the total body weight
  • treatment described herein can be effective to reduce the weight (e.g., the total body weight) of an obese mammal by from about 3% to about 40% (e.g., from about 3% to about 35%, from about 3% to about 30%, from about
  • treatment described herein can be effective to reduce the weight (e.g., the total body weight) of an obese mammal by from about 3 kg to about 100 kg (e.g., about 5 kg to about 100 kg, about 8 kg to about 100 kg, about 10 kg to about 100 kg, about 15 kg to about 100 kg, about 20 kg to about 100 kg, about 30 kg to about 100 kg, about 40 kg to about 100 kg, about 50 kg to about 100 kg, about 60 kg to about 100 kg, about 70 kg to about 100 kg, about 80 kg to about 100 kg, about 90 kg to about 100 kg, about 3 kg to about 90 kg, about 3 kg to about 80 kg, about 3 kg to about 70 kg, about 3 kg to about 60 kg, about 3 kg to about 50 kg, about 3 kg to about 40 kg, about 3 kg to about 30 kg, about 3 kg to about 20 kg, about 3 kg to about 10 kg, about 5 kg to about 90 kg, about 10 kg to about 75 kg, about 15 kg to about 50 kg, about 20 kg to about 40 kg, or about 25 kg to about 30 kg).
  • treatment described herein can be effective to reduce the waist circumference of an obese mammal by from about 1 inches to about 10 inches (e.g., about 1 inches to about 9 inches, about 1 inches to about 8 inches, about 1 inches to about 7 inches, about 1 inches to about 6 inches, about 1 inches to about 5 inches, about 1 inches to about 4 inches, about 1 inches to about 3 inches, about 1 inches to about 2 inches, about 2 inches to about 10 inches, about 3 inches to about 10 inches, about 4 inches to about 10 inches, about 5 inches to about 10 inches, about 6 inches to about 10 inches, about 7 inches to about 10 inches, about 8 inches to about 10 inches, about 9 inches to about 10 inches, about 2 inches to about 9 inches, about 3 inches to about 8 inches, about 4 inches to about 7 inches, or about 5 inches to about 7 inches).
  • about 1 inches to about 10 inches e.g., about 1 inches to about 9 inches, about 1 inches to about 8 inches, about 1 inches to about 7 inches, about 1 inches to about 6 inches, about 1 inches to about 5 inches, about 1 inches to
  • the methods and materials described herein can be used to improve (e.g., increase or decrease) the hemoglobin A1c of an obese mammal (e.g., an obese mammal having type 2 diabetes mellitus) to from about 0.4% to about 3% (e.g., from about 0.5% to about 3%, from about 1% to about 3%, from about 1.5% to about 3%, from about 2% to about 3%, from about 2.5% to about 3%, from about 0.4% to about 2.5%, from about 0.4% to about 2%, from about 0.4% to about 1.5%, from about 0.4% to about 1%, from about 0.5% to about 2.5%, or from about 1% to about 2%) hemoglobin A1c.
  • an obese mammal e.g., an obese mammal having type 2 diabetes mellitus
  • hemoglobin A1c e.g., an obese mammal having type 2 diabetes mellitus
  • the methods and materials described herein can be used to improve (e.g., increase or decrease) the fasting glucose of an obese mammal (e.g., an obese mammal having type 2 diabetes mellitus) to from about 10 mg/dl to about 200 mg/dl (e.g., from about 15 mg/dl to about 200 mg/dl, from about 25 mg/dl to about 200 mg/dl, from about 50 mg/di to about 200 mg/dl, from about 75 mg/dl to about 200 mg/dl, from about 100 mg/dl to about 200 mg/dl, from about 125 mg/dl to about 200 mg/dl, from about 150 mg/dl to about 200 mg/dl, from about 175 mg/di to about 200 mg/dl, from about 190 mg/dl to about 200 mg/dl, from about 10 mg/dl to about 175 mg/dl, from about 10 mg/dl to about 150 mg/dl, from about 10 mg/dl to about 150 mg/
  • mammal can be assessed and/or treated as described herein.
  • mammals that can be assessed and/or treated as described herein include, without limitation, primates (e.g., humans and monkeys), dogs, cats, horses, cows, pigs, sheep, rabbits, mice, and rats.
  • the mammal can a human.
  • a mammal can be an obese mammal.
  • obese humans can be assessed for intervention (e.g., a pharmacological intervention) responsiveness, and treated with one or more interventions as described herein.
  • the human can be of any race.
  • a human can be Caucasian or Asian.
  • Any appropriate method can be used to identify a mammal as being overweight (e.g., as being obese).
  • calculating body mass index (BMI) can be used to identify a mammal as being overweight (e.g., as being obese).
  • BMI body mass index
  • measuring waist and/or hip circumference can be used to identify a mammal as being overweight (e.g., as being obese).
  • health history e.g., weight history, weight-loss efforts, exercise habits, eating patterns, other medical conditions, medications, stress levels, and/or family health history
  • physical examination e.g., measuring your height, checking vital signs such as heart rate blood pressure, listening to your heart and lungs, and examining your abdomen
  • percentage of body fat and distribution e.g., percentage of visceral and organs fat, metabolic syndrome, and/or obesity related comorbidities
  • mammals e.g., humans
  • a BMI of greater than about 30 kg/m 2 can be used to identify mammals (e.g., Caucasian humans) as being obese.
  • a BMI of greater than about 27 kg/m 2 with a co-morbidity can be used to identify mammals (e.g., Asian humans) as being obese.
  • a mammal can be assessed to determine whether or not it is likely to respond to one or more interventions (e.g., pharmacological intervention, surgical intervention, weight loss device, diet intervention, behavior intervention, and/or microbiome intervention).
  • pharmacological intervention e.g., surgical intervention, weight loss device, diet intervention, behavior intervention, and/or microbiome intervention.
  • a sample obtained from the mammal can be assessed for pharmacological intervention responsiveness.
  • a panel of obesity analytes in a sample obtained from an obese mammal can be used to determine an obesity analyte signature of the mammal, and can be used in to determine an obesity phenotype of the mammal.
  • a sample can be a biological sample.
  • a sample can contain obesity analytes (e.g., DNA, RNA, proteins, peptides, metabolites, hormones, and/or exogenous compounds (e.g. medications)).
  • samples that can be assessed as described herein include, without limitation, fluid samples (e.g., blood, serum, plasma, urine, saliva, sweat, or tears), breath samples, cellular samples (e.g., buccal samples), tissue samples (e.g., adipose samples), stool samples, gastro samples, and intestinal mucosa samples.
  • a sample e.g., a blood sample
  • a sample can be collected while the mammal is fasting (e.g., a fasting sample such as a fasting blood sample).
  • a sample can be processed (e.g., to extract and/or isolate obesity analytes).
  • a serum sample can be obtained from an obese mammal and can be assessed to determine if the obese mammal is likely to be responsive to one or more interventions (e.g., pharmacological intervention, surgical intervention, weight loss device, diet intervention, behavior intervention, and/or microbiome intervention) based, at least in part, on an obesity phenotype, which is based, at least in part, on an obesity analyte signature in the sample.
  • interventions e.g., pharmacological intervention, surgical intervention, weight loss device, diet intervention, behavior intervention, and/or microbiome intervention
  • a urine sample can be obtained from an obese mammal and can be assessed to determine if the obese mammal is likely to be responsive to pharmacological intervention based, at least in part, on an obesity phenotype, which is based, at least in part, on an obesity analyte signature in the sample.
  • An obesity analyte signature can include any appropriate analyte.
  • Examples of analytes that can be included in an obesity analyte signature described herein include, without limitation, DNA, RNA, proteins, peptides, metabolites, hormones, and exogenous compounds (e.g. medications).
  • An obesity analyte signature can be evaluated using any appropriate methods. For example, metabolomics, genomics, microbiome, proteomic, peptidomics, and behavioral questionnaires can be used to evaluate and/or identify an obesity analyte signature described herein.
  • the obesity phenotype can be identified as described in the Examples.
  • the obesity phenotype can be identified by determining the obesity analyte signature in a sample (e.g., in a sample obtained from an obese mammal).
  • the obesity analyte signature can be obtained by detecting the presence, absence, or level of one or more metabolites, detecting the presence, r absence, or level one or more peptides (e.g., gastrointestinal peptides), and/or detecting the presence, absence, or level of one or more single nucleotide polymorphisms (SNPs).
  • SNPs single nucleotide polymorphisms
  • a metabolite can be any metabolite that is associated with obesity.
  • a metabolite can be an amino-compound.
  • a metabolite can be a neurotransmitter.
  • a metabolite can be a fatty acid (e.g., a short chain fatty acid).
  • a metabolite can be an amino compound.
  • a metabolite can be a bile acid.
  • a metabolite can be a compound shown in Table 2.
  • Examples of metabolites that can be used to determine the obesity analyte signature in a sample include, without limitation, 1-methylhistine, serotonin, glutamine, gamma-amino-n-butyric-acid, isocaproic, allo-isoleucine, hydroxy-proline, beta-aminoisobutyric-acid, alanine, hexanoic, tyrosine, phenylalanine ⁇ -aminobutyric acid, acetic, histidine, LCA, ghrelin, ADRA2A, cholesterol, glucose, acetylcholine, propionic, CDCA, PYY, ADRA2C, insulin, adenosine, isobutyric, 1-methylhistidine, DCA, CCK, GNB3, glucagon, aspartate, butyric, 3-methylhistidine, UDCA, GLP-1, FTO,
  • an obesity analyte signature can include 1-methylhistine, serotonin, glutamine, gamma-amino-n-butyric-acid, isocaproic, allo-isoleucine, hydroxyproline, beta-aminoisobutyric-acid, alanine, hexanoic, tyrosine, and phenylalanine.
  • a gastrointestinal peptide can be any gastrointestinal peptide that is associated with obesity.
  • a gastrointestinal peptide can be a peptide hormone.
  • a gastrointestinal peptide can be released from gastrointestinal cells in response to feeding.
  • a gastrointestinal peptide can be a peptide shown in Table 2.
  • Examples of gastrointestinal peptides that can be used to determine the obesity analyte signature in a sample include, without limitation, ghrelin, peptide tyrosine tyrosine (PYY), cholecystokinin (CCK), glucagon-like peptide-1 (GLP-1), GLP-2, glucagon, oxyntomodulin, neurotensin, fibroblast growth factor (FGF), GIP, OXM, FGF19, FGF19, and pancreatic polypeptide.
  • a SNP can be any SNP that is associate with obesity.
  • a SNP can be in a coding sequence (e.g., in a gene) or a non-coding sequence.
  • the coding sequence can be any appropriate coding sequence.
  • a coding sequence that can include a SNP associated with obesity can be a gene shown in Table 2.
  • Examples of coding sequences that a SNP associated with obesity can be in or near include, without limitation, ADRA2A, ADRA2C, GNB3, FTO, MC4R, TCF7L2, 5-HTTLPR, HTR2C, UCP2, UCP3, GPBAR1, NR1H4, FGFR4, PYY, GLP-1, CCK, leptin, adiponectin, neurotensin, ghrelin, GLP-1 receptor, GOAT, DPP4, POMC, NPY, AGRP, SERT, BDNF, SLC6A4, DRD2, LEP, LEPR, UCP1, KLF14, NPC1, LYPLAL1, ADRB2, ADRB3, BBS1, ACSL6, ADARB2, ADCY8, ADH1B, AJAP1, ATP2C2, ATP6V0D2, C21orf7, CAMKMT, CAP2, CASC4, CD48, CDC42SE2, CDYL, CES5AP1, CLMN, CNPY4,
  • a SNP can be a SNP shown in Table 3.
  • Examples of SNPS that can be used to determine the obesity analyte signature in a sample include, without limitation, rs657452, rs11583200, rs2820292, rs11126666, rs11688816, rs1528435, rs7599312, rs6804842, rs2365389, rs3849570, rs16851483, rs17001654, rs11727676, rs2033529, rs9400239, rs13191362, rs1167827, rs2245368, rs2033732, rs4740619, rs6477694, rs1928295, rs10733682, rs7899106, rs17094222, rs11191560, rs7903
  • An obesity analyte signature described herein can include any appropriate combination of analytes.
  • the analytes can include 1-methylhistine, serotonin, glutamine, gamma-amino-n-butyric-acid, isocaproic, allo-isoleucine, hydroxyproline, beta-aminoisobutyric-acid, alanine, hexanoic, tyrosine, phenylalanine, ghrelin, and PYY.
  • an obesity analyte signature includes 9 analytes
  • the analytes can include HTR2C, GNB3, FTO, isocaproic, beta-aminoisobutyric-acid, butyric, allo-isoleucine, tryptophan, and glutamine.
  • any appropriate method can be used to detect the presence, absence, or level of an obesity analyte within a sample.
  • mass spectrometry e.g., triple-stage quadrupole mass spectrometry coupled with ultra-performance liquid chromatography (UPLC)
  • radioimmuno assays e.g., radioimmuno assays
  • enzyme-linked immunosorbent assays can be used to determine the presence, absence, or level of one or more analyte in a sample.
  • identifying the obesity phenotype can include obtaining results from all or part of one or more questionnaires.
  • a questionnaire can be associated with obesity.
  • a questionnaire can be answered the time of the assessment.
  • a questionnaire can be answered prior to the time of assessment. For example, when a questionnaire is answered prior to the time of the assessment, the questionnaire results can be obtained by reviewing a patient history (e.g., a medical chart).
  • a questionnaire can be a behavioral questionnaire (e.g., psychological welfare questionnaires, alcohol use questionnaires, eating behavior questionnaires, body image questionnaires, physical activity level questionnaire, and weight management questionnaires.
  • a questionnaire can be a HADS questionnaire.
  • a questionnaire can be a TFEQ.
  • an obesity analyte signature can include the presence of serotonin, glutamine, isocaproic, allo-isoleucine, hydroxyproline, beta-aminoisobutyric-acid, alanine, hexanoic, tyrosine, and PYY.
  • an obesity phenotype Group 1 can have an obesity analyte signature that includes the presence of serotonin, glutamine, isocaproic, allo-isoleucine, hydroxyproline, beta-aminoisobutyric-acid, alanine, hexanoic, tyrosine, and PYY.
  • an obesity phenotype Group 1 can have an obesity analyte signature that has an absence of (e.g., lacks the presence of) 1-methylhistine, gamma-amino-n-butyric-acid, phenylalanine, ghrelin, and includes a HADS questionnaire result that does not indicate an anxiety subscale (HADS-A; e.g., includes a HADS-A questionnaire result).
  • HADS-A e.g., includes a HADS-A questionnaire result
  • an obesity analyte signature can include the presence of 1-methylhistine, allo-isoleucine, hydroxyproline, beta-aminoisobutyric-acid, alanine, and phenylalanine.
  • an obesity phenotype Group 2 can have an obesity analyte signature that includes the presence of -methylhistine, allo-isoleucine, hydroxyproline, beta-aminoisobutyric-acid, alanine, and phenylalanine.
  • an obesity phenotype Group 2 can have an obesity analyte signature that has an absence of (e.g., lacks the presence of) serotonin, glutamine, gamma-amino-n-butyric-acid, isocaproic, hexanoic, tyrosine, ghrelin, PYY, and does not include a HADS questionnaire result that indicates an anxiety subscale (e.g., does not include a HADS-A questionnaire result)
  • an obesity analyte signature can include the presence of serotonin, and can include a HADS-A questionnaire.
  • an obesity phenotype Group 3 can have an obesity analyte signature that includes serotonin and includes a HADS-A questionnaire result.
  • an obesity phenotype Group 3 can have an obesity analyte signature that has an absence of (e.g., lacks the presence of) 1-methylhistine, glutamine, gamma-amino-n-butyric-acid, isocaproic, allo-isoleucine, hydroxyproline, beta-aminoisobutyric-acid, alanine, hexanoic, tyrosine, phenylalanine, ghrelin, and PYY.
  • an obesity analyte signature that has an absence of (e.g., lacks the presence of) 1-methylhistine, glutamine, gamma-amino-n-butyric-acid, isocaproic, allo-isoleucine, hydroxyproline, beta-aminoisobutyric-acid, alanine, hexanoic, tyrosine, phenylalanine, ghrelin, and PYY.
  • an obesity analyte signature can include the presence of 1-methylhistine, glutamine, gamma-amino-n-butyric-acid, isocaproic, allo-isoleucine, beta-aminoisobutyric-acid, alanine, hexanoic, tyrosine, phenylalanine, PYY, and includes a HADS-A questionnaire result.
  • an obesity phenotype Group 4 can have an obesity analyte signature that includes 1-methylhistine, glutamine, gamma-amino-n-butyric-acid, isocaproic, allo-isoleucine, beta-aminoisobutyric-acid, alanine, hexanoic, tyrosine, phenylalanine, PYY, and includes a HADS-A questionnaire result.
  • an obesity phenotype Group 4 can have an obesity analyte signature that has an absence of (e.g., lacks the presence of) serotonin, hydroxyproline, and ghrelin.
  • an obesity analyte signature can include the presence of serotonin, beta-aminoisobutyric-acid, alanine, hexanoic, phenylalanine, and includes a HADS-A questionnaire.
  • an obesity phenotype Group 5 can have an obesity analyte signature that includes the presence of serotonin, beta-aminoisobutyric-acid, alanine, hexanoic, phenylalanine, and includes a HADS-A questionnaire result.
  • an obesity phenotype Group 5 can have an obesity analyte signature that has an absence of (e.g., lacks the presence of) 1-methylhistine, glutamine, gamma-amino-n-butyric-acid, isocaproic, allo-isoleucine, and hydroxyproline.
  • an obesity analyte signature can include the presence of 1-methylhistine, serotonin, glutamine, gamma-amino-n-butyric-acid, isocaproic, allo-isoleucine, alanine, tyrosine, ghrelin, PYY, and includes a HADS-A questionnaire result.
  • an obesity phenotype Group 6 can have an obesity analyte signature that includes the presence of 1-methylhistine, serotonin, glutamine, gamma-amino-n-butyric-acid, isocaproic, allo-isoleucine, alanine, tyrosine, ghrelin, PYY, and includes a HADS-A questionnaire result.
  • an obesity phenotype Group 6 can have an obesity analyte signature that has an absence of (e.g., lacks the presence of) hydroxyproline, beta-aminoisobutyric-acid, hexanoic, and phenylalanine.
  • identifying the obesity phenotype also can include identifying one or more additional variables and/or one or more additional assessments. For example, identifying the obesity phenotype also can include assessing the microbiome of a mammal (e.g., an obese mammal). For example, identifying the obesity phenotype also can include assessing leptin levels. For example, identifying the obesity phenotype also can include assessing the metabolome of a mammal (e.g., an obese mammal). For example, identifying the obesity phenotype also can include assessing the genome of a mammal (e.g., an obese mammal).
  • identifying the obesity phenotype also can include assessing the proteome of a mammal (e.g., an obese mammal).
  • identifying the obesity phenotype also can include assessing the peptidome of a mammal (e.g., an obese mammal).
  • the mammal can be assessed to determine intervention (e.g., pharmacological intervention, surgical intervention, weight loss device, diet intervention, behavior intervention, and/or microbiome intervention) responsiveness, and a treatment option for the mammal can be selected.
  • intervention e.g., pharmacological intervention, surgical intervention, weight loss device, diet intervention, behavior intervention, and/or microbiome intervention
  • a treatment option for the mammal can be selected.
  • the obesity phenotype of a mammal can be used to select a treatment options as shown in FIG. 12 , and as set forth in Table 1.
  • Individualized pharmacological interventions for the treatment of obesity can include any one or more (e.g., 1, 2, 3, 4, 5, 6, or more) pharmacotherapies (e.g., individualized pharmacotherapies).
  • a pharmacotherapy can include any appropriate pharmacotherapy.
  • a pharmacotherapy can be an obesity pharmacotherapy.
  • a pharmacotherapy can be an appetite suppressant.
  • a pharmacotherapy can be an anticonvulsant.
  • a pharmacotherapy can be a GLP-1 agonist.
  • a pharmacotherapy can be an antidepressant.
  • a pharmacotherapy can be an opioid antagonist.
  • a pharmacotherapy can be a controlled release pharmacotherapy.
  • a controlled release pharmacotherapy can be an extended release (ER) and/or a slow release (SR) pharmacotherapy.
  • a pharmacotherapy can be a lipase inhibitor.
  • a pharmacotherapy can be a DPP4 inhibitor.
  • a pharmacotherapy can be a SGLT2 inhibitor.
  • a pharmacotherapy can be a dietary supplement.
  • Examples of pharmacotherapies that can be used in an individualized pharmacological intervention as described herein include, without limitation, orlistat, phentermine, topiramate, lorcaserin, naltrexone, bupropion, liraglutide, exenatide, metformin, pramlitide, Januvia, canagliflozin, dexamphetamines, prebiotics, probiotics, Ginkgo biloba , and combinations thereof.
  • combination pharmacological interventions for the treatment of obesity can include phentermine-topiramate ER, naltrexone-bupropion SR, phentermine-lorcaserin, lorcaserin-liraglutide, and lorcarserin-januvia.
  • a pharmacotherapy can be administered using any appropriate methods. In some cases, pharmacotherapy can be administered by continuous pump, slow release implant, intra-nasal administered, intra-oral administered, and/or topical administered.
  • a pharmacotherapy can be administered as described elsewhere (see, e.g., Sjostrom et al., 1998 Lancet 352:167-72; Hollander et al., 1998 Diabetes Care 21:1288-94; Davidson et al., 1999 JAMA 281:235-42; Gadde et al., 2011 Lancet 377:1341-52; Smith et al., 2010 New Engl. J. Med. 363:245-256; Apovian et al., 2013 Obesity 21:935-43; Pi-Sunyer et al., 2015 New Engl. J. Med. 373:11-22; and Acosta et al., 2015 Clin Gastroenterol Hepatol. 13:2312-9).
  • a mammal is identified as being responsive to one or more interventions (e.g., pharmacological intervention, surgical intervention, weight loss device, diet intervention, behavior intervention, and/or microbiome intervention) based, at least in part, on an obesity phenotype, which is based, at least in part, on an obesity analyte signature in the sample, the mammal can be administered or instructed to self-administer one or more individualized pharmacotherapies.
  • interventions e.g., pharmacological intervention, surgical intervention, weight loss device, diet intervention, behavior intervention, and/or microbiome intervention
  • the mammal can be administered or instructed to self-administer one or more pharmacotherapies.
  • a mammal is identified as having a low satiation (Group 1) phenotype, based, at least in part, on an obesity analyte signature
  • the mammal can be administered or instructed to self-administer phentermine-topiramate (e.g., phentermine-topiramate ER) to treat the obesity.
  • phentermine-topiramate e.g., phentermine-topiramate ER
  • a mammal when a mammal is identified as having a low satiation (Group 1) phenotype, based, at least in part, on an obesity analyte signature, the mammal can be administered or instructed to self-administer lorcaserin to treat the obesity.
  • Group 2 when a mammal is identified as having a low satiety (Group 2) phenotype, based, at least in part, on an obesity analyte signature, the mammal can be administered or instructed to self-administer liraglutide to treat the obesity.
  • naltrexone-bupropion e.g., naltrexone-bupropion SR
  • the mammal can be administered or instructed to self-administer naltrexone-bupropion (e.g., naltrexone-bupropion SR) to treat the obesity.
  • naltrexone-bupropion e.g., naltrexone-bupropion SR
  • the mammal can be administered or instructed to self-administer naltrexone-bupropion (e.g., naltrexone-bupropion SR) to treat the obesity.
  • a mammal when a mammal is identified as having a low resting energy expenditure (Group 6) phenotype, based, at least in part, on an obesity analyte signature, the mammal can be administered or instructed to self-administer phentermine, and can be instructed to increase physical activity to treat the obesity.
  • a low resting energy expenditure Group 6
  • the mammal can be administered or instructed to self-administer phentermine, and can be instructed to increase physical activity to treat the obesity.
  • one or more pharmacotherapies described herein can be administered to an obese mammal as a combination therapy with one or more additional agents/therapies used to treat obesity.
  • a combination therapy used to treat an obese mammal can include administering to the mammal one or more pharmacotherapies described herein and one or more obesity treatments such as weight-loss surgeries (e.g., gastric bypass surgery, laparoscopic adjustable gastric banding (LAGB), biliopancreatic diversion with duodenal switch, and a gastric sleeve), vagal nerve blockade, endoscopic devices (e.g.
  • a combination therapy used to treat an obese mammal can include administering to the mammal one or more pharmacotherapies described herein and one or more obesity therapies such as exercise modifications (e.g., increased physical activity), dietary modifications (e.g., reduced-calorie diet), behavioral modifications, commercial weight loss programs, wellness programs, and/or wellness devices (e.g. dietary tracking devices and/or physical activity tracking devices).
  • obesity therapies such as exercise modifications (e.g., increased physical activity), dietary modifications (e.g., reduced-calorie diet), behavioral modifications, commercial weight loss programs, wellness programs, and/or wellness devices (e.g. dietary tracking devices and/or physical activity tracking devices).
  • the one or more additional agents/therapies used to treat obesity can be administered/performed at the same time or independently.
  • the one or more pharmacotherapies described herein can be administered first, and the one or more additional agents/therapies used to treat obesity can be administered/performed second, or vice versa.
  • analytes associated with obesity can be used in an obesity analyte signature as described herein.
  • one or more analytes associated with obesity can be identified by using a combined logit regression model.
  • a combined logit regression model can include stepwise variable selection (e.g., to identify variables significantly associated with a specific obesity phenotype).
  • one or more analytes associated with obesity can be identified as described in, for example, the Examples section provided herein.
  • Obesity phenotypes were associated with higher BMI, distinguish obesity phenotypes, and can be used to predict responsiveness to obesity pharmacotherapy and endoscopic devices (see, e.g., Acosta et al., 2015 Gastroenterology 148:537-546). In this study, biomarkers specific to each obesity phenotype were identified using metabolomics.
  • the overall cohort demographics [median (IQR)] were age 36 (28-46) years, BMI 35 (32-38) kg/m 2 , 75% females, 100% Caucasians.
  • the group distribution in this cohort was: abnormal satiation (16%), abnormal satiety (16%), abnormal hedonic/psych (19%), slow metabolism/energy expenditure (32%), and mixed group (17%) ( FIG. 1 A ).
  • 1 B-E illustrate summarize characteristics of the quantitative changes in the subgroups: the satiation group consumed 591 (60%) more calories prior to reaching fullness; the satiety group emptied half of the solid 300 kcal meal 34 min (30%) faster; the hedonic group reported 2.8 times higher levels of anxiety; the slow metabolism group has 10% decreased predicted resting energy expenditure than other groups. These average differences were in comparison to the other groups, but excluding the group with participants with a mixed or overlapping phenotype.
  • PC principal components
  • a combined logit regression model using stepwise variable selection was created to identify variables that are significantly associated with each of the phenotypic classes.
  • Untargeted metabolomics identified unique metabolites in each group ( FIG. 2 A ). Each of these metabolites is independent from the other groups ( FIG. 2 B ). From these metabolites, a “VIP” (variable of importance) was identified for each group. Then, a targeted metabolomics was done with the VIP as well as neurotransmitters, amino compounds, fatty acids, and short chain fatty acids. Examples variables are as shown in Tables 2-5. For example, targeted metabolites, peptides, and SNPS analyzed are as shown in Table 2, other obesity related gene variants are as shown in in Table 3, targeted peptides are as shown in in Table 4, and targeted genes are as shown in in Table 5.
  • Table 6 summarizes the variables that were significantly associated with each of the phenotypic groups vs the rest of the groups.
  • SNP 1 low satiation HTR2C, POMC, NPY, rs1414334 AGRP, MC4R, GNB3, SERT, BDNF 2: low satiety PYY, GLP-1, MC4R, rs7903146 GPBAR1, TCF7L2, ADRA2A, PCSK, TMEM18 3: behavioral eating SLC6A4/SERT, DRD2 rs4795541 4: large fasting gastric volume TCF7L2, UCP3, rs1626521 ADRA2A, 5: mixed 6: low resting energy expenditure FTO, LEP, LEPR, rs2075577 UCP1, UCP2, UCP3, ADRA2, KLF14, NPC1, LYPLAL1, ADRB2, ADRB3, BBS1
  • Combinations of compounds were identified as significantly associated with each of the obesity phenotypic groups.
  • the variables that were significantly associated with each of the phenotypic groups included the following:
  • the following formulas were used to identify the obesity phenotype of a patient based upon the signature of the 14 compounds identified as being significantly associated with each of the obesity phenotypic groups.
  • the formulas predicted the phenotypes with a r2 of 0.90 and a probability Chi-square of less than 0.0001.
  • group 4 and mixed are removed from the equation, the obesity phenotypes can be predicted with 100% sensitivity and specificity.
  • Another multinomial logistic model contained 1 behavioral assessment, 3 germline variants, and 6 fasting targeted metabolomics.
  • the variables can be as shown in Table 8 plus questionnaire(s) (e.g., HADS and/or TEFQ21).
  • Simple-blood test biomarkers were identified that can classify obese patients into their related phenotypes. To achieve this, 25 individuals with unique obesity phenotypes were selected from the cohort of 180 participants and an untargeted metabolomics study was performed using their fasting blood samples. Thus, average of 3331 unique metabolites that are associated with each obesity-related phenotype were observed and this is illustrated through the VennDiagrams of Unique Metabolites per group using Positive-HILIC Untargeted Metabolomics ( FIG. 2 A ). These data supported the application of a targeted metabolomics approach, hypothesis-driven, to identify and quantify associated metabolites. A two-stage design was used to develop the composition of the blood test; the training and validation cohorts consisted of 102 and 78 obese patients, respectively.
  • the accuracy of the model was 86% in the whole cohort.
  • FIG. 3 shows the sub-classification prediction accuracy of this combined model and an ROC analysis showed that this model has >0.90 area under the curve (AUC) for all six classes.
  • FIG. 5 shows that the formula predicted the sub-groups with over 90% sensitivity and specificity.
  • Obesity is a chronic, relapsing, multifactorial, heterogeneous disease.
  • the heterogeneity within obesity is most evident when assessing treatment response to obesity interventions, which are generally selected based on BMI.
  • BMI obesity phenotypes
  • These standard approaches fail to address the heterogeneity of obesity.
  • obesity phenotypes were associated with higher BMI, distinguish obesity phenotypes.
  • This Example shows that obesity phenotypes respond differently to specific interventions (e.g., pharmacological interventions).
  • Obesity-related phenotypes were evaluated to facilitate the understanding of obesity pathophysiology, and identify sub-groups within the complex and heterogeneous obese population.
  • the specific characteristics of 180 participants with obesity were grouped based on their predominant obesity-related phenotype, based on a multiple step process (in addition to gender) to generate a homogeneous populations based on the 75 th percentile within the obese group for each well-validated variable: a) satiation [studied by nutrient drink test (maximal tolerated volume, 1 kcal/ml)], b) satiety [studied by gastric emptying (T 1/2 , min)], c) hedonic (hospital anxiety and depression score [HADS] questionnaire), d) other (none of the above) and e) mixed (two or more criteria met).
  • Accelerated gastric emptying was chosen as a surrogate for abnormal satiety based on the main fact that is an objective, reproducible test, whiles other tests, such as visual analog scores are subjective sensations of satiety.
  • Enteroendocrine (EE) cells are real-time nutrient, bile and microbiota sensors that regulate food intake, brain-gut communication, gastrointestinal motility, and glucose metabolism. EE cell function can be studied indirectly by measuring plasma levels of hormones such as GLP-1 or PYY, and less frequently EE cells are studied as part of whole intestinal tissue. These results suggested a hungry gut phenotype.
  • hedonic a sub-group within participants with obesity which have a very strong psychological component that may predispose them to obesity, labeled here as a ‘hedonic’ sub-group.
  • this group is acquiring most of their calories from emotional eating, cravings and reward-seeking behaviors while having appropriate sensations of satiation and satiety.
  • the slow metabolism group have significant lower measured resting energy expenditure (kcal/day) that other groups (p ⁇ 0.05) ( FIG. 9 B ).
  • PhenTop phentermine-topiramate-ER
  • exenatide 5 ⁇ g, SQ, twice daily for 30 days was evaluated on GE, satiety, and weight loss as described elsewhere (see, e.g., Acosta et al., 2015 Physiological Rep. 3(11)).
  • Exenatide a glucagon-like peptide-1 (GLP-1) agonist, had a very significant effect on GE of solids (p ⁇ 0.001) and reduced calorie intake at a buffet meal by an average 130 kcal compared to placebo.
  • the average weight loss was 1.3 kg for exenatide and 0.5 kg for the placebo group ( FIG. 11 ).
  • FIG. 12 shows exemplary individualized obesity interventions based upon obesity phenotypes.
  • Example 1 The algorithm described in Example 1 was applied to 29 new patients with obesity (Table 9). Data from (intervention) pharmacotherapy and controls were acquired retrospectively. Groups were matched for age, gender and BMI. Results were compared the outcome to 66 patients previously treated by obesity experts.
  • the algorithm predicted the obesity group and intervention responsiveness of the new participants with over 90% sensitivity and specificity ( FIG. 13 , FIG. 14 , and Table 10).
  • the controls were seen in the weight management clinic by a physician expert of obesity and offered standard of care for obesity management and pharmacotherapy.
  • the current standard of care suggests that pharmacotherapy needs to be selected based on patient—physician preference, mainly driven by side effects and other comorbidities.
  • the cases were seen in the weight management clinic by a physician expert of obesity and offered obesity-phenotype guided pharmacotherapy for obesity management.
  • the phenotypes seen were abnormal satiation (25%), abnormal satiety (20%), abnormal behavior (20%) and other (35%).
  • the intervention group had 74% responders (defined as those who loss more than 3% in the first month) compared to 33% in the control group.
  • the control group number of responders was similar to the published in the current obesity literature.
  • the significant improvement of responders resulted in a total body weight loss of 12.9 kg in the intervention group compared to 5.8 kg in the control group at 9 months.
  • the algorithm was also applied to 12 patients with obesity, who saw their weight loss plateau during the treatment for obesity with an intragastric balloon. These individuals saw weight loss plateau during month 3 and 6 of treatment with the balloon. At month 6, the algorithm was applied to the intervention group compared to the controls.
  • hedonic group In the hedonic group, there are increased levels of anxiety, depression, and cravings with low levels of serum tryptophan compared to the other groups.
  • the slow metabolism group has decreased resting energy expenditure compared to other groups. Since identifying the obesity subgroups by deep phenotyping is limited to few academic centers, a fasting blood multi-omic test was developed and validated that predict the obesity subgroups (ROC >90% AUC). This blood test provides segmentation of diverse sub-phenotypes of obesity, has the potential to select patients for individualized treatment from the sea of obesity heterogeneity, facilitates our understanding of human obesity, and may lead to future treatment based on actionable biomarkers.
  • obesity phenotype groups can be used to predict treatment response, and can be used to guide individualized treatment strategies (e.g., pharmacotherapy and/or bariatric endoscopy).
  • individualized treatment strategies e.g., pharmacotherapy and/or bariatric endoscopy.
  • the obesity phenotype guided intervention doubled the weight loss in patients with obesity.
  • each sub-group may have unique abnormalities compared to the other groups when tested with previously validated or reported findings in common obesity was interrogated.
  • Unique targets identified in a sub-population can serve to find a unique treatment: for example TCF7L/2 genetic variant can be used to identify a group with abnormal satiety; or a simple test such as gastric emptying can be used to clef ne abnormal satiety.
  • the model described above is also run independently for additional sub-populations of patients.
  • the model can be run on patients of specific ages (e.g., youth such as people from birth to about 18, adults such as people 18 or older), and specific life stages (e.g., perimenopausal women, menopausal women, post-menopausal women, and andropausal men).
  • specific ages e.g., youth such as people from birth to about 18, adults such as people 18 or older
  • specific life stages e.g., perimenopausal women, menopausal women, post-menopausal women, and andropausal men.
  • Sub-populations of patients demonstrated analyte differences between obesity groups that were not seen in a full population of patients.
  • his/her phenotype can assist in selecting a treatment.
  • the phenotypic studies include (all performed in same day in the following order): fasting blood collection, resting energy expenditure, gastric emptying with meal for breakfast, behavioral questionnaires, and buffet meal test for lunch.
  • Blood is collected for assessment of metabolomic biomarkers, gastrointestinal hormones, DNA (blood and buccal swab), and pharmacogenomics.
  • Stool samples are collected for microbiome and bile acid. Participants return to the CRTU to pick up medication based on the randomization and discuss the pharmacogenomics results. All participants are contacted at 4 and seen at 12 weeks (current standard in practice). A stool sample and a fasting blood sample are collected at the 12-week visit.
  • a computer generated randomization is based on guiding pharmacotherapy based on the phenotype or randomly as current standard of care. Allocations are concealed.
  • a study cohort includes 200 patients with obesity (BMI>30 kg/m 2 ). Participants that agree to pharmacotherapy treatment are invited to participate in the phenotypic assessment of their obesity that will guide (or not) the pharmacotherapy.
  • Anthropometrics Measurements are taken of hip-waist ratio, height, weight, blood pressure, pulse at baseline, randomization day and week 12.
  • Phenotype studies at baseline After an 8-hour fasting period, and the following validated quantitative traits (phenotypes) are measured at baseline:
  • Weight management Questionnaire Mayo Clinic®
  • HAD Anxiety and Depression Inventory
  • Pharmacotherapy for the treatment of obesity can be considered if a patient has a body mass index (BMI) ⁇ 30 kg/m 2 or BMI>27 kg/m 2 with a comorbidity such as hypertension, type 2 diabetes, dyslipidemia and obstructive sleep apnea.
  • Medical therapy should be initiated with dose escalation based on efficacy and tolerability to the recommended dose. An assessment of efficacy and safety at 4 weeks is done. In both groups, medications are assessed for drug interactions and potential side effects as standard of care.
  • Medication selection Once the phenotype tests are completed the results are filled in an algorithm to assist on the decision of the medication selection as described elsewhere (see, e.g., Acosta et al., 2015 Gastroenterology 148:537-546; Camilleri et al., 2016 Gastrointest. Endosc. 83:48-56; and Acosta et al., 2015 Physiological Rep. 3(11)).
  • An example is below:
  • Example 1 Example 2
  • Example 3 Example 4 Satiation >1139 kcal 1400 kcal 1000 kcal 1100 kcal 1050 kcal (Ad libitum Buffet Meal) Satiety SGE T 1/2 ⁇ 85 102 min 80 min 105 min 110 min (Gastric emptying) min or GE 1 hr >35% Behavioral Traits HADS A&D >6 points 5 4 9 3 (Questionnaires) Energy Expenditure ⁇ 85% predicted 92% 93% 95% 82% (Resting EE) Phenotype — Ab Satiation Ab Satiety Ab Psych Ab E.E.
  • Control Group Pharmacotherapy for Obesity
  • Standard of care pharmacotherapy for obesity recommends the following doses and regimen for weight loss:
  • Participants in the intervention group will have 4 tests to assess 1) satiation, 2) satiety/return to hunger, 3) behavioral, or 4) energy expenditure.
  • pharmacotherapy will by guide based on the phenotype. In case of a mixed pattern or multiple abnormal phenotypes, the most prominent phenotype is tackled.
  • the secondary end points will be percentage of responders (defined as number of participants who loss 5% or more of total body weight) compared to baseline in the obesity phenotype guided pharmacotherapy (intervention) group vs. standard of care at 4 and 12 weeks; percentage of responders with at least 10 and 15% at 12 weeks, and 10% at 6 months and 12 months; percentage of responders at 5%, 10% and 15%; percentage of responders within each obesity-phenotype group at 4 and 12 weeks; and side effects of medications.
  • the total body weight loss is assessed at 24 and 52 weeks in both groups.
  • Sample size assessment and power calculation The detectable effect size in weight loss between groups of interest (intervention vs. control) is given in Table 15. Using a SD for the overall weight change (pre-post) of 2.8 kg, the differences between groups that could be detected with approximately 80% power (2-sided a level of 0.05) for main effects are estimated. Thus, the sample size needed is 87 participants per group. In order to account for dropout, 100 participants per group are randomized.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Emergency Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)

Abstract

This document relates to methods and materials for assessing and/or treating obese mammals (e.g., obese humans). For example, methods and materials for using one or more interventions (e.g., one or more pharmacological interventions) to treat obesity and/or obesity-related comorbidities in a mammal (e.g., a human) identified as being likely to respond to a particular intervention (e.g., a pharmacological intervention) are provided.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a continuation of U.S. application Ser. No. 16/765,273, filed on May 19, 2020, which is a National Stage application under 35 U.S.C. § 371 of International Application No. PCT/US2018/062217, having an International Filing Date of Nov. 21, 2018, which claims the benefit of U.S. Patent Application No. 62/589,915, filed on Nov. 22, 2017. The disclosures of the prior applications are considered part of (and are incorporated by reference in) the disclosure of this application.
STATEMENT REGARDING FEDERAL FUNDING
This invention was made with government support under DK067071 and DK084567 awarded by the National Institutes of Health. The government has certain rights in the invention.
BACKGROUND 1. Technical Field
This document relates to methods and materials for assessing and/or treating obesity in mammals (e.g., humans). For example, this document provides methods and materials for determining an obesity analyte signature of a mammal. For example, this document provides methods and materials for determining an obesity phenotype of a mammal. For example, this document provides methods and materials for using one or more interventions (e.g., one or more pharmacological interventions) to treat obesity and/or obesity-related comorbidities in a mammal (e.g., a human) identified as being likely to respond to a particular intervention (e.g., a pharmacological intervention).
2. Background Information
Obesity prevalence continues to increase worldwide (Ng et al., 2014 Lancet 384:766-81) and, in the United States, 69% of adults are overweight or obese (Flegal et al., 2012 JAMA 307:491-497). Estimated costs to the healthcare system are more than $550 billion annually. Increased severity of obesity correlates with a higher prevalence of the associated co-morbidities. Likewise, obesity increases the risk of premature mortality (Hensrud et al., 2006 Mayo Clinic Proceedings 81(10 Suppl):S5-10). Obesity affects almost every organ system in the body and increases the risk of numerous diseases including type 2 diabetes mellitus, hypertension, dyslipidemia, cardiovascular disease, and cancer. It is estimated that a man in his twenties with a BMI over 45 will have a 22% reduction (13 years) in life expectancy.
SUMMARY
Despite advances in understanding aspects of obesity pathophysiology, weight loss with current treatments including diet, exercise, medications, endoscopy; and surgery is highly variable (Acosta et al., 2014 Gut 63:687-95). For example, some obese patients specifically respond to particular medications, and can lose as much weight and with fewer side effects than bariatric surgery. There is a need to be able to identify which intervention(s) an obese patient is likely to respond to in order to be able to select the right intervention for the right patient based on his/her pathophysiology.
This document provides methods and materials for assessing and/or treating obesity in mammals (e.g., humans). In some cases, this document provides methods and materials for identifying an obese mammal as being responsive to a pharmacological intervention (e.g., by identifying the mammal as having a pharmacotherapy responsive obesity analyte signature), and administering one or more interventions (e.g., pharmacological interventions) to treat the mammal. For example, a sample obtained from an obese mammal can be assessed to determine if the obese mammal is likely to be responsive to pharmacological intervention based; at least in part; on an obesity phenotype, which is based, at least in part, on an obesity analyte signature in the sample. As demonstrated herein, a distinct obesity analyte signature is present in each of six main obesity phenotype groups: 1) low satiation, 2) low satiety (e.g., rapid return to hunger), 3) behavioral eating (identified by questionnaire), 4) large fasting gastric volume, 5) mixed, and 6) low resting energy expenditure group; and each obesity phenotype is likely to be responsive to one or more particular interventions (e.g., pharmacological intervention, surgical intervention, weight loss device, diet intervention, behavior intervention, and/or microbiome intervention).
Having the ability to identify which intervention(s) an obese patient is likely to respond to provides a unique and unrealized opportunity to provide an individualized approach in selecting obesity treatments.
In general, one aspect of this document features a method for treating obesity in a mammal. The method includes, or consists essentially of, identifying the mammal as having an intervention responsive obesity analyte signature in a sample obtained from the mammal; and administering an intervention to the mammal. The sample can be a blood sample, a saliva sample, a urine sample, a breath sample, or a stool sample. For example, the sample can be a breath sample. For example, the method sample can be a stool sample. The mammal can be a human. In some cases, the obesity analyte signature can include 1-methylhistine, serotonin, glutamine, gamma-amino-n-butyric-acid, isocaproic, allo-isoleucine, hydroxyproline, beta-aminoisobutyric-acid, al anine, hexanoic, tyrosine, phenylalanine, ghrelin, and peptide tyrosine tyrosine (PYY). The intervention can be effective to reduce the total body weight of said mammal by at least 4%. The intervention can be effective to reduce the total body weight of said mammal by from about 3 kg to about 100 kg. The intervention can be effective to reduce the waist circumference of said mammal by from about 1 inches to about 10 inches. The identifying step also can include obtaining results from a Hospital Anxiety and Depression Scale (HADS) questionnaire and/or a Three Factor Eating questionnaire (TFEQ). In some cases, the obesity analyte signature can include a presence of serotonin, glutamine, isocaproic, allo-isoleucine, hydroxyproline, beta-aminoisobutyric-acid, alanine, hexanoic, tyrosine, and PYY, and an absence of (e.g., lacks the presence of) 1-methylhistine, gamma-amino-n-butyric-acid, phenylalanine, ghrelin; the HADS questionnaire result does not indicate an anxiety subscale; and the mammal can be responsive to intervention with phentermine-topiramate pharmacotherapy and/or lorcaserin pharmacotherapy. In some cases, the obesity analyte signature can include a presence of 1-methylhistine, allo-isoleucine, hydroxyproline, beta-aminoisobutyric-acid, alanine, and phenylalanine, and an absence of serotonin, glutamine, gamma-amino-n-butyric-acid, isocaproic, hexanoic, tyrosine, ghrelin, and PYY; the HADS questionnaire result not indicate an anxiety subscale; and the mammal can be responsive to intervention with liraglutide pharmacotherapy. In some cases, the obesity analyte signature can include a presence of serotonin, and an absence of 1-methylhistine, glutamine, gamma-amino-n-butyric-acid, isocaproic, allo-isoleucine, hydroxyproline, beta-aminoisobutyric-acid, alanine, hexanoic, tyrosine, phenylalanine, ghrelin, and PYY; the HADS questionnaire result indicates an anxiety subscale; and the mammal can be responsive to intervention with naltrexone-bupropion pharmacotherapy. In some cases, the obesity analyte signature can include a presence of 1-methylhistine, glutamine, gamma-amino-n-butyric-acid, isocaproic, allo-isoleucine, beta-aminoisobutyric-acid, alanine, hexanoic, tyrosine, phenylalanine, PYY, and an absence of serotonin, hydroxyproline, and ghrelin; the HADS questionnaire result indicates an anxiety subscale; and the mammal can be responsive to intervention with naltrexone-bupropion pharmacotherapy. In some cases, the obesity analyte signature can include a presence of 1-methylhistine, serotonin, glutamine, gamma-amino-n-butyric-acid, isocaproic, allo-isoleucine, alanine, tyrosine, ghrelin, PYY, and an absence of hydroxyproline, beta-aminoisobutyric-acid, hexanoic, and phenylalanine; the HADS questionnaire result indicates an anxiety subscale; and the mammal can be responsive to intervention with phentermine pharmacotherapy. In some cases, the obesity analyte signature can include HTR2C, GNB3, FTO, iso-caproic acid, beta-aminoisobutyricacid, butyric, allo-isoleucine, tryptophan, and glutamine. The identifying step also can include obtaining results from a HADS questionnaire. In some cases, the obesity analyte signature can include the presence of a single nucleotide polymorphism (SNP) in HTR2C, POMC, NPY, AGRP, MC4R, GNB3, SERT, and/or BDNF; the HADS questionnaire result does not indicate an anxiety subscale; and the mammal can be responsive to intervention with phentermine-topiramate pharmacotherapy and/or lorcaserin pharmacotherapy. The SNP can be rs1414334. In some cases, the obesity analyte signature can include the presence of a SNP in PYY, GLP-1, MC4R, GPBAR1, TCF7L2, ADRA2A,PCSK, and/or TMEM18; the HADS questionnaire result not indicate an anxiety subscale; and the mammal can be responsive to intervention with liraglutide pharmacotherapy. The SNP can be rs7903146. In some cases, the obesity analyte signature can include presence of a SNP in SLC6A4/SERT, and/or DRD2; the HADS questionnaire result indicates an anxiety subscale; and the mammal can be responsive to intervention with naltrexone-bupropion pharmacotherapy. The SNP can be rs4795541. In some cases, the obesity analyte signature can include the presence of a SNP in TCF7L2, UCP3, and/or ADRA2A; the HADS questionnaire result indicates an anxiety subscale; and the mammal can be responsive to intervention with naltrexone-bupropion pharmacotherapy. The SNP can be rs1626521. In some cases, the obesity analyte signature can include the presence of a SNP in FTO, LEP, LEPR, UCP1, UCP2, UCP3, ADRA2, KLF14, NPC1, LYPLAL1, ADRB2, ADRB3, and/or BBS1; the HADS questionnaire result indicates an anxiety subscale; and the mammal can be responsive to intervention with phentermine pharmacotherapy. The SNP can be rs2075577.
In another aspect, this document features a method for treating obesity in a mammal. The method includes, or consists essentially of, administering an intervention to a mammal that was identified as having an intervention responsive obesity analyte signature. The mammal can be a human. The obesity analyte signature can include 1-methylhistine, serotonin, glutamine, gamma-amino-n-butyric-acid, isocaproic, allo-isoleucine, hydroxyproline, beta-aminoisobutyric-acid, alanine, hexanoic, tyrosine, phenylalanine, ghrelin, and peptide tyrosine tyrosine (PYY). The intervention can be effective to reduce the total body weight of said mammal by at least 4%. The intervention can be effective to reduce the total body weight of said mammal by from about 3 kg to about 100 kg. The intervention can be effective to reduce the waist circumference of said mammal by from about 1 inches to about 10 inches. The identifying step also can include obtaining results from a Hospital Anxiety and Depression Scale (HADS) questionnaire. In some cases, the obesity analyte signature can include a presence of serotonin, glutamine, isocaproic, allo-isoleucine, hydroxyproline, beta-aminoisobutyric-acid, alanine, hexanoic, tyrosine, and PYY, and an absence of (e.g., lacks the presence of) 1-methylhistine, gamma-amino-n-butyric-acid, phenylalanine, ghrelin; the HADS questionnaire result does not indicate an anxiety subscale; and the mammal can be responsive to intervention with phentermine-topiramate pharmacotherapy and/or lorcaserin pharmacotherapy. In some cases, the obesity analyte signature can include a presence of 1-methylhistine, allo-isoleucine, hydroxyproline, beta-aminoisobutyric-acid, alanine, and phenylalanine, and an absence of serotonin, glutamine, gamma-amino-n-butyric-acid, isocaproic, hexanoic, tyrosine, ghrelin, and PYY; the HADS questionnaire result not indicate an anxiety subscale; and the mammal can be responsive to intervention with liraglutide pharmacotherapy. In some cases, the obesity analyte signature can include a presence of serotonin, and an absence of 1-methylhistine, glutamine, gamma-amino-n-butyric-acid, isocaproic, allo-isoleucine, hydroxyproline, beta-aminoisobutyric-acid, alanine, hexanoic, tyrosine, phenylalanine, ghrelin, and PYY; the HADS questionnaire result indicates an anxiety subscale; and the mammal can be responsive to intervention with naltrexone-bupropion pharmacotherapy. In some cases, the obesity analyte signature can include a presence of 1-methylhistine, glutamine, gamma-amino-n-butyric-acid, isocaproic, allo-isoleucine, beta-aminoisobutyric-acid, alanine, hexanoic, tyrosine, phenylalanine, PYY, and an absence of serotonin, hydroxyproline, and ghrelin; the HADS questionnaire result indicates an anxiety subscale; and the mammal can be responsive to intervention with naltrexone-bupropion pharmacotherapy. In some cases, the obesity analyte signature can include a presence of 1-methylhistine, serotonin, glutamine, gamma-amino-n-butyric-acid, isocaproic, allo-isoleucine, alanine, tyrosine, ghrelin, PYY, and an absence of hydroxyproline, beta-aminoisobutyric-acid, hexanoic, and phenylalanine; the HADS questionnaire result indicates an anxiety subscale; and the mammal can be responsive to intervention with phentermine pharmacotherapy.
In another aspect, this document features a method for identifying an obese mammal as being responsive to treatment with an intervention. The method includes, or consists essentially of, determining an obesity analyte signature in a sample obtained from a mammal, where the obesity analyte signature can include 1-methylhistine, serotonin, glutamine, gamma-amino-n-butyric-acid, isocaproic, allo-isoleucine, hydroxyproline, beta-aminoisobutyric-acid, alanine, hexanoic, tyrosine, phenylalanine, ghrelin, and PYY; and classifying the mammal as having an intervention responsive obesity analyte signature based upon the presence and absence of analytes in the obesity analyte signature. The mammal can be a human. The sample can be a blood sample, a saliva sample, a urine sample, a breath sample, or a stool sample. For example, the sample can be a breath sample. For example, the method sample can be a stool sample. The method also can include obtaining results from a HADS questionnaire. In some cases, the obesity analyte signature can include a presence of serotonin, glutamine, isocaproic, allo-isoleucine, hydroxyproline, beta-aminoisobutyric-acid, alanine, hexanoic, tyrosine, and PYY, and an absence of (e.g., lacks the presence of) 1-methylhistine, gamma-amino-n-butyric-acid, phenylalanine, ghrelin; the HADS questionnaire result does not indicate an anxiety subscale; and the mammal can be responsive to intervention with phentermine-topiramate pharmacotherapy and/or lorcaserin pharmacotherapy. In some cases, the obesity analyte signature can include a presence of 1-methylhistine, allo-isoleucine, hydroxyproline, beta-aminoisobutyric-acid, alanine, and phenylalanine, and an absence of serotonin, glutamine, gamma-amino-n-butyric-acid, isocaproic, hexanoic, tyrosine, ghrelin, and PYY; the HADS questionnaire result not indicate an anxiety subscale; and the mammal can be responsive to intervention with liraglutide pharmacotherapy. In some cases, the obesity analyte signature can include a presence of serotonin, and an absence of 1-methylhistine, glutamine, gamma-amino-n-butyric-acid, isocaproic, allo-isoleucine, hydroxyproline, beta-aminoisobutyric-acid, alanine, hexanoic, tyrosine, phenylalanine, ghrelin, and PYY; the HADS questionnaire result indicates an anxiety subscale; and the mammal can be responsive to intervention with naltrexone-bupropion pharmacotherapy. In some cases, the obesity analyte signature can include a presence of 1-methylhistine, glutamine, gamma-amino-n-butyric-acid, isocaproic, allo-isoleucine, beta-aminoisobutyric-acid, alanine, hexanoic, tyrosine, phenylalanine, PYY, and an absence of serotonin, hydroxyproline, and ghrelin; the HADS questionnaire result indicates an anxiety subscale; and the mammal can be responsive to intervention with naltrexone-bupropion pharmacotherapy. In some cases, the obesity analyte signature can include a presence of 1-methylhistine, serotonin, glutamine, gamma-amino-n-butyric-acid, isocaproic, allo-isoleucine, alanine, tyrosine, ghrelin, PYY, and an absence of hydroxyproline, beta-aminoisobutyric-acid, hexanoic, and phenylalanine; the HADS questionnaire result indicates an anxiety subscale; and the mammal can be responsive to intervention with phentermine pharmacotherapy.
In another aspect, this document features a identifying an obese mammal as being responsive to treatment with an intervention. The method includes, or consists essentially of, determining an obesity analyte signature in a sample obtained from an obese mammal, where the obesity analyte signature includes HTR2C, GNB3, FTO, iso-caproic acid, beta-aminoisobutyricacid, butyric, allo-isoleucine, tryptophan, and glutamine; obtaining results from a HADS questionnaire; and classifying the mammal as having a intervention responsive obesity analyte signature based upon the presence and absence of analytes in the obesity analyte signature. The mammal can be a human. The sample can be a blood sample, a saliva sample, a urine sample, a breath sample, or a stool sample. In some cases, the sample can be a breath sample. In some cases, the sample can be a stool sample. In some cases, the obesity analyte signature can include the presence of a SNP in HTR2C, POMC, NPY, AGRP, MC4R, GNB3, SERT, and/or BDNF; the HADS questionnaire result can not indicate an anxiety subscale; and the mammal can be classified as being responsive to intervention with phentermine-topiramate pharmacotherapy and/or lorcaserin pharmacotherapy. The SNP can be rs1414334. In some cases, the obesity analyte signature can include the presence of a SNP in PYY, GLP-1, MC4R, GPBAR1, TCF7L2, ADRA2A,PCSK, and/or TMEM18; the HADS questionnaire result can not indicate an anxiety subscale; and the mammal can be classified as being responsive to intervention with liraglutide pharmacotherapy. The SNP can be rs7903146. In some cases, the obesity analyte signature can include the presence of a SNP in SLC6A4/SERT, and/or DRD2; the HADS questionnaire result can indicate an anxiety subscale; and the mammal can be classified as being responsive to intervention with naltrexone-bupropion pharmacotherapy. The SNP can be rs4795541. In some cases, the obesity analyte signature can include the presence of a SNP in TCF7L2, UCP3, and/or ADRA2A; the HADS questionnaire result can indicate an anxiety subscale; and the mammal can be classified as being responsive to intervention with naltrexone-bupropion pharmacotherapy. The SNP can be rs1626521. In some cases, the obesity analyte signature can include the presence of a SNP in FTO, LEP, LEPR, UCP1, UCP2, UCP3, ADRA2, KLF14, NPC1, LYPLAL1, ADRB2, ADRB3, and/or BBS1; the HADS questionnaire result can indicate an anxiety subscale; and the mammal can be classified as being responsive to intervention with phentermine pharmacotherapy. The SNP can be rs2075577.
Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. Although methods and materials similar or equivalent to those described herein can be used to practice the invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.
The details of one or more embodiments of the invention are set forth in the accompanying drawings and the description below. Other features, objects, and advantages of the invention will be apparent from the description and drawings, and from the claims.
DESCRIPTION OF THE DRAWINGS
FIGS. 1A-1E shows classifications of obesity. A) 180 Caucasian participants with obesity (BMI>30 kg·m2) were sub classified into a) abnormal satiation (16%), abnormal satiety (16%), abnormal hedonic/behavior (19%), slow metabolism (32%) and mixed group (17%). The subgroups have unique characteristics as shown for food intake until reaching fullness tested in a nutrient drink test (B), gastric emptying rate, surrogate of satiety (C) and anxiety levels, surrogate of hedonic (D), and slow metabolism (E) based on the subgroups and gender (blue=females, red=males).
FIGS. 2A and 2B show biomarker discovery. A) Venn Diagrams of unique metabolites per obesity phenotype identified using positive-HILIC untargeted metabolomics. GP1—satiation; GP2—satiety (rapid return to hunger); Gp3—hedonic; and Gp4—energy expenditure. B) A score plot of a principal component analysis (PCA) of obesity phenotypes showing that obesity phenotype groups can be separated based on metabolic differences.
FIG. 3 is a receiver operating characteristic (ROC) curve showing the sensitivity and specificity of determining an obesity phenotype based on metabolic signature.
FIG. 4 is a ROC curve using Bayesian covariate predictors for low satiation, behavioral eating, and low resting energy expenditure.
FIG. 5 is a ROC curve showing the sensitivity and specificity of determining an obesity phenotype based on metabolic signature.
FIG. 6 shows food intake meal paradigms measuring ‘maximal’ fullness (MTV), ‘usual’ fullness (VTF) in a nutrient drink test and ‘usual’ fullness to mixed meal (solids) in an ad libitum buffet meal.
FIGS. 7A-7D shows abnormal satiety deeper phenotypes. A) Gastric emptying (GE) of solid T1/2 and T1/4 GE of liquids T1/5 for females and males. B) Fasting and postprandial gastric volume for females and males. C) Postprandial PYY3-36 and GLP-1 at 90 minutes. D) correlation of Postprandial PYY3-36 at 90 minutes and food intake by a nutrient drink test.
FIGS. 8A-8B show hedonic group deeper phenotypes. A) Anxiety, depression and self-esteem levels and B) fasting serum tryptophan levels in patients with hedonic obesity compared to normal.
FIGS. 9A-9D show slow metabolism deeper phenotypes. A) Predicted resting energy expenditure in patients with normal metabolism (other) compared to slow metabolism by gender (data in percentage). B) Resting energy expenditure in patients with normal metabolism (other) compared to slow metabolism (data in kcal/day). C) Body composition in different obesity-related phenotypes measured by DEXA. Top row is calculated BMI, med-row is total body fat and lower row is total lean mass. D) Levels of metabolites in patients with slow metabolism compared to normal metabolism (other or rest). Metabolites describes are Alanine, isocaproic acid, phosphoetahnol amine, phenylalanine, tyrosine, alpha-amino-N-butyric acid, sarcasine, and 1-methylhistidine.
FIG. 10 is a bar graph showing body weight change in response to treatment with placebo or a combination of phentermine and topiramate (PhenTop) and kcal intake at prior ad-libitum meal (satiation test).
FIG. 11 is a bar graph showing body weight change in response to treatment with placebo or exenatide in patients with a particular obesity phenotype.
FIGS. 12A-12C are a flow charts showing exemplary treatment interventions for obesity groups identified based, at least in part, on a patient's obesity analyte signature.
FIG. 13 is a bar graph showing total body weight loss (TBWL) in response to individualized intervention based on pre-selecting the specific individual patient's obesity analyte signature.
FIG. 14 is a line graph showing TBWL in response to individualized intervention over time.
 DETAILED DESCRIPTION
This document provides methods and materials for assessing and/or treating obesity in mammals (e.g., humans). In some cases, this document provides methods and materials for identifying an obese mammal as being responsive to a pharmacological intervention, and administering one or more pharmacological interventions to treat the mammal. For example, a sample obtained from an obese mammal can be assessed to determine if the obese mammal is likely to be responsive to intervention (e.g., pharmacological intervention, surgical intervention, weight loss device, diet intervention, behavior intervention, and/or microbiome intervention) based, at least in part, on an obesity phenotype, which is based, at least in part, on an obesity analyte signature in the sample. An obesity analyte signature can include the presence, absence, or level (e.g., concentration) of two or more (e.g., three, four, five, six, seven, eight, nine, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more) obesity analytes (e.g., biomarkers associated with obesity). In some cases, an obesity analyte signature can include 14 obesity analytes. For example, a pharmacotherapy responsive obesity analyte signature can be based, at least in part, on the presence, absence, or level of 14 obesity analytes. In some cases, an obesity analyte signature can include 9 obesity analytes. For example, a pharmacotherapy responsive obesity analyte signature can be based, at least in part, on the presence, absence, or level of 9 obesity analytes. In some cases, the methods and materials described herein can be used to predict further weight loss response (e.g., during the course of an obesity treatment). In some cases, the methods and materials described herein can be used to prevent plateaus (e.g., during the course of an obesity treatment). In some cases, the methods and materials described herein can be used to enhance weight loss maintenance (e.g., during the course of an obesity treatment). In some cases, the methods and materials described herein can be used to treat patients unable to lose and maintain weight with diet and exercise alone.
As described herein, a distinct obesity analyte signature can be present in each of six main obesity phenotypes: Group 1) low satiation, Group 2) low satiety (e.g., rapid return to hunger), Group 3) behavioral eating (e.g., as identified by questionnaire), Group 4) large fasting gastric volume, Group 5) mixed, and Group 6) low resting energy expenditure group. Also described herein, the obesity analyte signature in sample obtained from an obese mammal (and thus the obesity phenotype) can be used to predict intervention responsiveness. In some cases, obesity phenotype groups can be simplified as: 1) high energy intake, 2) behavioral/emotional eating, and 3) low energy expenditure; or can be simplified as 1) low satiation (fullness), 2) low satiety (return to hunger), 3) behavioral/emotional eating, 4) low energy expenditure, 5) mixed, and 6) other.
When treating obesity in a mammal (e.g., a human) as described herein, the mammal can also have one or more obesity-related (e.g., weight-related) co-morbidities. Examples of weight-related co-morbidities include, without limitation, hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, gastroesophageal reflux disease, weight baring joint arthritis, cancer, non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, depression, anxiety, and atherosclerosis (coronary artery disease and/or cerebrovascular disease). In some cases, the methods and materials described herein can be used to treat one or more obesity-related co-morbidities.
When treating obesity in a mammal (e.g., a human) as described herein, the treatment can be effective to reduce the weight, reduce the waist circumference, slow or prevent weight gain of the mammal, improve the hemoglobin A1c, and/or improve the fasting glucose. For example, treatment described herein can be effective to reduce the weight (e.g., the total body weight) of an obese mammal by at least 3% (e.g., at least 5%, at least 8%, at least 10%, at least 12%, at least 15%, at least 18%, at least 20%, at least 22%, at least 25%, at least 28%, at least 30%, at least 33%, at least 36%, at least 39%, or at least 40%). For example, treatment described herein can be effective to reduce the weight (e.g., the total body weight) of an obese mammal by from about 3% to about 40% (e.g., from about 3% to about 35%, from about 3% to about 30%, from about 3% to about 25%, from about 3% to about 20%, from about 3% to about 15%, from about 3% to about 10%, from about 3% to about 5%, from about 5% to about 40%, from about 10% to about 40%, from about 15% to about 40%, from about 20% to about 40%, from about 25% to about 40%, from about 35% to about 40%, from about 5% to about 35%, from about 10% to about 30%, from about 15% to about 25%, or from about 18% to about 22%). For example, treatment described herein can be effective to reduce the weight (e.g., the total body weight) of an obese mammal by from about 3 kg to about 100 kg (e.g., about 5 kg to about 100 kg, about 8 kg to about 100 kg, about 10 kg to about 100 kg, about 15 kg to about 100 kg, about 20 kg to about 100 kg, about 30 kg to about 100 kg, about 40 kg to about 100 kg, about 50 kg to about 100 kg, about 60 kg to about 100 kg, about 70 kg to about 100 kg, about 80 kg to about 100 kg, about 90 kg to about 100 kg, about 3 kg to about 90 kg, about 3 kg to about 80 kg, about 3 kg to about 70 kg, about 3 kg to about 60 kg, about 3 kg to about 50 kg, about 3 kg to about 40 kg, about 3 kg to about 30 kg, about 3 kg to about 20 kg, about 3 kg to about 10 kg, about 5 kg to about 90 kg, about 10 kg to about 75 kg, about 15 kg to about 50 kg, about 20 kg to about 40 kg, or about 25 kg to about 30 kg). For example, treatment described herein can be effective to reduce the waist circumference of an obese mammal by from about 1 inches to about 10 inches (e.g., about 1 inches to about 9 inches, about 1 inches to about 8 inches, about 1 inches to about 7 inches, about 1 inches to about 6 inches, about 1 inches to about 5 inches, about 1 inches to about 4 inches, about 1 inches to about 3 inches, about 1 inches to about 2 inches, about 2 inches to about 10 inches, about 3 inches to about 10 inches, about 4 inches to about 10 inches, about 5 inches to about 10 inches, about 6 inches to about 10 inches, about 7 inches to about 10 inches, about 8 inches to about 10 inches, about 9 inches to about 10 inches, about 2 inches to about 9 inches, about 3 inches to about 8 inches, about 4 inches to about 7 inches, or about 5 inches to about 7 inches). In some cases, the methods and materials described herein can be used to improve (e.g., increase or decrease) the hemoglobin A1c of an obese mammal (e.g., an obese mammal having type 2 diabetes mellitus) to from about 0.4% to about 3% (e.g., from about 0.5% to about 3%, from about 1% to about 3%, from about 1.5% to about 3%, from about 2% to about 3%, from about 2.5% to about 3%, from about 0.4% to about 2.5%, from about 0.4% to about 2%, from about 0.4% to about 1.5%, from about 0.4% to about 1%, from about 0.5% to about 2.5%, or from about 1% to about 2%) hemoglobin A1c. In some cases, the methods and materials described herein can be used to improve (e.g., increase or decrease) the fasting glucose of an obese mammal (e.g., an obese mammal having type 2 diabetes mellitus) to from about 10 mg/dl to about 200 mg/dl (e.g., from about 15 mg/dl to about 200 mg/dl, from about 25 mg/dl to about 200 mg/dl, from about 50 mg/di to about 200 mg/dl, from about 75 mg/dl to about 200 mg/dl, from about 100 mg/dl to about 200 mg/dl, from about 125 mg/dl to about 200 mg/dl, from about 150 mg/dl to about 200 mg/dl, from about 175 mg/di to about 200 mg/dl, from about 190 mg/dl to about 200 mg/dl, from about 10 mg/dl to about 175 mg/dl, from about 10 mg/dl to about 150 mg/dl, from about 10 mg/dl to about 125 mg/dl, from about 10 mg/dl to about 100 mg/dl, from about 10 mg/dl to about 75 mg/dl, from about 10 mg/dl to about 50 mg/dl, from about 10 mg/dl to about 25 mg/dl, or from about 10 mg/dl to about 20 mg/dl) glucose.
Any type of mammal can be assessed and/or treated as described herein. Examples of mammals that can be assessed and/or treated as described herein include, without limitation, primates (e.g., humans and monkeys), dogs, cats, horses, cows, pigs, sheep, rabbits, mice, and rats. In some cases, the mammal can a human. In some cases, a mammal can be an obese mammal. For example, obese humans can be assessed for intervention (e.g., a pharmacological intervention) responsiveness, and treated with one or more interventions as described herein. In cases where mammal is a human, the human can be of any race. For example, a human can be Caucasian or Asian.
Any appropriate method can be used to identify a mammal as being overweight (e.g., as being obese). In some cases, calculating body mass index (BMI), measuring waist and/or hip circumference, health history (e.g., weight history, weight-loss efforts, exercise habits, eating patterns, other medical conditions, medications, stress levels, and/or family health history), physical examination (e.g., measuring your height, checking vital signs such as heart rate blood pressure, listening to your heart and lungs, and examining your abdomen), percentage of body fat and distribution, percentage of visceral and organs fat, metabolic syndrome, and/or obesity related comorbidities can be used to identify mammals (e.g., humans) as being obese. For example, a BMI of greater than about 30 kg/m2 can be used to identify mammals (e.g., Caucasian humans) as being obese. For example, a BMI of greater than about 27 kg/m2 with a co-morbidity can be used to identify mammals (e.g., Asian humans) as being obese.
Once identified as being obese, a mammal can be assessed to determine whether or not it is likely to respond to one or more interventions (e.g., pharmacological intervention, surgical intervention, weight loss device, diet intervention, behavior intervention, and/or microbiome intervention). For example, a sample obtained from the mammal can be assessed for pharmacological intervention responsiveness. As described herein, a panel of obesity analytes in a sample obtained from an obese mammal can be used to determine an obesity analyte signature of the mammal, and can be used in to determine an obesity phenotype of the mammal.
Any appropriate sample from a mammal (e.g., a human) having obesity can be assessed as described herein. In some cases, a sample can be a biological sample. In some cases, a sample can contain obesity analytes (e.g., DNA, RNA, proteins, peptides, metabolites, hormones, and/or exogenous compounds (e.g. medications)). Examples of samples that can be assessed as described herein include, without limitation, fluid samples (e.g., blood, serum, plasma, urine, saliva, sweat, or tears), breath samples, cellular samples (e.g., buccal samples), tissue samples (e.g., adipose samples), stool samples, gastro samples, and intestinal mucosa samples. In some cases, a sample (e.g., a blood sample) can be collected while the mammal is fasting (e.g., a fasting sample such as a fasting blood sample). In some cases, a sample can be processed (e.g., to extract and/or isolate obesity analytes). For example, a serum sample can be obtained from an obese mammal and can be assessed to determine if the obese mammal is likely to be responsive to one or more interventions (e.g., pharmacological intervention, surgical intervention, weight loss device, diet intervention, behavior intervention, and/or microbiome intervention) based, at least in part, on an obesity phenotype, which is based, at least in part, on an obesity analyte signature in the sample. For example, a urine sample can be obtained from an obese mammal and can be assessed to determine if the obese mammal is likely to be responsive to pharmacological intervention based, at least in part, on an obesity phenotype, which is based, at least in part, on an obesity analyte signature in the sample.
An obesity analyte signature can include any appropriate analyte. Examples of analytes that can be included in an obesity analyte signature described herein include, without limitation, DNA, RNA, proteins, peptides, metabolites, hormones, and exogenous compounds (e.g. medications). An obesity analyte signature can be evaluated using any appropriate methods. For example, metabolomics, genomics, microbiome, proteomic, peptidomics, and behavioral questionnaires can be used to evaluate and/or identify an obesity analyte signature described herein.
Any appropriate method can be used to identify an obesity phenotype as described herein. In some cases, the obesity phenotype can be identified as described in the Examples. For example, the obesity phenotype can be identified by determining the obesity analyte signature in a sample (e.g., in a sample obtained from an obese mammal). In some cases, the obesity analyte signature can be obtained by detecting the presence, absence, or level of one or more metabolites, detecting the presence, r absence, or level one or more peptides (e.g., gastrointestinal peptides), and/or detecting the presence, absence, or level of one or more single nucleotide polymorphisms (SNPs).
A metabolite can be any metabolite that is associated with obesity. In some cases, a metabolite can be an amino-compound. In some cases, a metabolite can be a neurotransmitter. In some cases, a metabolite can be a fatty acid (e.g., a short chain fatty acid). In some cases, a metabolite can be an amino compound. In some cases, a metabolite can be a bile acid. In some cases, a metabolite can be a compound shown in Table 2. Examples of metabolites that can be used to determine the obesity analyte signature in a sample (e.g., in a sample obtained from an obese mammal) include, without limitation, 1-methylhistine, serotonin, glutamine, gamma-amino-n-butyric-acid, isocaproic, allo-isoleucine, hydroxy-proline, beta-aminoisobutyric-acid, alanine, hexanoic, tyrosine, phenylalanine γ-aminobutyric acid, acetic, histidine, LCA, ghrelin, ADRA2A, cholesterol, glucose, acetylcholine, propionic, CDCA, PYY, ADRA2C, insulin, adenosine, isobutyric, 1-methylhistidine, DCA, CCK, GNB3, glucagon, aspartate, butyric, 3-methylhistidine, UDCA, GLP-1, FTO, leptin, dopamine, valeric, asparagine, HDCA, GLP-2, MC4R, adiponectin, D-serine, isovaleric, phosphoethanolamine, CA, glucagon, TCF7L2, glutamate, hexanoic, arginine, GLCA, oxyntomodulin, 5-HTTLPR, glycine, octanoic, carnosine, GCDCA, neurotensin, HTR2C, myristic, taurine, GDCA, FGF, UCP2, norepinephrine, palmitic, anserine, GUDCA, GIP, UCP3, serotonin, palmitoleic, serine, GHDCA, OXM, GPBAR1, taurine, palmitelaidic, glutamine, GCA, FGF19, NR1H4, stearic, ethanolamine, TLCA, FGF21, FGFR4, oleic, glycine, TCDCA, LDL, elaidic, aspartic acid, TDCA, insulin, GLP-1, linoleic, sarcosine, TUDCA, glucagon, CCK, a-linolenic, proline, THDCA, amylin, arachidonic, alpha-aminoadipic-acid, TCA, pancreatic polypeptide, eicosapentaenoic, DHCA, neurotensin, docosahexaenoic, alpha-amino-N-butyric-acid, THCA, ornithine, GLP-1 receptor, triglycerides, cystathionine 1, GOAT, cystine, DPP4, lysine, methionine, valine, isoleucine, leucine, homocystine, tryptophan, citrulline, glutamic acid, beta-alanine, threonine, hydroxylysine 1, acetone, and acetoacetic acid. In some cases, an obesity analyte signature can include 1-methylhistine, serotonin, glutamine, gamma-amino-n-butyric-acid, isocaproic, allo-isoleucine, hydroxyproline, beta-aminoisobutyric-acid, alanine, hexanoic, tyrosine, and phenylalanine.
A gastrointestinal peptide can be any gastrointestinal peptide that is associated with obesity. In some cases, a gastrointestinal peptide can be a peptide hormone. In some cases, a gastrointestinal peptide can be released from gastrointestinal cells in response to feeding. In some cases, a gastrointestinal peptide can be a peptide shown in Table 2. Examples of gastrointestinal peptides that can be used to determine the obesity analyte signature in a sample (e.g., in a sample obtained from an obese mammal) include, without limitation, ghrelin, peptide tyrosine tyrosine (PYY), cholecystokinin (CCK), glucagon-like peptide-1 (GLP-1), GLP-2, glucagon, oxyntomodulin, neurotensin, fibroblast growth factor (FGF), GIP, OXM, FGF19, FGF19, and pancreatic polypeptide.
A SNP can be any SNP that is associate with obesity. A SNP can be in a coding sequence (e.g., in a gene) or a non-coding sequence. For example, in cases where a SNP is in a coding sequence, the coding sequence can be any appropriate coding sequence. In some cases, a coding sequence that can include a SNP associated with obesity can be a gene shown in Table 2. Examples of coding sequences that a SNP associated with obesity can be in or near include, without limitation, ADRA2A, ADRA2C, GNB3, FTO, MC4R, TCF7L2, 5-HTTLPR, HTR2C, UCP2, UCP3, GPBAR1, NR1H4, FGFR4, PYY, GLP-1, CCK, leptin, adiponectin, neurotensin, ghrelin, GLP-1 receptor, GOAT, DPP4, POMC, NPY, AGRP, SERT, BDNF, SLC6A4, DRD2, LEP, LEPR, UCP1, KLF14, NPC1, LYPLAL1, ADRB2, ADRB3, BBS1, ACSL6, ADARB2, ADCY8, ADH1B, AJAP1, ATP2C2, ATP6V0D2, C21orf7, CAMKMT, CAP2, CASC4, CD48, CDC42SE2, CDYL, CES5AP1, CLMN, CNPY4, COL19A1, COL27A1, COL4A3, CORO1C, CPZ, CTIF, DAAM2, DCHS2, DOCK8, EGFLAM, FAM125B, FAM71E2, FRMD3, GALNTL4, GLT1D1, HHAT, KRT23, LHPP, L1NC00578, LINC00620, LIPC, LOC100128714, LOC100287160, LOC 100289473, LOC100293612|LINC00620, LOC100506869, LOC100507053, LOC100507053|ADH1A, LOC100507053|ADH, LOC100507443, LOC1009965711|CYYR1, LOC152225, LOC255130, LPAR1, LUZP2, MCM7, MICAL3, MMS19, MYBPC1, NR2F2-AS1, NSMCE2, NTN1, O3FAR1, OAZ2, OSBP2, P4HA2, PADI1, PARD3B, PARK2, PCDH15, PIEZO2, PKIB, PRH1-PRR4, PTPRD, RALGPS1|ANGPTL2, RPS24P10, RTN4RL1, RYR2, SCN2A, SEMA3C, SEMA5A, SFMBT2, SGCG, SLC22A15, SLC2A2, SLCO1B1, SMOC2, SNCAIP, SNX18, SRRM4, SUSD1, TBC1D16, TCERG1L, TENM3, TJP3, TLL1, TMEM9B, TPM1, VTI1A, VWF, WWOX, WWTR1, ZFYVE28, ZNF3, ZNF609, and ZSCAN21. In some cases, a SNP can be a SNP shown in Table 3. Examples of SNPS that can be used to determine the obesity analyte signature in a sample (e.g., in a sample obtained from an obese mammal) include, without limitation, rs657452, rs11583200, rs2820292, rs11126666, rs11688816, rs1528435, rs7599312, rs6804842, rs2365389, rs3849570, rs16851483, rs17001654, rs11727676, rs2033529, rs9400239, rs13191362, rs1167827, rs2245368, rs2033732, rs4740619, rs6477694, rs1928295, rs10733682, rs7899106, rs17094222, rs11191560, rs7903146, rs2176598, rs12286929, rs11057405, rs10132280, rs12885454, rs3736485, rs758747, rs2650492, rs9925964, rs1000940, rs1808579, rs7243357, rs17724992, rs977747, rs1460676, rs17203016, rs13201877, rs1441264, rs7164727, rs2080454, rs9914578, rs2836754, rs492400, rs16907751, rs9374842, rs9641123, rs9540493, rs4787491, rs6465468, rs7239883, rs3101336, rs12566985, rs12401738, rs11165643, rs17024393, rs543874, rs13021737, rs10182181, rs1016287, rs2121279, rs13078960, rs1516725, rs10938397, rs13107325, rs2112347, rs205262, rs2207139, rs17405819, rs10968576, rs4256980, rs11030104, rs3817334, rs7138803, rs12016871, rs12429545, rs11847697, rs7141420, rs16951275, rs12446632, rs3888190, rs1558902, rs12940622, rs6567160, rs29941, rs2075650, rs2287019, rs3810291, rs7715256, rs2176040, rs6091540, rs1800544, Ins-Del-322, rs5443, rs1129649, rs1047776, rs9939609, rs17782313, rs7903146, rs4795541, rs3813929, rs518147, rs1414334, rs659366, -3474, rs2075577, rs15763, rs1626521, rs11554825, rs4764980, rs434434, rs351855, and rs2234888.
An obesity analyte signature described herein can include any appropriate combination of analytes. For example, when an obesity analyte signature includes 14 analytes, the analytes can include 1-methylhistine, serotonin, glutamine, gamma-amino-n-butyric-acid, isocaproic, allo-isoleucine, hydroxyproline, beta-aminoisobutyric-acid, alanine, hexanoic, tyrosine, phenylalanine, ghrelin, and PYY. For example, when an obesity analyte signature includes 9 analytes, the analytes can include HTR2C, GNB3, FTO, isocaproic, beta-aminoisobutyric-acid, butyric, allo-isoleucine, tryptophan, and glutamine.
Any appropriate method can be used to detect the presence, absence, or level of an obesity analyte within a sample. For example, mass spectrometry (e.g., triple-stage quadrupole mass spectrometry coupled with ultra-performance liquid chromatography (UPLC)), radioimmuno assays, and enzyme-linked immunosorbent assays can be used to determine the presence, absence, or level of one or more analyte in a sample.
In some cases, identifying the obesity phenotype can include obtaining results from all or part of one or more questionnaires. A questionnaire can be associated with obesity. In some cases, a questionnaire can be answered the time of the assessment. In some cases, a questionnaire can be answered prior to the time of assessment. For example, when a questionnaire is answered prior to the time of the assessment, the questionnaire results can be obtained by reviewing a patient history (e.g., a medical chart). A questionnaire can be a behavioral questionnaire (e.g., psychological welfare questionnaires, alcohol use questionnaires, eating behavior questionnaires, body image questionnaires, physical activity level questionnaire, and weight management questionnaires. Examples of questionnaires that can be used to determine the obesity phenotype of a mammal (e.g., an obese mammal) include, without limitation, The Hospital Anxiety and Depression Scale (HADS) questionnaire, The Hospital Anxiety and Depression Inventory questionnaire, The Questionnaire on Eating and Weight Patterns, The Weight Efficacy Life-Style (WEL) Questionnaire, The Multidimensional Body-Self Relations Questionnaire, The Questionnaire on Eating and Weight Patterns-Revised, The Weight Efficacy Life-Style, Physical Activity Level-item Physical Activity Stages of Change Questionnaire, The Exercise Regulations Questionnaire (BREQ-3), Barriers to Being Active Quiz, and The Three Factor Eating Questionnaire (TFEQ). For example, a questionnaire can be a HADS questionnaire. For example, a questionnaire can be a TFEQ.
In some cases, an obesity analyte signature can include the presence of serotonin, glutamine, isocaproic, allo-isoleucine, hydroxyproline, beta-aminoisobutyric-acid, alanine, hexanoic, tyrosine, and PYY. For example, an obesity phenotype Group 1 can have an obesity analyte signature that includes the presence of serotonin, glutamine, isocaproic, allo-isoleucine, hydroxyproline, beta-aminoisobutyric-acid, alanine, hexanoic, tyrosine, and PYY. For example, an obesity phenotype Group 1 can have an obesity analyte signature that has an absence of (e.g., lacks the presence of) 1-methylhistine, gamma-amino-n-butyric-acid, phenylalanine, ghrelin, and includes a HADS questionnaire result that does not indicate an anxiety subscale (HADS-A; e.g., includes a HADS-A questionnaire result).
In some cases, an obesity analyte signature can include the presence of 1-methylhistine, allo-isoleucine, hydroxyproline, beta-aminoisobutyric-acid, alanine, and phenylalanine. For example, an obesity phenotype Group 2 can have an obesity analyte signature that includes the presence of -methylhistine, allo-isoleucine, hydroxyproline, beta-aminoisobutyric-acid, alanine, and phenylalanine. For example, an obesity phenotype Group 2 can have an obesity analyte signature that has an absence of (e.g., lacks the presence of) serotonin, glutamine, gamma-amino-n-butyric-acid, isocaproic, hexanoic, tyrosine, ghrelin, PYY, and does not include a HADS questionnaire result that indicates an anxiety subscale (e.g., does not include a HADS-A questionnaire result)
In some cases, an obesity analyte signature can include the presence of serotonin, and can include a HADS-A questionnaire. For example, an obesity phenotype Group 3 can have an obesity analyte signature that includes serotonin and includes a HADS-A questionnaire result. For example, an obesity phenotype Group 3 can have an obesity analyte signature that has an absence of (e.g., lacks the presence of) 1-methylhistine, glutamine, gamma-amino-n-butyric-acid, isocaproic, allo-isoleucine, hydroxyproline, beta-aminoisobutyric-acid, alanine, hexanoic, tyrosine, phenylalanine, ghrelin, and PYY.
In some cases, an obesity analyte signature can include the presence of 1-methylhistine, glutamine, gamma-amino-n-butyric-acid, isocaproic, allo-isoleucine, beta-aminoisobutyric-acid, alanine, hexanoic, tyrosine, phenylalanine, PYY, and includes a HADS-A questionnaire result. For example, an obesity phenotype Group 4 can have an obesity analyte signature that includes 1-methylhistine, glutamine, gamma-amino-n-butyric-acid, isocaproic, allo-isoleucine, beta-aminoisobutyric-acid, alanine, hexanoic, tyrosine, phenylalanine, PYY, and includes a HADS-A questionnaire result. For example, an obesity phenotype Group 4 can have an obesity analyte signature that has an absence of (e.g., lacks the presence of) serotonin, hydroxyproline, and ghrelin.
In some cases, an obesity analyte signature can include the presence of serotonin, beta-aminoisobutyric-acid, alanine, hexanoic, phenylalanine, and includes a HADS-A questionnaire. For example, an obesity phenotype Group 5 can have an obesity analyte signature that includes the presence of serotonin, beta-aminoisobutyric-acid, alanine, hexanoic, phenylalanine, and includes a HADS-A questionnaire result. For example, an obesity phenotype Group 5 can have an obesity analyte signature that has an absence of (e.g., lacks the presence of) 1-methylhistine, glutamine, gamma-amino-n-butyric-acid, isocaproic, allo-isoleucine, and hydroxyproline.
In some cases, an obesity analyte signature can include the presence of 1-methylhistine, serotonin, glutamine, gamma-amino-n-butyric-acid, isocaproic, allo-isoleucine, alanine, tyrosine, ghrelin, PYY, and includes a HADS-A questionnaire result. For example, an obesity phenotype Group 6 can have an obesity analyte signature that includes the presence of 1-methylhistine, serotonin, glutamine, gamma-amino-n-butyric-acid, isocaproic, allo-isoleucine, alanine, tyrosine, ghrelin, PYY, and includes a HADS-A questionnaire result. For example, an obesity phenotype Group 6 can have an obesity analyte signature that has an absence of (e.g., lacks the presence of) hydroxyproline, beta-aminoisobutyric-acid, hexanoic, and phenylalanine.
In some cases, identifying the obesity phenotype also can include identifying one or more additional variables and/or one or more additional assessments. For example, identifying the obesity phenotype also can include assessing the microbiome of a mammal (e.g., an obese mammal). For example, identifying the obesity phenotype also can include assessing leptin levels. For example, identifying the obesity phenotype also can include assessing the metabolome of a mammal (e.g., an obese mammal). For example, identifying the obesity phenotype also can include assessing the genome of a mammal (e.g., an obese mammal). For example, identifying the obesity phenotype also can include assessing the proteome of a mammal (e.g., an obese mammal). For example, identifying the obesity phenotype also can include assessing the peptidome of a mammal (e.g., an obese mammal).
Once the obesity phenotype of the mammal has been identified, the mammal can be assessed to determine intervention (e.g., pharmacological intervention, surgical intervention, weight loss device, diet intervention, behavior intervention, and/or microbiome intervention) responsiveness, and a treatment option for the mammal can be selected. In some cases, the obesity phenotype of a mammal can be used to select a treatment options as shown in FIG. 12 , and as set forth in Table 1.
TABLE 1
Treatment options.
Obesity Phenotype Group Pharmacotherapy Exemplary Intervention
Pharmacotherapy Intervention: FDA approved medications
1: Iow satiation appetite suppressant in combination phentermine-topiramate
with an anticonvusIant
appetite suppressant Iorcaserin, desvenIafaxine
2: Iow satiety GLP-1 anaIog, GLP-1 receptor IiragIutide, exenatide, metformin,
agonist, amyIin anaIogs pramIitide
3: behavioraI eating antidepressant in combination with naItrexone-bupropion
an opioid antagonist
4: Iargc fasting gastric antidcprcssant in combination with naItrcxonc-bupropion
voIume an opioid antagonist
5: mixed combination based on the
combination of phenotypes
6: Iow resting energy appetite suppressant in combination phentermine + increased physicaI
cxpcnditurc with physicaI activity activity
Pharmacotherapy Intervention: medications not-FDA approved
1: Iow satiation meIanocortin receptor MK-0493
RM-493
appetite suppressants
CCK anaIogs
2: Iow satiety GLP-1 anaIog - GLP-1 receptor semagIutide,
agonists - GLP-1/gIucagon veInerperit (s-2367)
coagonists obinepitide
PYY anaIogs - Y receptors Conjugated biIe acids
agonists/antagonists
OxyntomoduIin anaIogs
GhreIin antagonists
TGR5 agonists
FGF-19/21 anaIogs
FXR agonists
GRP-119
GRP-120
Combinations of these meds
3: bchavioraI cating antidcprcssant bupropion + zonisamidc
opioid antagonist Tesofensine
anti-anxiety Buspirone
cannabionids antagonists rimonabant
4: Iargc fasting gastric ghrcIin antagonist
voIume
5: mixed combination based on the
combination of phenotypes
6: Iow resting energy Ieptin moduIators metroIeptin
expenditure MetAP2 inhibitors ZGN-1061, beIoranib
B3 agonists mirabegron
Weight Loss Devices
Obesity Phenotype Group Surgical procedure and devices Exemplary Intervention
1: Iow satiation vagaI stimuIant V-bIoc
mouth occupying devices Retrograde gastric pacing
intra-gastric space occupying Smartbyte ™
devices gastric baIIoon
sIeeve gastropIasty
2: Iow satiety duodenaI bypass or mucosaI Endobarrier
resurfacing (exampIe: abIation) gastric baIIoon
intra-gastric space occupying transpyIoric shuttIe
devices
maIabsorptive procedures
3: behavioraI eating gastric emptying devices Aspire assist
4: Iargc fasting gastric gastric cmptying dcviccs Aspirc assist
voIume intra-gastric space occupying gastric baIIoon
devices
sIeeve gastropIasty
5: mixed combination based on the
combination of phcnotypcs
6: Iow resting energy phentermine + increased physicaI
expenditure activity
1: Iow satiation Gastric occupying space TransoraI endoscopic restrictive
Brain stimuIant impIant system
deep transcraniaI magnetic
stimuIation
2: Iow satiety DuodenaI bypass or mucosaI FractyI - duodenaI abIation
rcsurfacing (cxampIc: abIation) Intragastric baIIoons - adjustabIe
Intra-gastric space occupying Magnet therapy (Incision-Iess
devices Anastomosis System)
MaIabsorptive procedures
3: behavioraI eating
4: Iarge fasting gastric Intra-gastric space occupying Intragastric baIIoons - adjustabIe
voIume devices POSE
Gastric pIications
5: mixed combination based on the
combination of phenotypes
6: Iow resting energy MuscIe stimuIants PuIse muscIe stimuIator
expenditure Energy trackers CoId vests
CoId inducers (stimuIates BAT)
Diet Intervention
Obesity Phenotype Group Diet Exemplary Intervention
1: Iow satiation SIow eating Legnmes, fruits, beans, whoIe grains
voIumetric diet Atkins diet
high fat - high protein - Iow carb Keto diet
2: Iow saticty High protcin - Iow carb - avcragc PaIco-dict
fat Mediterranean diet
3: behavioraI eating ScheduIe 2-3 meaIs daiIy. No snacks Crash diet
4: Iarge fasting gastric High soIubIe fiber Fiber suppIements,
voIume
5: mixed
6: Iow rcsting cncrgy Low fat - Avcragc protcin, avcragc 13-day MctaboIism dict
expenditure carbs
SurgicaI Intervention
Obesity Phenotype Group Surgical procedure Exemplary Intervention
1: Iow satiation Restrictive procedures SIeeve
RYGB
Lap-band
2: Iow satiety MaIabsorptive procedures RYGB - SIeeve pIus duodenaI
switch
3: behavioraI eating
4: Iarge fasting gastric Restrictive procedures SIeeve
voIume RYGB
5: mixed
6: Iow resting energy MaIabsorptive procedures RYGB - duodenaI switch
expenditure
Microbiome Intervention
Obesity Phenotype Group Microbiome status Exemplary Intervention
1: Iow satiation Microbiota inflammatory inducing Reduce microbiome LPS induction
2: Iow satiety Low microbiome richness Increase richness of microbiota
(probiotic mix) to increase SCFA in
GI Iumen
3: behavioraI eating Serotonin producing bacteria Reduced serotonin producing
bacteria: restore Bacteroides spp
4: Iarge fasting gastric Low microbiome richness Increase primary BA microbiota
voIume
5: mixed
6: Iow resting energy Low fatty acids producing bacteria Increase fatty acid metaboIism
expenditure producing bacteria
Individualized pharmacological interventions for the treatment of obesity (e.g., based on the obesity phenotypes as described herein) can include any one or more (e.g., 1, 2, 3, 4, 5, 6, or more) pharmacotherapies (e.g., individualized pharmacotherapies). A pharmacotherapy can include any appropriate pharmacotherapy. In some cases, a pharmacotherapy can be an obesity pharmacotherapy. In some cases, a pharmacotherapy can be an appetite suppressant. In some cases, a pharmacotherapy can be an anticonvulsant. In some cases, a pharmacotherapy can be a GLP-1 agonist. In some cases, a pharmacotherapy can be an antidepressant. In some cases, a pharmacotherapy can be an opioid antagonist. In some cases, a pharmacotherapy can be a controlled release pharmacotherapy. For example, a controlled release pharmacotherapy can be an extended release (ER) and/or a slow release (SR) pharmacotherapy. In some cases, a pharmacotherapy can be a lipase inhibitor. In some cases, a pharmacotherapy can be a DPP4 inhibitor. In some cases, a pharmacotherapy can be a SGLT2 inhibitor. In some cases, a pharmacotherapy can be a dietary supplement. Examples of pharmacotherapies that can be used in an individualized pharmacological intervention as described herein include, without limitation, orlistat, phentermine, topiramate, lorcaserin, naltrexone, bupropion, liraglutide, exenatide, metformin, pramlitide, Januvia, canagliflozin, dexamphetamines, prebiotics, probiotics, Ginkgo biloba, and combinations thereof. For example, combination pharmacological interventions for the treatment of obesity (e.g., based on the obesity phenotypes as described herein) can include phentermine-topiramate ER, naltrexone-bupropion SR, phentermine-lorcaserin, lorcaserin-liraglutide, and lorcarserin-januvia. A pharmacotherapy can be administered using any appropriate methods. In some cases, pharmacotherapy can be administered by continuous pump, slow release implant, intra-nasal administered, intra-oral administered, and/or topical administered. In some cases, a pharmacotherapy can be administered as described elsewhere (see, e.g., Sjostrom et al., 1998 Lancet 352:167-72; Hollander et al., 1998 Diabetes Care 21:1288-94; Davidson et al., 1999 JAMA 281:235-42; Gadde et al., 2011 Lancet 377:1341-52; Smith et al., 2010 New Engl. J. Med. 363:245-256; Apovian et al., 2013 Obesity 21:935-43; Pi-Sunyer et al., 2015 New Engl. J. Med. 373:11-22; and Acosta et al., 2015 Clin Gastroenterol Hepatol. 13:2312-9).
Once a mammal is identified as being responsive to one or more interventions (e.g., pharmacological intervention, surgical intervention, weight loss device, diet intervention, behavior intervention, and/or microbiome intervention) based, at least in part, on an obesity phenotype, which is based, at least in part, on an obesity analyte signature in the sample, the mammal can be administered or instructed to self-administer one or more individualized pharmacotherapies.
When a mammal is identified as having an obesity phenotype that is responsive to treatment with one or more pharmacotherapies, the mammal can be administered or instructed to self-administer one or more pharmacotherapies. For example, when a mammal is identified as having a low satiation (Group 1) phenotype, based, at least in part, on an obesity analyte signature, the mammal can be administered or instructed to self-administer phentermine-topiramate (e.g., phentermine-topiramate ER) to treat the obesity. For example, when a mammal is identified as having a low satiation (Group 1) phenotype, based, at least in part, on an obesity analyte signature, the mammal can be administered or instructed to self-administer lorcaserin to treat the obesity. For example, when a mammal is identified as having a low satiety (Group 2) phenotype, based, at least in part, on an obesity analyte signature, the mammal can be administered or instructed to self-administer liraglutide to treat the obesity. For example, when a mammal is identified as having a behavioral eating (Group 3) phenotype, based, at least in part, on an obesity analyte signature, the mammal can be administered or instructed to self-administer naltrexone-bupropion (e.g., naltrexone-bupropion SR) to treat the obesity. For example, when a mammal is identified as having a large fasting gastric volume (Group 4) phenotype, based, at least in part, on an obesity analyte signature, the mammal can be administered or instructed to self-administer naltrexone-bupropion (e.g., naltrexone-bupropion SR) to treat the obesity. For example, when a mammal is identified as having a low resting energy expenditure (Group 6) phenotype, based, at least in part, on an obesity analyte signature, the mammal can be administered or instructed to self-administer phentermine, and can be instructed to increase physical activity to treat the obesity.
In some cases, one or more pharmacotherapies described herein can be administered to an obese mammal as a combination therapy with one or more additional agents/therapies used to treat obesity. For example, a combination therapy used to treat an obese mammal (e.g., an obese human) can include administering to the mammal one or more pharmacotherapies described herein and one or more obesity treatments such as weight-loss surgeries (e.g., gastric bypass surgery, laparoscopic adjustable gastric banding (LAGB), biliopancreatic diversion with duodenal switch, and a gastric sleeve), vagal nerve blockade, endoscopic devices (e.g. intragastric balloons or endoliners, magnets), endoscopic sleeve gastroplasty, and/or gastric or duodenal ablations. For example, a combination therapy used to treat an obese mammal (e.g., an obese human) can include administering to the mammal one or more pharmacotherapies described herein and one or more obesity therapies such as exercise modifications (e.g., increased physical activity), dietary modifications (e.g., reduced-calorie diet), behavioral modifications, commercial weight loss programs, wellness programs, and/or wellness devices (e.g. dietary tracking devices and/or physical activity tracking devices). In cases where one or more pharmacotherapies described herein are used in combination with one or more additional agents/therapies used to treat obesity, the one or more additional agents/therapies used to treat obesity can be administered/performed at the same time or independently. For example, the one or more pharmacotherapies described herein can be administered first, and the one or more additional agents/therapies used to treat obesity can be administered/performed second, or vice versa.
This document provides methods and materials for identifying one or more analytes associated with obesity. In some cases, analytes associated with obesity can be used in an obesity analyte signature as described herein. For example, one or more analytes associated with obesity can be identified by using a combined logit regression model. In some cases, a combined logit regression model can include stepwise variable selection (e.g., to identify variables significantly associated with a specific obesity phenotype). For example, one or more analytes associated with obesity can be identified as described in, for example, the Examples section provided herein.
The invention will be further described in the following examples, which do not limit the scope of the invention described in the claims.
EXAMPLES Example 1: Identification of Obesity Biomarkers
Obesity phenotypes were associated with higher BMI, distinguish obesity phenotypes, and can be used to predict responsiveness to obesity pharmacotherapy and endoscopic devices (see, e.g., Acosta et al., 2015 Gastroenterology 148:537-546). In this study, biomarkers specific to each obesity phenotype were identified using metabolomics.
The overall cohort demographics [median (IQR)] were age 36 (28-46) years, BMI 35 (32-38) kg/m2, 75% females, 100% Caucasians. The groups based on phenotype > or <75% ile were not statistically different for body weight, waist circumference, hip circumference, fasting glucose. The group distribution in this cohort was: abnormal satiation (16%), abnormal satiety (16%), abnormal hedonic/psych (19%), slow metabolism/energy expenditure (32%), and mixed group (17%) (FIG. 1A). FIGS. 1B-E illustrate summarize characteristics of the quantitative changes in the subgroups: the satiation group consumed 591 (60%) more calories prior to reaching fullness; the satiety group emptied half of the solid 300 kcal meal 34 min (30%) faster; the hedonic group reported 2.8 times higher levels of anxiety; the slow metabolism group has 10% decreased predicted resting energy expenditure than other groups. These average differences were in comparison to the other groups, but excluding the group with participants with a mixed or overlapping phenotype.
Gastrointestinal Traits (Phenotypes) Associated with Obesity
Gastrointestinal functions, satiation, and satiety were characterized in 509 participants across the normal weight to obesity spectrum. Obesity was associated with decreased satiation (higher caloric intake before feeling full, measure by volume to fullness [VTF] p=0.038), large fasting gastric volume (GV, p=0.03), accelerated gastric emptying (GE) T1/2 (solids: p<0.001; liquids: p=0.011), and lower postprandial peak plasma levels of PYY (p=0.003). In addition, principal components (PC) analysis identified latent dimensions (LDs) accounting for −81% of OW-OB variation and sub-classifies obesity in satiation (21%), gastric capacity (15%), behavioral (13%), gastric sensorimotor (11%) factors, GLP-1 levels (9%), and others (31%) (Acosta et al., 2015 Gastroenterology 148:537-546).
Identification of Biomarkers
An analysis of 102 patients with obesity, matched for gender, age and BMI was done. These individuals were non-diabetic and were in not medications for weight loss. Based on the profile of each patient we were able to validate the main groups in obesity in 1) low satiation, 2) rapid return to hunger, 3) behavioral eating (identified by questionnaire), 4) large fasting gastric volume, 5) mixed, and 6) low resting energy expenditure group.
A combined logit regression model using stepwise variable selection was created to identify variables that are significantly associated with each of the phenotypic classes. Untargeted metabolomics identified unique metabolites in each group (FIG. 2A). Each of these metabolites is independent from the other groups (FIG. 2B). From these metabolites, a “VIP” (variable of importance) was identified for each group. Then, a targeted metabolomics was done with the VIP as well as neurotransmitters, amino compounds, fatty acids, and short chain fatty acids. Examples variables are as shown in Tables 2-5. For example, targeted metabolites, peptides, and SNPS analyzed are as shown in Table 2, other obesity related gene variants are as shown in in Table 3, targeted peptides are as shown in in Table 4, and targeted genes are as shown in in Table 5.
TABLE 2
Analytes Examined using SNPs, Hormones, Peptides and Targeted Metabolomics.
Fatty SNP-
Neuro- acids and Amino Bile containing
transmitters Lipid Compounds acids Peptides Genes Hormones carbohydrates
γ-aminobutyric acetic Histidine LCA ghreIin ADRA2A cholesterol glucose
acid
AcetyIchoIine propionic HydroxyproIine CDCA PYY ADRA2C insulin
Adenosine isobutyric 1-MethyIhistidine DCA CCK GNB3 glucagon
aspartate butyric 3-MethyIhistidine UDCA GLP-1 FTO leptin
Dopamine vaIeric Asparagine HDCA GLP-2 MC4R adiponectin
D-serine isovaIeric PhosphoethanoIamine CA gIucagon TCF7L2
GIutamate hexanoic Arginine GLCA oxyntomoduIin 5-HTTLPR
GIycine octanoic Carnosine GCDCA neurotensin HTR2C
Histidine myristic Taurine GDCA FGF UCP2
Norepinephrine paImitic Anserine GUDCA GIP UCP3
Serotonin paImitoleic Serine GHDCA OXM GPBAR1
Taurine paImiteIaidic GIutamine GCA FGF19 NR1H4
stearic EthanoIamine TLCA FGF21 FGFR4
oIeic GIycine TCDCA LDL PYY
eIaidic Aspartic Acid TDCA insuIin GLP-1
IinoIeic Sarcosine TUDCA glucagon CCK
a-IinoIenic ProIine THDCA amylin Leptin
arachidonic aIpha- TCA pancreatic Adiponectin
Aminoadipic- polypeptide
acid
eicosapentaenoic beta- DHCA leptin Neurotensin
Aminoisobutyric-
acid
docosahexaenoic alpha-Amino- THCA adiponectin GhreIin
N-butyric-acid
LDL Ornithine GLP-1
receptor
triglycerides Cystathionine 1 GOAT
Cystine DPP4
Lysine
Tyrosine
Methionine
VaIine
IsoIeucine
Leucine
Homocystine
PhenyIaIanine
Tryptophan
CitruIIine
GIutamic Acid
beta-AIanine
Threonine
Alanine
HydroxyIysine 1
Acetone
Acetoacetic
Acid
TABLE 3
SNPs associated with obesity [Is this title accurate?[
SNP Chr. Position (bp) Nearest Genes
rs657452 1 49,362,434 AGBL4
rs11583200 1 50,332,407 ELAVL4
rs2820292 1 200,050,910 NAV1
rs11126666 2 26,782,315 KCNK3
rs11688816 2 62,906,552 EHBP1
rs1528435 2 181,259,207 UBE2E3
rs7599312 2 213,121,476 ERBB4
rs6804842 3 25,081,441 RARB
rs2365389 3 61,211,502 FHIT
rs3849570 3 81,874,802 GBE1
rs16851483 3 142,758,126 RASA2
rs17001654 4 77,348,592 SCARB2
rs11727676 4 145,878,514 HHIP
rs2033529 6 40,456,631 TDRG1
rs9400239 6 109,084,356 FOXO3
rs13191362 6 162,953,340 PARK2
rs1167827 7 75,001,105 HIP1
rs2245368 7 76,446,079 DTX2P1
rs2033732 8 85,242,264 RALYL
rs4740619 9 15,624,326 C9orf93
rs6477694 9 110,972,163 EPB41L4B
rs1928295 9 119,418,304 TLR4
rs10733682 9 128,500,735 LMX1B
rs7899106 10 87,400,884 GRID1
rs17094222 10 102,385,430 HIF1AN
rs11191560 10 104,859,028 NT5C2
rs7903146 10 114,748,339 TCF7L2
rs2176598 11 43,820,854 HSD17B12
rs12286929 11 114,527,614 CADM1
rs11057405 12 121,347,850 CLIP1
rs10132280 14 24,998,019 STXBP6
rs12885454 14 28,806,589 PRKD1
rs3736485 15 49,535,902 DMXL2
rs758747 16 3,567,359 NLRC3
rs2650492 16 28,240,912 SBK1
rs9925964 16 31,037,396 KAT8
rs1000940 17 5,223,976 RABEP1
rs1808579 18 19,358,886 C18orf8
rs7243357 18 55,034,299 GRP
rs17724992 19 18,315,825 PGPEP1
rs977747 1 47,457,264 TAL1
rs1460676 2 164,275,935 FIGN
rs17203016 2 207,963,763 CREB1
rs13201877 6 137,717,234 IFNGR1
rs1441264 13 78,478,920 MIR548A2
rs7164727 15 70,881,044 LOC100287559
rs2080454 16 47,620,091 CBLN1
rs9914578 17 1,951,886 SMG6
rs2836754 21 39,213,610 ETS2
rs492400 2 219,057,996 USP37
rs16907751 8 81,538,012 ZBTB10
rs9374842 6 120,227,364 LOC285762
rs9641123 7 93,035,668 CALCR
rs9540493 13 65,103,705 MIR548X2
rs4787491 16 29,922,838 INO80E
rs6465468 7 95,007,450 ASB4
rs7239883 18 38,401,669 LOC284260
rs3101336 1 72,523,773 NEGR1
rs12566985 1 74,774,781 FPGT
rs12401738 1 78,219,349 FUBP1
rs11165643 1 96,696,685 PTBP2
rs17024393 1 109,956,211 GNAT2
rs543874 1 176,156,103 SEC16B
rs13021737 2 622,348 TMEM18
rs10182181 2 25,003,800 ADCY3
rs1016287 2 59,159,129 LINC01122
rs2121279 2 142,759,755 LRP1B
rs13078960 3 85,890,280 CADM2
rs1516725 3 187,306,698 ETV5
rs10938397 4 44,877,284 GNPDA2
rs13107325 4 103,407,732 SLC39A8
rs2112347 5 75,050,998 POC5
rs205262 6 34,671,142 C6orf106
rs2207139 6 50,953,449 TFAP2B
rs17405819 8 76,969,139 HNF4G
rs10968576 9 28,404,339 LINGO2
rs4256980 11 8,630,515 TRIM66
rs11030104 11 27,641,093 BDNF
rs3817334 11 47,607,569 MTCH2
rs7138803 12 48,533,735 BCDIN3D
rs12016871 13 26,915,782 MTIF3
rs12429545 13 53,000,207 OLFM4
rs11847697 14 29,584,863 PRKD1
rs7141420 14 78,969,207 NRXN3
rs16951275 15 65,864,222 MAP2K5
rs12446632 16 19,842,890 GPRC5B
rs3888190 16 28,796,987 ATP2A1
rs1558902 16 52,361,075 FTO
rs12940622 17 76,230,166 RPTOR
rs6567160 18 55,980,115 MC4R
rs29941 19 39,001,372 KCTD15
rs2075650 19 50,087,459 TOMM40
rs2287019 19 50,894,012 QPCTL
rs3810291 19 52,260,843 ZC3H4
rs7715256 5 153,518,086 GALNT10
rs2176040 2 226,801,046 LOC646736
rs6091540 20 50,521,269 ZFP64
SNP Chr. Position (bp) Genes
rs1800544 ADRA2A
Ins-Del-322 ADRA2C
rs5443 GNB3
rs1129649 GNB3
rs1047776 GNB3
rs9939609 FTO
rs17782313 MC4R
rs7903146 TCF7L2
rs4795541 5-HTTLPR
rs3813929 HTR2C
rs518147 HTR2C
rs1414334 HTR2C
rs659366 UCP2
−3474, UCP2
rs2075577 UCP3
rs15763 UCP3
rs1626521 UCP3
rs11554825 GPBAR1
rs4764980 NR1H4
rs434434 FGFR4
rs351855 FGFR4
RSID Gene_Symbol
exm2261885 .
exm2264702 .
kgp10003923 .
kgp10360658 .
kgp10374580 .
kgp1093561 .
kgp11089754 .
kgp11154375 .
kgp11564777 .
kgp11808957 .
kgp11836456 .
kgp11902597 .
SNP Chr. Position (bp) Nearest Genes
kgp12031075 z z .
kgp12088423 .
kgp1283935 .
kgp1287405 .
kgp129784 .
kgp1371036 .
kgp1419661 .
kgp1612367 .
kgp16387096 .
kgp16914214 .
kgp2241756 .
kgp2251945 .
kgp238191 .
kgp2727759 .
kgp2735253 .
kgp2925720 .
kgp3186084 .
kgp3371090 .
kgp3712407 .
kgp3846165 .
kgp3847753 .
kgp429141 .
kgp4433253 .
kgp447667 .
kgp4725781 .
kgp5201059 .
kgp5201171 .
kgp5269120 .
kgp5471252 .
kgp5829795 .
kgp599811 .
kgp6037240 .
kgp6508014 .
kgp6615769 .
kgp6816777 .
kgp7069937 .
kgp7157564 .
kgp7328604 .
kgp7496475 .
kgp7707096 .
kgp7798504 .
kgp8018963 .
kgp8206543 .
kgp8818851 .
kgp8860587 .
kgp9190754 .
kgp9456377 .
kgp9526272 .
kgp9629679 .
rs10489944 .
rs10504589 .
rs10808295 .
rs11060968 .
rs11225943 .
rs11720464 .
rs12354667 .
rs12427263 .
rs13130205 .
rs1372851 .
rs1493716 .
rs1541616 .
rs1674070 .
rs1873367 .
rs1889757 .
rs2470000 .
rs2470029 .
rs2647979 .
rs2720400 .
rs2851820 .
rs2851836 .
rs288756 .
rs348337 .
rs4707490 .
rs6005420 .
rs6008618 .
rs6472339 .
rs6776731 .
rs6828992 .
rs6888630 .
rs6957234 .
rs7082638 .
rs7297442 .
rs7658020 .
rs7803317 .
rs8141901 .
rs849309 .
rs9511655 .
rs9810198 .
rs9860734 .
exm2264762 .
exm2271737 .
exm2272553 .
kgp10285805 .
kgp10360658 .
kgp10548537 .
kgp10901790 .
kgp11044637 .
kgp11343144 .
kgp11430653 .
kgp11530429 .
kgp11836456 .
kgp11960081 .
kgp11974172 .
kgp12031075 .
kgp12088423 .
kgp12289889 .
kgp127695 .
kgp1278486 .
kgp1586406 .
kgp16387096 .
kgp1727603 .
kgp1887803 .
kgp1939387 .
kgp2241672 .
kgp22776953 .
kgp227938 .
kgp2369570 .
kgp3371090 .
kgp3406296 .
kgp3660486 .
kgp3662728 .
kgp3712407 .
kgp374568 .
kgp3846165 .
kgp4074864 .
kgp429141 .
kgp447667 .
kgp4534617 .
kgp4799975 .
kgp4944907 .
kgp5201171 .
kgp5329941 .
kgp5471252 .
kgp563498 .
kgp5671927 .
kgp5780899 .
kgp5829795 .
kgp6037240 .
kgp6688816 .
kgp6827318 .
kgp7048855 .
kgp7069937 .
kgp7235499 .
kgp7945681 .
kgp8628976 .
kgp8860587 .
kgp9190754 .
kgp9231149 .
kgp9578092 .
kgp965777 .
rs10150519 .
rs10161070 .
rs10451103 .
rs10742039 .
rs10877143 .
rs11720464 .
rs12506204 .
rs12593784 .
rs12937299 .
rs13338004 .
rs1372851 .
rs1493716 .
rs1512840 .
rs1541616 .
rs16822391 .
rs17076260 .
rs17453871 .
rs1873367 .
rs201607 .
rs202558 .
rs2169564 .
rs2647979 .
rs2720400 .
rs2761413 .
rs2957787 .
rs3762535 .
rs4313958 .
rs4461665 .
rs4543516 .
rs4707490 .
rs4964150 .
rs6008618 .
rs6448182 .
rs6585563 .
rs6828992 .
rs6957234 .
rs7297442 .
rs7658020 .
rs768969 .
rs7846145 .
rs7981554 .
rs8002390 .
rs8141901 .
rs935201 .
rs9378848 .
rs9810198 .
rs9860734 .
rs9864846 .
kgp2297621 ACSL6
rs440970 ACSL6
kgp10461170 ADARB2
kgp7332119 ADARB2
rs12415114 ADARB2
kgp9064589 ADCY8
rs13133908 ADH1B
kgp12414761 ADH1B
rs13133908 ADH1B
rs2075633 ADH1B
rs7518469 AJAP1
rs429790 ATP2C2
kgp3288649 ATP6V0D2
rs2832231 C21orf7
kgp10136381 CAMKMT
kgp3161157 CAMKMT
kgp3203202 CAMKMT
kgp3968222 CAMKMT
kgp4140267 CAMKMT
rs13406580 CAMKMT
rs1551882 CAMKMT
rs17032193 CAMKMT
rs7593926 CAMKMT
kgp4005992 CAP2
kgp7298922 CASC4
kgp1789974 CD48
kgp5511006 CD48
kgp1789974 CD48
kgp5511006 CD48
kgp7256435 CDC42SE2
rs4706020 CDC42SE2
rs3812178 CDYL
rs3812179 CDYL
kgp3731792 CES5AP1
kgp6395031 CLMN
kgp6395031 CLMN
kgp4873414 CNPY4
rs3806043 COL19A1
kgp3071123 COL27A1
kgp6064462 COL27A1
kgp6796371 COL27A1
rs1249745 COL27A1
kgp5314602 COL4A3
kgp11506369 CORO1C
kgp6473219 CORO1C
kgp10992142 CPZ
rs8087866 CTIF
kgp7710562 DAAM2
exm430196 DCHS2
exm430197 DCHS2
kgp49288 DCHS2
kgp766527 DCHS2
rs4696584 DCHS2
kgp3890072 DOCK8
rs1980876 DOCK8
exm451231 EGFLAM
rs6897179 EGFLAM
kgp10622968 FAM125B
kgp5732367 FAM71E2
kgp10294313 FRMD3
kgp2344514 FRMD3
kgp7900743 FRMD3
kgp3392580 GALNTL4
kgp4456104 GLT1D1
kgp5287249 HHAT
exm1319778 KRT23
rs8037 KRT23
rs9257 KRT23
kgp10012744 LHPP
kgp1057196 LINC00578
kgp8853148 LINC00578
rs6799682 LINC00578
rs7632844 LINC00578
kgp11567842 LINC00620
rs12495328 LINC00620
kgp4159029 LIPC
kgp1640513 LOC100128714
kgp4598936 LOC100128714
kgp5262759 LOC100128714
rs11635697 LOC100128714
rs12593847 LOC100128714
rs8023270 LOC100128714
kgp1743339 LOC100287160
kgp7667092 LOC100289473
rs6135960 LOC100289473
rs6135960 LOC100289473
kgp5351206 LOC100293612|LINC00620
kgp10995216 LOC100506869
kgp22804264 LOC100506869
rs4760137 LOC100506869
rs1566141 LOC100507053
kgp10134243 LOC100507053
rs10008281 LOC100507053
rs1229966 LOC100507053
rs1566141 LOC100507053
rs2051428 LOC100507053
rs3819197 LOC100507053|ADH1A
rs3819197 LOC100507053|ADH1A
rs9995799 LOC100507053|ADH6
kgp1289034 LOC100507443
rs9981988 LOC100996571|CYYR1
kgp258053 LOC152225
kgp6272649 LOC152225
kgp2759189 LOC255130
kgp2759189 LOC255130
rs10980642 LPAR1
kgp5423754 LUZP2
kgp8988372 LUZP2
kgp9462081 MCM7
rs2261360 MCM7
kgp8065051 MICAL3
kgp4439669 MMS19
kgp18459 MYBPC1
kgp1800707 NR2F2-AS1
rs7831515 NSMCE2
rs16958048 NTN1
kgp7166603 OAZ2
kgp7077044 O3FAR1
kgp2414524 OSBP2
kgp2580452 OSBP2
kgp7020841 OSBP2
rs4820897 OSBP2
kgp7020841 OSBP2
kgp7082195 P4HA2
rs6667138 PADl1
rs6667138 PADll
kgp7908292 PARD3B
rs7558785 PARD3B
kgp11077304 PARK2
exm-rs2795918 PCDH15
kgp1058322 PCDH15
kgp11029138 PCDH15
kgp11410092 PCDH15
kgp2961930 PCDH15
kgp5544438 PCDH15
kgp9631691 PCDH15
rs4082042 PCDH15
kgp9916431 PK1B
rs13218313 PK1B
kgp4769029 PRH1-PRR4
kgp9716281 PTPRD
rs7045790 RALGPS1|ANGPTL2
rs17081778 RPS24P10
kgp10074267 RTN4RL1
kgp11049623 RYR2
kgp8225782 SCN2A
rs2075703 SCN2A
rs6744911 SCN2A
rs12706974 SEMA3C
rs1358340 SEMA3C
kgp7788385 SEMA5A
rs3822799 SEMA5A
kgp3608544 SFMBT2
rs1887757 SGCG
rs9580573 SGCG
kgp390881 SLC22A15
kgp2776219 SLC2A2
exm988933 SLCO1B1
rs2306283 SLCO1B1
rs4149040 SLCO1B1
exm988933 SLCO1B1
rs2306283 SLCO1B1
rs4149040 SLCO1B1
kgp8338369 SMOC2
kgp12080543 SNCA1P
kgp4607090 SNCA1P
rs4895350 SNCA1P
kgp1043980 SNX18
kgp2071353 SRRM4
kgp7567091 SUSD1
kgp7567091 SUSD1
kgp12526521 TBC1D16
kgp5557307 TCERG1L
rs13340295 TENM3
kgp3414710 TJP3
kgp10345778 TLL1
rs4690833 TLL1
rs2568085 TMEM9B
rs1071646 TPM1
rs6738 TPM1
rs1071646 TPM1
rs6738 TPM1
rs1408817 VTl1A
rs216905 VWF
kgp2039705 WWOX
rs6804325 WWTR1
exm382632 ZFYVE28
rs12532238 ZNF3
rs6592 ZNF3
kgp6175568 ZNF609
rs11558476 ZSCAN21
TABLE 4
Gastrointestinal peptides associated with obesity.
Hormone Source Normal function
Cholecystokinin (CCK) Duodenum lncrease satiation
Ghrelin Gastric fundus Stimulate appetite
Glucagon-like Distal small lncrease satiety
peptide 1 (GLP-1) intestine and colon
Peptide YY (PYY) Distal small lncrease satiety
intestine and colon
* Low calorie diet can alter peptide concentrations.
TABLE 5
Genes associated with obesity.
Genotype potentially
affecting organ or
Primary mechanisms associated
Endpoints Quantitative Trait with trait
Satiety Postprandial GLP-1 TCF7L2, GNB3, MC4R
and PYY
Satiation VTF, MTV (kcal) MC4R, GNB3, HTR2C, UCP3
Gastric GE (solids) TCF7L2, ADRA2A, UCP3
Emptying
Appetite Fasting Ghrelin MC4R, FTO, GNB3
* Gene variants were selected based on association with BMI and mechanism of action.
Table 6 summarizes the variables that were significantly associated with each of the phenotypic groups vs the rest of the groups.
TABLE 6
SNPs present in each obesity group
Obesity Exemplary
Phenotype Group Gene SNP
1: low satiation HTR2C, POMC, NPY, rs1414334
AGRP, MC4R, GNB3,
SERT, BDNF
2: low satiety PYY, GLP-1, MC4R, rs7903146
GPBAR1, TCF7L2,
ADRA2A, PCSK,
TMEM18
3: behavioral eating SLC6A4/SERT, DRD2 rs4795541
4: large fasting gastric volume TCF7L2, UCP3, rs1626521
ADRA2A,
5: mixed
6: low resting energy expenditure FTO, LEP, LEPR, rs2075577
UCP1, UCP2, UCP3,
ADRA2, KLF14,
NPC1, LYPLAL1,
ADRB2, ADRB3,
BBS1
Combinations of compounds (amino-compounds, neurotransmitters fatty acids, metabolic peptides, and metabolic gene) were identified as significantly associated with each of the obesity phenotypic groups. The variables that were significantly associated with each of the phenotypic groups included the following:
Questionnaire results:
    • hospital anxiety and depression scale—anxiety subscale (HADS-A),
      Metabolites:
    • 1-methylhistine
    • seratonin
    • glutamine
    • gamma-amino-n-butyric-acid
    • isocaproic
    • allo-isoleucine
    • hydroxyproline
    • beta-aminoisobutyric-acid
    • alanine
    • hexanoic
    • tyrosine
    • phenylalanine
      Gastrointestinal Peptides:
    • fasting ghrelin
    • fasting PYY
      Algorithm
The following formulas were used to identify the obesity phenotype of a patient based upon the signature of the 14 compounds identified as being significantly associated with each of the obesity phenotypic groups. The formulas predicted the phenotypes with a r2 of 0.90 and a probability Chi-square of less than 0.0001.
Lin[1[
    • (−1552.38148595936)
    • +40.797700201235*:Name(“HADS-A”)
    • +1.32549623006262*:Glutamine
    • +−0.111622239757052*:Alanine
    • +−616.954862561479*:Name(“gamma-Amino-N-butyric-acid”)
    • +89.402967640225*:Name(“beta-Aminoisobutyric-acid”)
    • +1.73891527871898*:Tyrosine
    • +6.24138513457712*:Phenylalanine
    • +2148.66822848398*:isocaproic
    • +−20.6187102527618*:hexanoic
    • +56.3110714341266*:Name(“Log(Hydravproline)”)
    • +82.3818646650792*:Name(“Log(1-Methylhistine)”)
    • +26.8826686365131*:Name(“Log(seratonin)”)
    • +0.245926705626903*:Name(“PYY_-15”)
    • +1.89180999803712*:Name(“Ghrelin_-15”)
    • +75.8755521857061*:Name(“allo-Isoleucine”)
      Lin [2[
    • (−2031.26556804871)
    • +56.9736558824775*:Name(“HADS-A”)
    • +0.0118072070103887*:Glutamine
    • +−0.0995668418558728*:Alanine
    • +1609.83650774629*:Name(“gamma-Amino-N-butyric-acid”)
    • +123.106026249695*:Name(“beta-Aminoisobutyric-acid”)
    • +13.0377088181536*:Tyrosine
    • +−2.42979784589652*:Phenylalanine
    • +3057.74326808551*:isocaproic
    • +63.6119366218627*:hexanoic
    • +99.2853520251878*:Name(“Log(Hydroxyproline)”)
    • +0.166314503531418*:Name(“Log(1-Methylhistine)”)
    • +6.21451740476229*:Name(“Log(seratonin)”)
    • +0.696742681406157*:Name(“PYY_-15”)
    • +2.30188885859994*:Name(“Ghrelin_-15”)
    • +220.083419205279*:Name(“allo-Isoleucine”)
      Lin [3[
    • (−735.067323742327)
    • +84.6709055694921*:Name(“HADS-A”)
    • +0.739638607406857*:Glutamine
    • +0.0161670919675227*:Alanine
    • +1.70702352345921*:Name(“gamma-Amino-N-butyric-acid”)
    • +4.08385430756663*:Name(“beta-Aminoisobutyric-acid”)
    • +4.83658065569896*:Tyrosine
    • +−7.4973831454893*:Phenylalanine
    • +1467.49860590747*:isocaproic
    • +51.4109043756237*:hexanoic
    • +−56.3364437814115*:Name(“Log(Hydroxyproline)”)
    • +45.3693267895892*:Name(“Log(1-Methylhistine)”)
    • +24.1167481430051*:Name(“Log(seratonin)”)
    • +1.56458536889981*:Name(“PYY_-15”)
    • +2.15880622406247*:Name(“Ghrelin_-15”)
    • +72.4632042822316*:Name(“allo-Isoleucine”)
      Lin[4[
    • (−38.8679541168302)
    • +1.54112014174663*:Name(“HADS-A”)
    • +0.00119976598048842*:Glutamine
    • +0.056518755537321*:Alanine
    • +34.9734228686154*:Name(“gamma-Amino-N-butyric-acid”)
    • +2.64367056830481*:Name(“beta-Aminoisobutyric-acid”)
    • +0.0996495148185086*:Tyrosine
    • +−0.14869421223421*:Phenylalanine
    • +8.69300091428836*:isocaproic
    • +1.77363291550863*:hexanoic
    • +−1.58953123143685*:Name(“Log(Hydroxyproline)”)
    • +0.127307799711255*:Name(“Log(1-Methylhistine)”)
    • +3.33170879355105*:Name(“Log(seratonin)”)
    • +0.0387731073018872*:Name(“PYY_-15”)
    • +0.0662851699121999*:Name(“Ghrelin_-15”)
    • +1.4086102207227*:Name(“allo-Isoleucine”)
      1/(1+Exp(−(“Lin[1]”))+Exp((“Lin[2]”)−(“Lin[1]”))+Exp((“Lin[3]”)−(“Lin[1]”))+Exp((“Lin[4]”)−(“Lin[1]”)))  Prob[1[
      1/(1+Exp((“Lin[1]”)−(“Lin[2]”))+Exp(−(“Lin[2]”))+Exp((“Lin[3]”)−(“Lin[2]”))+Exp((“Lin[4]”)−(“Lin[2]”)))  Prob[2[
      1(1+Exp(“Lin[1]”)−(“Lin[3]”))+Exp((“Lin[2]”)−(“Lin[3]”))+Exp(−(“Lin[3]”))+Exp((“Lin[4]”)−(“Lin[3]”)))  Prob [3[
      1/(1+Exp((“Lin[1]”)−(“Lin[4]”))+Exp((“Lin[2]”)−(“Lin[4]”))+Exp((“Lin[3]”)−(“Lin[4]”))+Exp(−(“Lin[4]”)))  Prob [4 [
      1/(1+Exp((“Lin[1]”))+Exp((“Lin[2]”))+Exp((“Lin[3]”))+Exp((“Lin[4]”)))  Prob [6 [
      Table 7 summarizes variables (14 analytes and a questionnaire) that were significantly associated with each of the phenotypic groups with the ROC of the group vs the rest of the groups.
TABLE 7
Compounds present in each obesity group
Source Group 1 Group 2 Group 3 Group 4 Group 5 Group 6
1-Methylhistine + + +
seratonin + + + +
Glutamine + + +
gamma-Amino-N-butyric-acid + +
isocaproic + + +
allo-lsoleucine + + + +
Hydroxyproline + +
beta-Aminoisobutyric-acid + + + +
Alanine + + + + +
hexanoic + + +
Tyrosine + + +
Phenylalanine + + +
Ghrelin +
PYY + + +
HADS-A + + + +
p value of whole model test 0.006 <0.001 <0.001 <0.001 0.01 <0.001
ROC value (group vs rest) 0.90 0.86 0.91 0.89 0.86 0.96
One multinomial logistic model contained 14 compounds and one questionnaire, and the obesity phenotypes were predicted with more than 97% sensitivity and specificity (group 1=1, group 2=1, group 3=1, group 4=0.97 and group 6=0.96). When a mixed group is added to the equation, the obesity phenotypes can be predicted with more than 91% sensitivity and specificity (group 1=0.95, group 2=0.92, group 3=1, group 4=0.96, group 5=0.96 and group 6=0.97). When group 4 and mixed are removed from the equation, the obesity phenotypes can be predicted with 100% sensitivity and specificity.
Another multinomial logistic model contained 1 behavioral assessment, 3 germline variants, and 6 fasting targeted metabolomics. The variables can be as shown in Table 8 plus questionnaire(s) (e.g., HADS and/or TEFQ21).
TABLE 8
Variables (9 analytes and a questionnaire) that were significantly
associated with each of the phenotypic groups with the
ROC of the group vs the rest of the groups.
SNP Gene Name Panel Peptide
rs9939609.n FTO cystathionine1 amino compound fasting
pyy
rs1626521.n UCP3 glycine amino compound fasting
ghrelin
rs3813929.n 5-HT2CR valine amino compound
rs5443.n GNB3 serotonin neurotransmitter
rs1800544.n ADRA2a glutamic acid amino compound
rs2234888.n ADRA2c tryptophan amino compound
rs17782313 MC4R histidine amino compound
methylhistidine1 amino compound
methionine amino compound
isocaproic amino compound
hydroxylysine2 amino compound
ethanolamine amino compound
hydroxyproline amino compound
gamma-amino- neurotransmitter
n-butyric acid
threonine amino compound
alpha- amino compound
aminoadipic acid
sarcosine amino compound
arginine amino compound
histidine neurotransmitter
proline amino compound

Obesity Phenotypes Biomarker
Simple-blood test biomarkers were identified that can classify obese patients into their related phenotypes. To achieve this, 25 individuals with unique obesity phenotypes were selected from the cohort of 180 participants and an untargeted metabolomics study was performed using their fasting blood samples. Thus, average of 3331 unique metabolites that are associated with each obesity-related phenotype were observed and this is illustrated through the VennDiagrams of Unique Metabolites per group using Positive-HILIC Untargeted Metabolomics (FIG. 2A). These data supported the application of a targeted metabolomics approach, hypothesis-driven, to identify and quantify associated metabolites. A two-stage design was used to develop the composition of the blood test; the training and validation cohorts consisted of 102 and 78 obese patients, respectively. Based on the profile of each patient, we were able to validate the main groups in obesity cohorts, that is 1) abnormal satiation, 2) rapid return to hunger, 3) behavioral eating; 4) abnormal energy expenditure; 5) a “mixed” group. Using a multinomial logistic regression was used to develop a classification model using elastic net shrinkage for variable selection. Discrimination was evaluated using concordance index (c-index). Receiving operating characteristic curves (ROC) for the models were constructed and area under the curve (AUC) estimated. The variables were applied to a prediction model or algorithm diagnostic (patent submitted) to identify the phenotypes. The model predicted the phenotypes with an ROC of 0.91 (AUC) for the training cohort and 0.71 for the validation cohort (FIG. 3 and FIG. 5 ). The accuracy of the model was 86% in the whole cohort. When the model was applied to the two previously completed placebo-controlled, randomized trials, the weight loss after 2 weeks of phentermine-topiramate ER was 58% higher in the predicted group (n=3, 2.4±0.4 kg) compared to the other groups (n=9, 1.4±0.2 kg), and after 4 weeks of exenatide, weight loss was 65% higher in the predicted group (n=6; 1.5±0.6 kg) compared to the other groups (n=4, 0.9±0.7 kg).
In summary, using this actionable classification decreases obesity heterogeneity, and facilitate our understanding of human obesity. Furthermore, we have developed and validated a novel, first-of-its-kind, simple, fasting, blood-based biomarker for obesity phenotypes.
Sensitivity and Specificity of Biomarkers
To confirm the sensitivity and specificity of the biomarkers significantly associated with each of the obesity phenotypic groups, a receiver operating characteristic (ROC) analysis was done.
FIG. 3 shows the sub-classification prediction accuracy of this combined model and an ROC analysis showed that this model has >0.90 area under the curve (AUC) for all six classes.
Next, binary classification models were derived that can predict whether a patient belongs to one group over the others. Bayesian covariate predictors were derived for low satiation, behavioral eating, and low resting energy expenditure. These models yielded an ROC AUC of 1 (FIG. 4 ). These data suggested that the serum metabolite levels hold all the information needed to predict obesity subclasses.
Validation of Biomarkers
To further validate the ability to phenotype obesity based on variables significantly associated with each of the phenotypic groups, the formula was applied to 60 new participants with obesity, and a ROC analysis was done.
FIG. 5 shows that the formula predicted the sub-groups with over 90% sensitivity and specificity.
Summary
These results demonstrate that serum biomarkers can be used to classify obesity patients into obesity phenotype groups.
Example 2: Obesity Phenotypes and Intervention Responsiveness
Obesity is a chronic, relapsing, multifactorial, heterogeneous disease. The heterogeneity within obesity is most evident when assessing treatment response to obesity interventions, which are generally selected based on BMI. These standard approaches fail to address the heterogeneity of obesity. As described in Example 1, obesity phenotypes were associated with higher BMI, distinguish obesity phenotypes. This Example shows that obesity phenotypes respond differently to specific interventions (e.g., pharmacological interventions). Obesity-related phenotypes were evaluated to facilitate the understanding of obesity pathophysiology, and identify sub-groups within the complex and heterogeneous obese population. A novel classification based on identifying actionable traits in the brain-gut axis in humans (see, e.g., Acosta et al., 2015 Gastroenterology 148:537-546 e534; and Camilleri et al., 2016 Gastrointest Endosc. 83:48-56) was applied to understand, in a more homogenous, phenotype-defined population, the unique or specific characteristics within each sub-group of obesity.
The specific characteristics of 180 participants with obesity (defined as BMI>30 kg/m2) were grouped based on their predominant obesity-related phenotype, based on a multiple step process (in addition to gender) to generate a homogeneous populations based on the 75th percentile within the obese group for each well-validated variable: a) satiation [studied by nutrient drink test (maximal tolerated volume, 1 kcal/ml)], b) satiety [studied by gastric emptying (T1/2, min)], c) hedonic (hospital anxiety and depression score [HADS] questionnaire), d) other (none of the above) and e) mixed (two or more criteria met).
The overall cohort demographics were as described in Example 1. Then, with the intention to validate further the applicability of the obesity phenotypes, the fact that each sub-group may have unique abnormalities compared to the other groups when tested with previously validated or reported findings in common obesity was interrogated.
Abnormal Satiation Group
Individuals with obesity typically consume more calories prior to reach ‘usual’ fullness—for every 5 kg/m2 of BMI increase, participants consumed 50 calories more (see, e.g., Acosta et al., 2015 Gastroenterology 148:537-546). Here, participants with obesity and abnormal satiation were compared to the other groups with the same validated two food intake (meal) paradigms test to measure satiation (FIG. 6A). During a nutrient drink test, females with abnormal satiation consumed 235 calories more prior to reach ‘usual’ fullness (p<0.001) and 600 calories more prior to reach ‘maximal’ fullness (p<0.001); males with abnormal satiation consumed 514 calories more prior to reach ‘usual’ fullness (p<0.001) and 752 calories more prior to reach ‘maximal’ fullness (p<0.001) compared to individuals with obesity and normal satiation. During the ad libitum buffet meal, females with abnormal satiation consumed 287 calories more prior to reach fullness (p<0.001) and males consumed 159 calories more prior to reach fullness (p=0.03) compared to individuals with obesity and normal satiation. Within obesity the sub-group with abnormal—or lack of—satiation consumed significant more calories in one meal, suggesting a deficiency in the stop signals and a hungry brain phenotype.
Abnormal Satiety Group
Accelerated gastric emptying was chosen as a surrogate for abnormal satiety based on the main fact that is an objective, reproducible test, whiles other tests, such as visual analog scores are subjective sensations of satiety. In female participants with obesity and abnormal satiety, their gastric emptying (GE) was 40% GE solids T1/4 (p<0.001), 30% GE solids T1/2 (p<0.001) and 22% GE liquids T1/5 (p=0.01) faster compared to normal satiety. In male participants with obesity and abnormal satiety, their gastric emptying was 44% GE solids T1/4 (p=0.005), 38% GE solids T1/2 (p<0.001) and 33% GE liquids T1/2 (p=0.05) faster compared to normal satiety (FIG. 7A). The gastric volume fasting and postprandial is smaller in participants with abnormal satiety compared to those with normal satiety when measured by SPECT (FIG. 7B). Additionally, individuals with abnormal satiety have lower levels of gastrointestinal satiety hormones, GLP-1 (p=0.005) and PYY3-36 (p=0.01) at 90 minutes after a meal. Individuals with abnormal satiation have gastrointestinal satiety hormones similar to historical controls with normal weight (see, e.g., Acosta et al., 2015 Gastroenterology 148:537-546); and individuals in the ‘other’ group also have very low levels of these hormones, despite of having normal gastric emptying. However, the correlation of food intake when reach ‘usual’ fullness in the nutrient drink test to the secretion of PYY3-36 is linear (r=0.42, p<0.001) and significant in individuals with normal satiety and this correlation disappear in individuals with normal satiety, suggesting an inadequate response of the PYY3-36 secreting enteroendocrine (EE) cells to the meal challenge. Enteroendocrine (EE) cells are real-time nutrient, bile and microbiota sensors that regulate food intake, brain-gut communication, gastrointestinal motility, and glucose metabolism. EE cell function can be studied indirectly by measuring plasma levels of hormones such as GLP-1 or PYY, and less frequently EE cells are studied as part of whole intestinal tissue. These results suggested a hungry gut phenotype.
Hedonic Group
There is a sub-group within participants with obesity which have a very strong psychological component that may predispose them to obesity, labeled here as a ‘hedonic’ sub-group. Likely this group is acquiring most of their calories from emotional eating, cravings and reward-seeking behaviors while having appropriate sensations of satiation and satiety. Individuals in the hedonic group have higher levels of anxiety (p<0.001) and depression (p<0.001); and lower levels of self-esteem (p=0.002) when compared to other individuals with obesity. The hedonic group has a lower level of serum fasting tryptophan compared to the other groups (p=0.004, FIG. 8 ). Tryptophan is a precursor of serotonin and melatonin, which has been associated with depression, cravings and obesity.
Slow Metabolism Group
A sub-cohort of our population who completed indirect calorimetry testing was studied and individuals in the slow metabolism group have significant lower resting energy expenditure (90% of predicted) compared to the other groups of obesity (100% of predicted, p=0.032) were identified (FIG. 9A). The slow metabolism group have significant lower measured resting energy expenditure (kcal/day) that other groups (p<0.05) (FIG. 9B). Individuals with slow metabolism have lower systolic blood pressure (p=0.019), higher heart rate (p=0.05) higher self-steem (p=0.004). When body composition was measured using a dexa scan, there was not difference in calculated BMI or measured total fat mass among the obesity groups, however, individuals with slow metabolism had lower muscle (lean) mass compared to the other obesity groups (ANOVA p<0.05), FIG. 9C). Metabolites in patients with slow metabolism compared to normal metabolism (other or rest) were significant different (p<0.05): higher than other groups: alanine, isocaproic acid, phosphoetahnolamine, phenylalanine, tyrosine, alpha-amino-N-butyric acid, sarcasine, and lower than other groups: 1-methylhistidine (FIG. 9D).
Obesity Phenotypes Biomarker
The applicability of obesity-related phenotypes as actionable biomarkers was tested in three pilot, proof of concept studies (see, e.g., Acosta et al., 2015 Gastroenterology 148:537-546; Acosta et al., 2015 Physiol Rep 3; and Halawi et al., 2017 Lancet Gastroenterol Hepatol 2:890-899). First, in a single-center, randomized, parallel-group, double-blind, placebo-controlled, 14-day study, the effects of Phentermine-topiramate-ER (PhenTop) (7.5/46 mg, orally, daily) on gastric emptying (GE) and volume, satiation, satiety, and fasting and postprandial GI hormones was evaluated in 24 obese adults. Patients with an abnormal baseline satiation test had greater mean weight loss to PhenTop ER compared to those with normal satiation (p=0.03). In a second placebo-controlled trial, the effect of exenatide was studied, 5 μg SQ, twice daily for 30 days, on GE, satiety, satiation and weight loss in 20 obese participants with obesity and abnormal satiety. The average weight loss was 1.3 kg for exenatide and 0.5 kg for the placebo group (p=0.06), suggesting that patients with abnormal satiety may be good candidates for weight loss with a GLP-1 receptor agonist). Subsequently, in a prospective, NIH-funded, randomized, placebo controlled clinical trial to study the effects of liraglutide 3 mg, SQ, over 16 weeks on obesity phenotypes and weight in 40 obese patients. Compared to placebo, liraglutide delayed GE of solids at 5 (p<0.0001) and 16 (p=0.025) weeks, caused significant weight loss and increased satiation. At 5 and 16 weeks, GE T1/2 correlated with change in weight loss on liraglutide (all p<0.02). These results demonstrate that obesity-related phenotypes can predict response to obesity pharmacotherapy.
Phentermine-Topiramate and Obesity Phenotypes
The effects of phentermine-topiramate-ER (PhenTop) (7.5/46 mg, orally, daily) was evaluated on GE, GV, satiation, satiety, and fasting and postprandial gut hormones as described elsewhere (see, e.g., Acosta et al., 2015 Gastroenterology 148:537-546). PhenTop was associated with reduced food intake at buffet meal (mean Δ 260 kcal, p=0.032) and delayed GE solids (mean Δ GE4h 6%, p=0.03; and Δ GE T½ 19 min, p=0.057). There were no significant differences in GV, satiation, GE of liquids and GI hormones. Patients on PhenTop had greater mean weight loss of 1.4 kg than placebo (p=0.03). Weight loss on PhenTop was significantly associated with kcal intake at a prior satiety test. These results demonstrate that PhenTop reduces food intake and delays GE of solids, indicating that patients having an obesity phenotype of Group 1 (low satiation), are likely responsive to treatment with PhenTop.
Exenatide and Obesity Phenotypes
The effects of exenatide (5 μg, SQ, twice daily for 30 days) was evaluated on GE, satiety, and weight loss as described elsewhere (see, e.g., Acosta et al., 2015 Physiological Rep. 3(11)). Exenatide, a glucagon-like peptide-1 (GLP-1) agonist, had a very significant effect on GE of solids (p<0.001) and reduced calorie intake at a buffet meal by an average 130 kcal compared to placebo. The average weight loss was 1.3 kg for exenatide and 0.5 kg for the placebo group (FIG. 11 ). These results demonstrate that exenatide reduces food intake and delays GE of solids, indicating that a prior accelerated gastric emptying test predicts weight loss with exenatide; see, also, Acosta et al., 2015 Physiological Rep. 3(11)).
Surgery and Obesity Phenotypes
The best responders to the intragastric balloon therapy were identified as described elsewhere (see, e.g., Abu Dayyeh et al., “Baseline Gastric Emptying and its Change in Response to Diverse Endoscopic Bariatric TherapiesGastric Emptying Predict Weight Change Response to Endoscopic Bariatric Therapies in a Large Cohort,” IFSO annual meeting, 2015) as individuals with an accelerated gastric emptying (p<0.001) and the greater delay in gastric emptying after intragastric balloon placement (p<0.001).
Liraglutide and Obesity Phenotypes
A prospective, randomized clinical trial with liraglutide, a long-acting GLP-1 receptor agonist, was completed. The effects of liraglutide and placebo were compared over 16 weeks on gastric motor functions, satiation, satiety and weight in obese patients. The study was a randomized, double-blind, placebo-controlled trial of subcutaneous liraglutide, 3 mg, with standardized nutritional and behavioral counseling. Forty adult, otherwise healthy local residents with BMI≥30 kg/m2 were randomized. Liraglutide or placebo was escalated by 0.6 mg/day each week for 5 weeks and continued until week 16. At baseline and after 16 weeks' treatment, weight, gastric emptying of solids (GES, primary endpoint), large fasting gastric volumes, satiation, and satiety were measured. GES was also measured at 5 weeks. Statistical analysis compared treatment effects using ANCOVA (with baseline measurement as covariate). Effect of liraglutide on GES T1/2 at 5 and 16 weeks in the liraglutide group was analyzed by paired t-test. Seventeen participants were analyzed in the liraglutide group (n=19 randomized) and 18 in the placebo group (n=21 randomized).
Compared to placebo, liraglutide retarded GES at 5 (p<0.0001) and 16 (p=0.025) weeks, caused significant weight loss and increased satiation. In 16 weeks, the total body weight loss for the liraglutide group was 6.1±2.8 kg (SD) compared to 2.2±5 kg control group (p=0.0096). There was tachyphylaxis to GES effects of liraglutide from 5 to 16 weeks' treatment. At 5 and 16 weeks, GES T1/2 correlated with A weight loss on liraglutide (all p<0.02). Nausea was the most common adverse event in the liraglutide group (63.2%) compared to placebo (9.5%). Liraglutide, 3.0 mg, significantly delays GES after 5 and 16 weeks' treatment; effects on weight loss are associated with absolute value of GES T1/2 on liraglutide.
These results demonstrate that liraglutide significant weight loss and increased satiation, indicating that a prior low satiety test predicts weight loss with liraglutide.
Individualized Therapy
The identification of obesity-related phenotypes based on an ‘actionable’ classification and potential applicability for management of obesity could have a significant impact on the obesity epidemic.
FIG. 12 shows exemplary individualized obesity interventions based upon obesity phenotypes.
The algorithm described in Example 1 was applied to 29 new patients with obesity (Table 9). Data from (intervention) pharmacotherapy and controls were acquired retrospectively. Groups were matched for age, gender and BMI. Results were compared the outcome to 66 patients previously treated by obesity experts.
TABLE 9
Obesity Patient Characteristics.
Historical P
Demographics Cases Controls value
N 55 175 
Age   46 ± 1.8 50 ± 1 0.03
Gender (F) 67% 73%
Race (W) 93% 89%
Weight (kg) 115 ± 3  116 ± 1.8
BMI 39.8 ± 1  41.6 ± 0.6
Co-morbidities % 47/41/45/49/36 43/33/35/36/30
(DM/HTN/DJD/OSA/HLD)*
MEDS % 24 22
Phentermine 25 23
Phen-Top ER  6 10
Lorcaserin 19 25
Liraglutide 3 mg 12  4
Bupropion-Naltrexone SR  4  6
Other
Ns: not statistical significant difference
The algorithm predicted the obesity group and intervention responsiveness of the new participants with over 90% sensitivity and specificity (FIG. 13 , FIG. 14 , and Table 10). The controls were seen in the weight management clinic by a physician expert of obesity and offered standard of care for obesity management and pharmacotherapy. The current standard of care suggests that pharmacotherapy needs to be selected based on patient—physician preference, mainly driven by side effects and other comorbidities. The cases were seen in the weight management clinic by a physician expert of obesity and offered obesity-phenotype guided pharmacotherapy for obesity management. The phenotypes seen were abnormal satiation (25%), abnormal satiety (20%), abnormal behavior (20%) and other (35%).
TABLE 10
Total body weight in response to individualized intervention.
Total Body Weight Loss, % Controls Cases P value
3 months (# patients) 2.7 ± 0.5 (66)  6.1 ± 0.8 (29) 0.0008
6 months (# patients) 4.7 ± 0.7 (57) 10.7 ± 1.2 (22) 0.0001
9-12 months (# patients) 5.7 ± 1.2 (36) 12.9 ± 1.9 (15) 0.0025
The intervention group had 74% responders (defined as those who loss more than 3% in the first month) compared to 33% in the control group. The control group number of responders was similar to the published in the current obesity literature. The significant improvement of responders resulted in a total body weight loss of 12.9 kg in the intervention group compared to 5.8 kg in the control group at 9 months.
The algorithm was also applied to 12 patients with obesity, who saw their weight loss plateau during the treatment for obesity with an intragastric balloon. These individuals saw weight loss plateau during month 3 and 6 of treatment with the balloon. At month 6, the algorithm was applied to the intervention group compared to the controls.
Summary
It was found that obesity can be sub-grouped in: abnormal satiation (16%), abnormal satiety (16%), hedonic (19%), slow metabolism (32%) and mixed group (17%). Deeper characterization within each subgroup identifies specific disturbances of function. Thus, in the group with abnormal satiation measured by two different feeding paradigms (ad libitum buffet meal and nutrient drink test), compared to lean controls and other groups of obesity; this is summarized as “hungry brain phenotype”. In the group with abnormal satiety, there is a suboptimal response of the gut to food intake, manifested as accelerated gastric emptying and decrease in peak postprandial levels of satiety hormones suggesting a “hungry gut phenotype”. In the hedonic group, there are increased levels of anxiety, depression, and cravings with low levels of serum tryptophan compared to the other groups. The slow metabolism group has decreased resting energy expenditure compared to other groups. Since identifying the obesity subgroups by deep phenotyping is limited to few academic centers, a fasting blood multi-omic test was developed and validated that predict the obesity subgroups (ROC >90% AUC). This blood test provides segmentation of diverse sub-phenotypes of obesity, has the potential to select patients for individualized treatment from the sea of obesity heterogeneity, facilitates our understanding of human obesity, and may lead to future treatment based on actionable biomarkers.
These results demonstrate that obesity phenotype groups can be used to predict treatment response, and can be used to guide individualized treatment strategies (e.g., pharmacotherapy and/or bariatric endoscopy). The obesity phenotype guided intervention doubled the weight loss in patients with obesity.
Example 3: Obesity Phenotypes and Patient Sub-Populations
To validate further the applicability of the obesity phenotypes, the fact that each sub-group may have unique abnormalities compared to the other groups when tested with previously validated or reported findings in common obesity was interrogated.
The model described above was run independently for female and male sub-populations of patients. Characteristics of a complete population is as denoted in Table 11.
TABLE 11
Whole Cohort (181 patients).
Mean + #pts w/ #pts w/
Trait SD >2 SD # pts Median >90% trait % pts >75% trait % pts
HADS-A 3.4 + 2.5 9 17 3 7 29 16% 6 46 25%
HADS-D 1.54 + 1.74 5 20 1 4 25 14% 3 24 13%
VTF 706 + 296 1337 9 630 1080 21 12% 900 44 24%
MTV 1286 + 417  2142 13 1272 1896 24 13% 1539 46 25%
VAS - Full 70 + 14 −40 2 72 48 18 10% 61 44 24%
SGE T½ 99.5 + 25.8 −47 5 98 70.8 17  9% 81 43 24%
Buffett 917 + 295 1604 16 916 1357 23 13% 1184 44 24%
Unique analytes were identified when this cohort was separated into female and male sub-populations as shown in Table 12 and Table 13.
TABLE 12
Female sub-population (134 patients).
Mean + #pts w/ #pts w/
Trait SD >2 SD # pts Median >90% trait % pts >75% trait % pts
HADS-A 4 9 3 7 20 15% 6 34 25%
HADS-D 2 5 1 4 13 10% 2 30 22%
VTF 632 1123 600 990 14 10% 750 40 30%
MTV 1174 1879 1185 1618 13 10% 1422 35 26%
VAS - Full 70 39 72 49 14 10% 61 34 25%
SGE T½ 105 56 102 77 14 10% 90 32 24%
Buffett 896 1394 848 1279 13 10% 1028 34 25%
TABLE 13
Male sub-population (47 patients).
Mean + #pts w/ #pts w/
Trait SD >2 SD # pts Median >90% trait % pts >75% trait % pts
HADS-A 4 9 4 7 8 17%  6 12 26%
HADS-D 2 7 2 5 6 13%  3 17 36%
VTF 959 1659 900 1524 4 9% 1125 11 23%
MTV 1626 2517 1659 2180 4 9% 1951 11 23%
VAS - Full 69 41 72 47 4 9% 63 11 23%
SGE T½ 83 34 78 56 6 13%  68 11 23%
Buffett 1248 1893 1222 1693 4 9% 1469 11 23%
When analytes were identified in female and male sub-populations, the concentration of metabolites differed. See the concentrations as shown in Table 14.
TABLE 14
Concentrations of analytes in targeted metabolites.
highest lower limit of Coefficient
standard quantification of variation
analyte concentration (LOQ) (CV)
Histidine 930 0.155 1.2%
Hydroxyproline 930 0.155 1.5%
1-Methylhistidine 930 0.155 0.5%
3-Methylhistidine 930 0.155 0.8%
Asparagine 1000 0.167 0.7%
Phosphoethanolamine 1000 0.167 0.4%
Arginine 930 0.155 0.5%
Carnosine 930 0.155 2.0%
Taurine 930 0.155 1.5%
Anserine 930 0.155 2.2%
Serine 930 0.155 0.7%
Glutamine 4000 0.667 0.2%
Ethanolamine 930 0.155 2.0%
Glycine 930 0.155 1.6%
Aspartic Acid 930 0.155 0.7%
Sarcosine 930 0.155 0.4%
Citrulline 930 0.155 1.6%
Glutamic Acid 930 0.155 0.6%
beta-Alanine 930 0.155 0.5%
Threonine 930 0.155 1.0%
Alanine 930 0.155 0.5%
gamma-Amino- 930 0.155 1.3%
N-butyric-acid
alpha-Aminoadipic- 930 0.155 0.0%
acid
beta-Aminoisobutyric- 930 0.155 0.4%
acid
Proline 930 0.155 1.0%
Hydroxylysine 1 930 0.155 0.6%
Hydroxylysine 2 930 0.155 0.3%
alpha-Amino- 930 0.155 0.0%
N-butyric-acid
Ornithine 930 0.155 0.9%
Cystathionine 1 930 0.155 1.0%
Cystathionine 2 930 0.155 0.6%
Lysine 930 0.155 0.2%
Cystine 930 0.155 1.7%
Tyrosine 930 0.155 0.4%
Methionine 930 0.155 1.2%
Valine 930 0.155 1.7%
Isoleucine 930 0.155 2.3%
allo-Isoleucine 930 0.155 0.9%
Homocystine 930 0.155 1.0%
Leucine 930 0.155 0.5%
Phenylalanine 930 0.155 1.6%
Tryptophan 930 0.155 1.1%
Acetylcholine 1600 0.10 5.6%
Adenosine 1600 0.10 0.5%
Norepinephrine 1600 0.10 1.0%
Dopamine 1600 0.10 0.7%
Serotonin 1600 0.10 1.0%
acetic acid 6651 5.5  25%
propionic acid 4955 1.03  7%
isobutyric acid 4792 1.00  2%
butyric acid 5379 1.12  4%
isovaleric acid 4030 0.84  15%
valeric acid 5393 1.12  5%
isocaproic acid 3532 0.74  12%
caproic acid 2901 0.60  8%
Unique targets identified in a sub-population can serve to find a unique treatment: for example TCF7L/2 genetic variant can be used to identify a group with abnormal satiety; or a simple test such as gastric emptying can be used to clef ne abnormal satiety.
The model described above is also run independently for additional sub-populations of patients. For example, the model can be run on patients of specific ages (e.g., youth such as people from birth to about 18, adults such as people 18 or older), and specific life stages (e.g., perimenopausal women, menopausal women, post-menopausal women, and andropausal men).
Sub-populations of patients demonstrated analyte differences between obesity groups that were not seen in a full population of patients.
Example 4: Selecting Treatment(s) for Obesity Therapy
When an individual is treated with any weight loss intervention, his/her phenotype can assist in selecting a treatment.
Study Design
In a 12 week, randomized, double-blinded, active controlled trial, with 9 month open-label extension of 200 participants with obesity; the weight loss response rate to obesity-phenotype-guided pharmacotherapy (intervention) vs. non-phenotype guided (randomly selected) pharmacotherapy (control) in patients with obesity is compared. All 200 participants are phenotyped and the medication selection is randomly and double blinded (to physician, study team, and participant) to the FDA-approved medicine suggested by the phenotype or to another FDA-approved medicine not suggested by the phenotype.
All participants receive a standard intense lifestyle intervention, which consists of 2 visits with registered dietitian. The phenotypic studies include (all performed in same day in the following order): fasting blood collection, resting energy expenditure, gastric emptying with meal for breakfast, behavioral questionnaires, and buffet meal test for lunch. Blood is collected for assessment of metabolomic biomarkers, gastrointestinal hormones, DNA (blood and buccal swab), and pharmacogenomics. Stool samples are collected for microbiome and bile acid. Participants return to the CRTU to pick up medication based on the randomization and discuss the pharmacogenomics results. All participants are contacted at 4 and seen at 12 weeks (current standard in practice). A stool sample and a fasting blood sample are collected at the 12-week visit. At the 12-week visit, participants will be unblinded to their “obesity-related phenotype” and they could contact their physician to continue a FDA-approved medication as part of clinical care. Study team will prospectively follow the patients' weight, waist circumference and use of obesity medications every 3 months for 1 year.
Randomization and Allocation
A computer generated randomization is based on guiding pharmacotherapy based on the phenotype or randomly as current standard of care. Allocations are concealed.
Participants
A study cohort includes 200 patients with obesity (BMI>30 kg/m2). Participants that agree to pharmacotherapy treatment are invited to participate in the phenotypic assessment of their obesity that will guide (or not) the pharmacotherapy.
Inclusion Criteria
    • a) Adults with obesity (BMI≥30 Kg/m2); these are otherwise healthy individuals with no unstable psychiatric disease and controlled comorbidities or other diseases.
    • b) Age: 18-75 years.
    • c) Gender: Men or women. Women of childbearing potential have negative pregnancy tests within 48 hours of enrolment and before each radiation exposure.
      Exclusion Criteria
    • a) Abdominal bariatric surgery
    • b) Positive history of chronic gastrointestinal diseases, or systemic disease that could affect gastrointestinal motility, or use of medications that may alter gastrointestinal motility, appetite or absorption, e.g., orlistat, within the last 6 months.
    • c) Significant untreated psychiatric dysfunction based upon screening with the Hospital Anxiety and Depression Inventory (HAD), and the Questionnaire on Eating and Weight Patterns (binge eating disorders and bulimia). If such a dysfunction is identified by an anxiety or depression score >11 or difficulties with substance or eating disorders, the participant will be excluded and given a referral letter to his/her primary care doctor for further appraisal and follow-up.
    • d) Hypersensitivity to any of the study medications.
    • e) No contraindications to all FDA-approved medications
      Anthropometrics and Phenotype Studies
Anthropometrics Measurements: are taken of hip-waist ratio, height, weight, blood pressure, pulse at baseline, randomization day and week 12.
Phenotype studies at baseline: After an 8-hour fasting period, and the following validated quantitative traits (phenotypes) are measured at baseline:
    • a) The DEXA scan (dual energy x-ray absorptiometry) measures body composition.
    • b) Resting energy expenditure: is assessed by indirect calorimetry with a ventilated hood.
    • c) Gastric emptying (GE) of solids by scintigraphy: The primary-endpoint is gastric half-emptying time (GE t1/2) as described elsewhere (see, e.g., Acosta et al., 2015 Gastroenterology 148:537-546; Vazquez et al., 2006 Gastroenterology 131:1717-24; and Camilleri et al., 2012 Neurogastroenterology and Motility 24:1076).
    • d) Appetite (hunger level) by visual analog score fasting and after standard meal for GE and prior to the Satiation test as described elsewhere (see, e.g., Acosta et al., 2015 Gastroenterology 148:537-546).
    • e) Satiation is measured by ad-libitum buffet meal to measure total caloric intake and macronutrient distribution in the chosen food. Satiation is reported in calories consumed at fullness (satiation) as described elsewhere (see, e.g., Acosta et al., 2015 Gastroenterology 148:537-546).
    • f) Satiety by visual analog score postprandial after standard meal for GE and after to the Ad-libitum meal test for every 30 minutes for 2 hours as described elsewhere (see, e.g., Acosta et al., 2015 Gastroenterology 148:537-546). Satiety is measured in length of time of fullness.
    • g) Self-administered questionnaires assessing affect, physical activity levels, attitudes, body image, and eating behavior; details of each questionnaire are provided below.
    • h) Sample collection, handling and storage: Samples are collected after an overnight fast (of at least 8 hours) in the morning. Plasma was preserved following standard guidelines and protein degradation inhibitors, kalikrein and DPP-IV inhibitors are added to preserve the samples. Samples are stored at −80° C.
      • a. Plasma gastrointestinal hormones (Total and active Ghrelin, GLP-1, CCK. PYY and bile acids) by radioimmunoassay, measured fasting, and 15, 45, and 90 minutes postprandial, with the primary endpoint being the peak postprandial level (test should be done simultaneously to GE).
      • b. Targeted Metabolomics: Targeted metabolomics of salient classes of compounds in plasma samples are performed using mass spectrometry. Amino acids plus amino metabolites are quantified in plasma by derivatizing with 6-aminoquinolyl-N-hydroxysuccinimidyl carbamate according to Waters MassTrak kit. A 10-point calibration standard curve is used for quantification of unknowns using a triple-stage quadrupole mass spectrometer (Thermo Scientific TSQ Quantum Ultra) coupled with an ultra-performance liquid chromatography (UPLC) system (Waters Acquity UPLC). Data acquisition is performed using multiple-reaction monitoring (MRM). Concentrations of 42 analytes in each sample are calculated against their respective calibration curves with a measurement precision of <5%. Essential nonesterified fatty acid (NEFA) concentrations, such as myristic, palmitic, palmetoleic palmitoelaidic, stearic, oleic, elaidic, linoleic, linolenic and arachidonic, are measured against a six-point standard curve by LC/MS/MS, underivatized after extraction from plasma via negative electrospray ionization (ESI) and multiple reaction monitoring conditions. This technique was developed to replace the GC/MS method where NEFAs required methylation before analysis. This technique reduces the uncertainty as to whether the methylation step increases FFA concentrations by inadvertently hydrolyzing other lipid classes. Intra CV is <3% for all analytes.
      • c. Blood DNA.
      • d. Buccal Swab DNA for OneOme pharmacogenomics testing.
        • i. Pharmacogenomics: Patients who have met the inclusion and exclusion criteria provide a one-time buccal scraping. 72 variants in 22 pharmacogenes, with seven cytochrome P450 enzymes (CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5) covering approximately 90 percent of human drug oxidation and nearly 50 percent of commonly used medications, and 15 genes related to drug action or metabolism (COMT, DPYD, DRD2, F2, F5, GRIK4, HTR2A, HTR2C, IL28B, NUDT15, OPRM1, SLCO1B1, TPMT, UGT1A1, and VKORC1) are assessed. Results for the patient are placed into the patient EHR to be utilized for clinical treatment decisions. Through chart review, including the patient's current medication list as stated in the EHR, previously reported medication inefficacy and intolerance is documented. This data is entered into a database.
    • i) Stool is collected and stored to study microbiome, short chain fatty acids, and bile acids.
      Studies at 12-Week Visit:
    • j) Stool and fasting blood sample are collected and stored. Stool is used to measure microbiome, short chain fatty acids and bile acids (as above). Fasting blood will be used to GI hormones and metabolomics (as above).
      Questionnaires to Assess GI Symptoms and Behavioral Disorders
Participants complete a series of questionnaires: Weight management Questionnaire (Mayo Clinic®), the and the Hospital Anxiety and Depression Inventory [HAD (see, e.g., Zigmond et al., 1983 Acta Psychiatrica Scandinavica 67:361-70)] to appraise the contribution of affective disorder.
Behavioural Questionnaires
    • a. AUDIT-C Alcoholism Screening Test—This score is used in screening by the study physician/nurse coordinator.
    • b. Eating Disorders Questionnaire—The Questionnaire on Eating and Weight Patterns-Revised, is a valid measure of screening for eating disorders which has been used in several national multi-site field trials. Respondents are classified as binge eating disorder, purging bulimia nervosa, non-purging bulimia nervosa, or anorexia nervosa.
    • c. Body Image Satisfaction—The Multidimensional Body-Self Relations Questionnaire provides a standardized attitudinal assessment of body image, normed from a national body-image survey. Items are rated on a 5-point scale, ranging from 1=Definitely Disagree to 5=Definitely Agree. A sub-scale, the Body Areas Satisfaction Scale, is used to measure feelings of satisfaction with discrete aspects of physical appearance (e.g., face, weight, hair). Cronbach's a values range from 0.70 to 0.89.
    • d. Eating Behaviors—The Weight Efficacy Life-Style Questionnaire [WEL] is a 20-item eating self-efficacy scale consisting of a total score and five situational factors: negative emotions, availability, social pressure, physical discomfort, and positive activities. Subjects are asked to rate their confidence about being able to successfully resist the urge to eat using a 10-point scale ranging from 0=not confident to 9=very confident.
    • e. Physical Activity Level—The four-item Physical Activity Stages of Change Questionnaire will be utilized to assess the physical activity level of participants.
      Standard of Care:
All participants receive standard of care which consists of 1) Intense lifestyle intervention, behavioral evaluation and treatment, and a medication as part of the regular clinic management for obesity.
Intense Lifestyle Intervention and Behavioral Treatment
All the participants will meet the multidisciplinary team which consists of an Obesity Expert physician a registered dietitian nutritionist as standard of care in our clinical practice. These appointments will be schedule in the clinic and will not be covered by the current protocol. All participants are guided to 1) Nutrition: Reduce dietary intake below that required for energy balance by consuming 1200-1500 calories per day for women and 1500-1800 calories per day for men; 2) Physical Activity: reach the goal of 10,000 steps or more per day; 3) Exercise: reach the goal of 150 minutes or more of cardiovascular exercise/week; 4) Limit consumption of liquid calories (i.e. sodas, juices, alcohol, etc.).
Pharmacotherapy for Obesity
Pharmacotherapy for the treatment of obesity can be considered if a patient has a body mass index (BMI)≥30 kg/m2 or BMI>27 kg/m2 with a comorbidity such as hypertension, type 2 diabetes, dyslipidemia and obstructive sleep apnea. Medical therapy should be initiated with dose escalation based on efficacy and tolerability to the recommended dose. An assessment of efficacy and safety at 4 weeks is done. In both groups, medications are assessed for drug interactions and potential side effects as standard of care.
Medication selection: Once the phenotype tests are completed the results are filled in an algorithm to assist on the decision of the medication selection as described elsewhere (see, e.g., Acosta et al., 2015 Gastroenterology 148:537-546; Camilleri et al., 2016 Gastrointest. Endosc. 83:48-56; and Acosta et al., 2015 Physiological Rep. 3(11)). An example is below:
TEST Abnormal result Example 1 Example 2 Example 3 Example 4
Satiation >1139 kcal 1400 kcal 1000 kcal 1100 kcal 1050 kcal
(Ad libitum Buffet
Meal)
Satiety SGE T1/2 <85 102 min 80 min 105 min 110 min
(Gastric emptying) min or GE
1 hr >35%
Behavioral Traits HADS A&D >6 points 5 4 9 3
(Questionnaires)
Energy Expenditure <85% predicted 92% 93% 95% 82%
(Resting EE)
Phenotype — Ab Satiation Ab Satiety Ab Psych Ab E.E.
Once the decision is made on the “phenotype-guided” medication, pharmacy will assess whether patient is randomized to “intervention” or “control”. Based on the randomization, patient picks up the prescription for 3 months. During the 3-month visit, participants are offered a prescription to continue the medication (if randomized to the intervention group) or to switch to the phenotype guided medication (if randomized to the control group). Patients who continue obesity pharmacotherapy are contact every three months for one year to monitor their weight and comorbidities.
Control Group: Pharmacotherapy for Obesity
Standard of care pharmacotherapy for obesity recommends the following doses and regimen for weight loss:
    • Phentermine: 15-37.5 mg oral daily
    • Phentermine-Topiramate Extended Release (Qsymiak) at dose of 7.5/46 mg oral daily
    • Oral naltrexone extended-release/bupropion extended-release (NBSR; Contrave®) at dose of 32/360 mg oral daily (divided in 2 tables in morning and 2 tablets in evening)
    • Liraglutide (Saxenda®) at dose of 3 mg subcutaneous daily
      Intervention Group: By Obesity Phenotype Guided Pharmacotherapy
Participants in the intervention group will have 4 tests to assess 1) satiation, 2) satiety/return to hunger, 3) behavioral, or 4) energy expenditure. As described in FIG. 12 pharmacotherapy will by guide based on the phenotype. In case of a mixed pattern or multiple abnormal phenotypes, the most prominent phenotype is tackled.
Algorithm diagnostic:
    • 1. satiation: Phentermine-Topiramate Extended Release (Qsymia®) at dose of 7.5/46 mg oral daily
    • 2. Satiety/return to hunger: Liraglutide 3 mg SQ daily
    • 3. Behavioral/Psychological: Oral naltrexone extended-release/bupropion extended-release (NBSR; Contrave®) at dose of 32/360 mg oral daily (divided in 2 tables in morning and 2 tablets in evening); or
    • 4. Energy expenditure: Phentermine 15 mg daily plus increase physical activity.
      Statistical Analyses
Primary endpoint: Total Body Weight Loss, kg (defined as weight changed from baseline to 12 weeks) in the obesity phenotype-guided pharmacotherapy (intervention) vs. the randomly assigned pharmacotherapy (control) group.
The secondary end points will be percentage of responders (defined as number of participants who loss 5% or more of total body weight) compared to baseline in the obesity phenotype guided pharmacotherapy (intervention) group vs. standard of care at 4 and 12 weeks; percentage of responders with at least 10 and 15% at 12 weeks, and 10% at 6 months and 12 months; percentage of responders at 5%, 10% and 15%; percentage of responders within each obesity-phenotype group at 4 and 12 weeks; and side effects of medications. In the open-label extension, the total body weight loss is assessed at 24 and 52 weeks in both groups.
Statistical Analyses: A randomized, double-blinded, active controlled trial of 200 participants with obesity to compare effects of intervention compared to controls in weight loss. The analysis involves an ANCOVA models, with the response being actual weight change; the covariates to be considered include gender, and BMI (at baseline) at baseline.
Sample size assessment and power calculation: The detectable effect size in weight loss between groups of interest (intervention vs. control) is given in Table 15. Using a SD for the overall weight change (pre-post) of 2.8 kg, the differences between groups that could be detected with approximately 80% power (2-sided a level of 0.05) for main effects are estimated. Thus, the sample size needed is 87 participants per group. In order to account for dropout, 100 participants per group are randomized.
TABLE 15
Mean difference (Δ) of total body Intervention Control
weight loss in controls group (mean (# of (# of
average 6.1 kg) vs. intervention group. participants) participants)
Mean difference of 10% [6.7 vs. 6.1 kg) 343 343
Mean difference of 20% [7.3 vs. 6.1 kg) 87 87
Mean difference of 30% [7.9 vs. 6.1 kg) 39 39
As each 50 patients complete the 12-week treatment phase, an interim analysis is conducted by the study statistician for the purpose of ensuring (based on the observed coefficient of variation in the primary responses such as the proportion of weight difference of 20%) that the study still has sufficient power based on the sample size proposed in the study.
OTHER EMBODIMENTS
It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.

Claims (9)

What is claimed is:
1. A method of assaying a sample obtained from a mammal with a body mass index (BMI) of >30 kg/m2 or a BMI>27 kg/m2 and a comorbidity, the method comprising detecting the presence, absence or level of one or more single nucleotide polymorphisms (SNPs) at or near each of a plurality of genes consisting of FTO, TCF7L2, UCP2, GLP-1 receptor, and LEPR in the sample obtained from the mammal using a genotyping method.
2. The method of claim 1, wherein the mammal is a human.
3. The method of claim 1, wherein the sample is selected from the group consisting of a blood sample, a saliva sample, a urine sample, a buccal sample and a stool sample.
4. The method of claim 1, further comprising obtaining results of a behavioral assessment of the mammal, wherein the behavioral assessment comprises a behavioral questionnaire.
5. The method of claim 4, wherein the behavioral questionnaire is a Hospital Anxiety and Depression Scale (HADS) questionnaire or a Three Factor Eating questionnaire (TFEQ).
6. The method of claim 1, further comprising detecting the presence, absence or level of one or more analytes selected from the group consisting of metabolites, gastrointestinal peptides, carbohydrates and any combination of distinct analytes thereof from an additional sample obtained from the mammal using mass spectrometry, radioimmunoassays, or enzyme-linked immunosorbent assays.
7. The method of claim 6, wherein the metabolite is selected from the group consisting of an amino-compound, neurotransmitter, a fatty acid, a bile acid and any combination of distinct analytes thereof.
8. The method of claim 6, wherein the gastrointestinal peptide is selected from the group consisting of ghrelin, peptide tyrosine tyrosine (PYY), cholecystokinin (CCK), glucagon-like peptide-1 (GLP-1), GLP-2, glucagon, oxyntomodulin (OXM), neurotensin, fibroblast growth factor (FGF), gastric inhibitory polypeptide (GIP), FGF19, FGF21, LDL, insulin, amylin, leptin, adiponectin, pancreatic polypeptide and any combination of distinct gastrointestinal peptides thereof.
9. The method of claim 6, wherein the additional sample is selected from the group consisting of a blood sample, a saliva sample, a urine sample, a buccal sample and a stool sample.
US18/221,036 2017-11-22 2023-07-12 Methods and materials for assessing and treating obesity Active US12474353B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US18/221,036 US12474353B2 (en) 2017-11-22 2023-07-12 Methods and materials for assessing and treating obesity

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762589915P 2017-11-22 2017-11-22
PCT/US2018/062217 WO2019104146A1 (en) 2017-11-22 2018-11-21 Methods and materials for assessing and treating obesity
US202016765273A 2020-05-19 2020-05-19
US18/221,036 US12474353B2 (en) 2017-11-22 2023-07-12 Methods and materials for assessing and treating obesity

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US16/765,273 Continuation US11740247B2 (en) 2017-11-22 2018-11-21 Methods and materials for assessing and treating obesity
PCT/US2018/062217 Continuation WO2019104146A1 (en) 2017-11-22 2018-11-21 Methods and materials for assessing and treating obesity

Publications (2)

Publication Number Publication Date
US20230358765A1 US20230358765A1 (en) 2023-11-09
US12474353B2 true US12474353B2 (en) 2025-11-18

Family

ID=66631195

Family Applications (2)

Application Number Title Priority Date Filing Date
US16/765,273 Active 2039-12-10 US11740247B2 (en) 2017-11-22 2018-11-21 Methods and materials for assessing and treating obesity
US18/221,036 Active US12474353B2 (en) 2017-11-22 2023-07-12 Methods and materials for assessing and treating obesity

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US16/765,273 Active 2039-12-10 US11740247B2 (en) 2017-11-22 2018-11-21 Methods and materials for assessing and treating obesity

Country Status (5)

Country Link
US (2) US11740247B2 (en)
EP (1) EP3713478A4 (en)
AU (2) AU2018371776A1 (en)
CA (1) CA3080932A1 (en)
WO (1) WO2019104146A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019104146A1 (en) 2017-11-22 2019-05-31 Mayo Foundation For Medical Education And Research Methods and materials for assessing and treating obesity
CN111662977A (en) * 2020-06-30 2020-09-15 西安市精神卫生中心 Gene probe, chip and kit for detecting metabolic influence of anti-psychotropic drugs and application of gene probe, chip and kit
CA3220596A1 (en) * 2021-05-21 2022-11-24 Mayo Foundation For Medical Education And Research Assessing and treating obesity
CN114854869B (en) * 2022-04-15 2022-12-09 中国农业科学院北京畜牧兽医研究所 SNP (Single nucleotide polymorphism) marker related to goat heat-resistant character and application
WO2023220618A1 (en) * 2022-05-10 2023-11-16 Mayo Foundation For Medical Education And Research Individualized lifestyle intervention for obesity management based on obesity phenotypes
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Citations (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030092028A1 (en) 2001-06-01 2003-05-15 Yuanhong Ma Methods and Reagents For Diagnosis and Treatment of Insulin Resistance and Related Condition
US7005255B2 (en) 2000-04-14 2006-02-28 Metabolon, Inc. Methods for drug discovery, disease treatment, and diagnosis using metabolomics
US20090104615A1 (en) 2006-05-02 2009-04-23 Keith Malcolm Godfrey Phenotype prediction
US20090155826A1 (en) 2007-07-17 2009-06-18 Metabolon, Inc. Biomarkers for pre-diabetes, cardiovascular diseases, and other metabolic-syndrome related disorders and methods using the same
US20110124121A1 (en) 2009-10-15 2011-05-26 Allergan, Inc. Methods for predicting weight loss success
US20140093478A1 (en) 2006-12-18 2014-04-03 The Washington University Gut microbiome as a biomarker and therapeutic target for treating obesity or an obesity related disorder
US20140093487A1 (en) 2011-04-08 2014-04-03 Chr. Hansen A/S Synergistic antimicrobial effect
US20160331272A1 (en) 2015-05-14 2016-11-17 Invoy Technologies, Llc Breath analysis system, device and method employing nanoparticle-based sensor
EP2979097B1 (en) 2013-03-28 2016-12-28 Nestec S.A. Trimethylamine as a biomarker of prebiotic efficacy for weight gain prevention
US20170007598A1 (en) 2003-04-29 2017-01-12 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
US20180066315A1 (en) 2012-09-21 2018-03-08 Ethicon Endo-Surgery, Inc. Clinical predictors of weight loss
US20180094318A1 (en) 2015-03-18 2018-04-05 Patia Biopharmia, S.A. De C.V. Methods, tools and systems for the assessment, prevention, management and treatment selection for type 2 diabetes
US20190062811A1 (en) 2017-06-01 2019-02-28 Gelesis Llc Compositions and methods for predicting and promoting weight loss
US20190254331A1 (en) 2016-06-10 2019-08-22 Gelesis Llc Methods of inducing weight loss, treating obesity and preventing weight gain
CN112292697A (en) 2018-04-13 2021-01-29 弗里诺姆控股股份有限公司 Machine learning embodiments for multi-analyte determination of biological samples
US20210072259A1 (en) 2017-11-22 2021-03-11 Mayo Foundation For Medical Education And Research Methods and materials for assessing and treating obesity
WO2021072322A1 (en) 2019-10-09 2021-04-15 Mayo Foundation For Medical Education And Research Treatment for gastrointestinal disorders
WO2022246203A1 (en) 2021-05-21 2022-11-24 Mayo Foundation For Medical Education And Research Assessing and treating obesity
WO2023220618A1 (en) 2022-05-10 2023-11-16 Mayo Foundation For Medical Education And Research Individualized lifestyle intervention for obesity management based on obesity phenotypes

Patent Citations (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7005255B2 (en) 2000-04-14 2006-02-28 Metabolon, Inc. Methods for drug discovery, disease treatment, and diagnosis using metabolomics
US20030092028A1 (en) 2001-06-01 2003-05-15 Yuanhong Ma Methods and Reagents For Diagnosis and Treatment of Insulin Resistance and Related Condition
US20170007598A1 (en) 2003-04-29 2017-01-12 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
US20090104615A1 (en) 2006-05-02 2009-04-23 Keith Malcolm Godfrey Phenotype prediction
US20140093478A1 (en) 2006-12-18 2014-04-03 The Washington University Gut microbiome as a biomarker and therapeutic target for treating obesity or an obesity related disorder
US20160178620A1 (en) 2007-07-17 2016-06-23 Metabolon, Inc. Biomarkers for Pre-Diabetes, Cardiovascular Diseases, and other Metabolic-Syndrome Related Disorders and Methods Using the Same
US20090155826A1 (en) 2007-07-17 2009-06-18 Metabolon, Inc. Biomarkers for pre-diabetes, cardiovascular diseases, and other metabolic-syndrome related disorders and methods using the same
US20110124121A1 (en) 2009-10-15 2011-05-26 Allergan, Inc. Methods for predicting weight loss success
US20140093487A1 (en) 2011-04-08 2014-04-03 Chr. Hansen A/S Synergistic antimicrobial effect
US20180066315A1 (en) 2012-09-21 2018-03-08 Ethicon Endo-Surgery, Inc. Clinical predictors of weight loss
EP2979097B1 (en) 2013-03-28 2016-12-28 Nestec S.A. Trimethylamine as a biomarker of prebiotic efficacy for weight gain prevention
US20180094318A1 (en) 2015-03-18 2018-04-05 Patia Biopharmia, S.A. De C.V. Methods, tools and systems for the assessment, prevention, management and treatment selection for type 2 diabetes
US20160331272A1 (en) 2015-05-14 2016-11-17 Invoy Technologies, Llc Breath analysis system, device and method employing nanoparticle-based sensor
US20190254331A1 (en) 2016-06-10 2019-08-22 Gelesis Llc Methods of inducing weight loss, treating obesity and preventing weight gain
US20190062811A1 (en) 2017-06-01 2019-02-28 Gelesis Llc Compositions and methods for predicting and promoting weight loss
US20210072259A1 (en) 2017-11-22 2021-03-11 Mayo Foundation For Medical Education And Research Methods and materials for assessing and treating obesity
US11740247B2 (en) 2017-11-22 2023-08-29 Mayo Foundation For Medical Education And Research Methods and materials for assessing and treating obesity
CN112292697A (en) 2018-04-13 2021-01-29 弗里诺姆控股股份有限公司 Machine learning embodiments for multi-analyte determination of biological samples
WO2021072322A1 (en) 2019-10-09 2021-04-15 Mayo Foundation For Medical Education And Research Treatment for gastrointestinal disorders
WO2022246203A1 (en) 2021-05-21 2022-11-24 Mayo Foundation For Medical Education And Research Assessing and treating obesity
US20240252593A1 (en) 2021-05-21 2024-08-01 Mayo Foundation For Medical Education And Research Assessing and treating obesity
WO2023220618A1 (en) 2022-05-10 2023-11-16 Mayo Foundation For Medical Education And Research Individualized lifestyle intervention for obesity management based on obesity phenotypes

Non-Patent Citations (358)

* Cited by examiner, † Cited by third party
Title
Abadi et al. Penetrance of Polygenic Obesity Susceptibility Loci across the Body Mass Index Distribution. The American Journal of Human Genetics 101, 925-938, Dec. 7, 2017. (Year: 2017). *
Abell et al., "Consensus Recommendations for Gastric Emptying Scintigraphy: A Joint Report of the American Neurogastroenterology and Motility Society and the Society of Nuclear Medicine," Journal of Nuclear Medicine Technology, 2008; 36: 44-54.
Acosta et al., "Exenatide in obesity with accelerated gastric emptying: a randomized, pharmacodynamics study," Physiol. Reports, Nov. 2015, 3(11):e12610, 10 pages.
Acosta et al., "Quantitative Gastrointestinal and Psychological Traits Associated With Obesity and Response to Weight-Loss Therapy," Gastroenterology, Mar. 1, 2015, 148(3):537-546.e4.
Acosta et al., "Recent advances in clinical practice challenges and opportunities in the management of Obesity," Gut, Apr. 2014, 63(4):687-695.
Acosta et al., "Relamorelin Relieves Constipation and Accelerates Colonic Transit in a Phase 2, Placebo-Controlled Randomized Trial," Clin. Gastroenterol. Hepatology, Dec. 2015, 13(12):2312-2319.e1.
Acosta et al., "Selection of Antiobesity Medications Based on Phenotypes Enhances Weight Loss: A Pragmatic Trial in an Obesity Clinic," Obesity (Silver Spring), 2021, 29(4): 662-671.
Acosta et al., "White-Paper AGA:. POWER—Practice Guide on Obesity and Weight Management, Education and Resources," Clin. Gastroenterol. Hepatology, May 2017, 15(5);631-649.10.
Adams et al., "Long-Term Mortality after Gastric Bypass Surgery," N. Engl. J. Medicine, Aug. 23, 2007, 357(8):753-761.
Allison et al., "Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP)," Obesity, Feb. 2012, 20(2):330-342.
Alvarez-Castro et al.,, "Ghrelin in obesity, physiological and pharmacological considerations," Mini Rev. Med. Chem., Apr. 2013; 13(4):541-552.
Apovian et al., "A Randomized, Phase 3 Trial of Naltrexone SR/Bupropion SR on Weight and. Obesity-related Risk Factors (COR-II)" Obesity, May 2013 21(5):935-943.
Apovian, C.M. et al. (2015). "Pharmacological management of obesity: an endocrine Society clinical practice guideline," J. Clin. Endocrinol. Metab. 100:342-362.
Begriche et al., "β-Aminoisobutyric Acid Prevents Diet-induced Obesity in Mice With Partial Leptin Deficiency," Obesity, Sep. 2008, 16(9):2053-2067.
Bellicha et al., "Effect of exercise training on weight loss, body composition changes, and weight maintenance in adults with overweight or obesity: An overview of 12 systematic reviews and 149 studies," Obesity Reviews, 2021, 22(Suppl 4):e13256, 13 pages.
Berkland et al., "A Worksite Wellness Intervention: Improving Happiness, Life Satisfaction, and Gratitude in Health Care Workers," Mayo Clinic Proceedings: Innovations, Quality & Outcomes, 2017, 1(3): 203-210.
Bouras et al., "SPECT imaging of the stomach: comparison with barostat and effects of sex, age, body mass index, and fundoplication," Gut 2002;51:781-786.
Brownell KD, The LEARN® Program for Weight Control. Tenth Edition. American Health Publishing Company, 2004. Summary only, 1 page.
Buchwald et al., "Weight and Type 2 Diabetes after Bariatric Surgery:. Systematic Review and Meta-analysis.," Am. J. Medicine, Mar. 2009, 122(3):248-256.e5.
Burton-Freeman, B., "Dietary fiber and energy regulation," The Journal of Nutrition, 2000, 130(2S Suppl): 272S-275S.
Bush et al., "The AUDIT Alcohol Consumption Questions (AUDIT-C): An Effective Brief Screening Test for Problem Drinking," Arch Intern Med. 1998;158:1789-1795.
Cabanac, "Regulation and the ponderostat," Int. J. Obes. Relat. Metab. Disorders, Dec. 2001, 25(Suppl 5):S7-12.
Camilleri et al., "Performance characteristics of scintigraphic measurement of gastric emptying of solids in healthy participants," Neurogastroenterol. Motility, Dec. 2012, 24(12):1076-e562.
Camilleri et al., Gastrointestinal traits: individualizing therapy for obesity with drugs and devices, Gastrointest. Endoscopy, Jan. 1, 2016, 83(1):48-56.
Chedid et al., "Allelic Variant in the Glucagon-Like Peptide 1 Receptor Gene Associated with Greater Effect of Liraglutide and Exenatide on Gastric Emptying: A Pilot Pharmacogenetics Study," Neurogastroenterol Motil. 2018;30(15):e13313 (15 pages).
Chial et al., "A nutrient drink test to assess maximum tolerated volume and postprandial symptoms: effects of gender, body mass index and age in health," Neurogastroenterol Motil. 2002; 14:249-253.
Cifuentes and Acosta, "Homeostatic regulation of food intake," Clinics and Research in Hepatology and Gastroenterology, 2022, 46(2): 101794 (Author manuscript, 18 pages).
Cifuentes et al., "Gastric Sensory and Motor Functions and Energy Intake in Health and Obesity—Therapeutic Implications," Nutrients 2021; 13: 1158, 30 pages.
Cifuentes., et al., Phenotype tailored lifestyle intervention on weight loss and cardiometabolic risk factors in adults with obesity: a single-centre, non-randomised, proof-of-concept study, EClinicalMedicine, vol. 58, No. 101923, Apr. 2023, pp. 1-11.
Clark et al., "Improvements in Health Behaviors, Eating Self-Efficacy, and Goal-Setting Skills Following Participation in Wellness Coaching," Am J Health Promot., 2016, 30(6): 458-464.
Clark et al., "Self-efficacy in weight management," Journal of Consulting and Clinical Psychology, 1991, 59(5), 739-744.
ClinicalTrials.gov [online], "Peripheral Pharmacodynamics of Phentermine-Topiramate in Obese Patients," NCT01834404, last updated Feb. 23, 2015: retrieved on Feb. 2, 2021, retrieved from URL https://clinicaltrials.gov/ct2/show/study/NCT01834404, 38 pages.
ClinicalTrials.gov, "Individualized Lifestyle Intervention for Obesity Management Based on Obesity Phenotypes," NCT04073394, Last updated Feb. 3, 2023, retrieved from https://www.clinicaltrials.gov/study/NCT04073394, 9 pages.
Connolly et al., "Valvular Heart Disease Associated with Fenflurimine-Phentermine," N. Engl. J Medicine, Aug. 28, 1997, 337(9):581-588.
Coveleskie et al. The effect of the GLP-1 analogue Exenatide on functional connectivity within an NTS-based network in women with and without obesity. Obes Sci Pract. 2017;3:434-445.
Curbelo Montañez et al., "Machine Learning Approaches for the Prediction of Obesity using Publicly Available Genetic Profiles," IEEE, 2017, pp. 2743-2750.
Dahl et al., "Oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying, in subjects with type 2 diabetes," Diabetes Obes Metab. 2021;23:1594-1603.
Dansinger et al., "Comparison of the Atkins; Ornish, Weight Watchers, and Zone Diets for Weight Loss and Heart Disease Risk Reduction: A. Randomized Trial," JAMA, Jan. 5, 2005, 293(1):43-53.
Davidson et al., "Weight Control and Risk Factor Reduction in Obese , Subjects Treated for 2 Years With Orlistat: A Randomized. Controlled Trial," JAMA, Jan. 20, 1999, 281(3):235-242.
De Luis et al. rs6923761 gene variant in glucagon-like peptide 1 receptor: Allelic frequencies and influence on cardiovascular risk factors in a multicenter study of Castilla-Leon. Clinical Nutrition 37 (2018) 2144e2148. Available online: Nov. 2, 2017. (Year: 2018). *
De Luis et al., "Evaluation of weight loss and metabolic changes in diabetic patients treated with liraglutide, effect of RS6923761 gene variant of glucagon-like peptide 1 receptor," J Diabetes Complications 2015;29:595-598.
Deane et al., "Endogenous Glucagon-Like Peptide-1 Slows Gastric Emptying in Healthy Subjects, Attenuating Postprandial Glycemia," J Clin Endocrinol Metab. 2010;95:215-221.
Delgado-Aros et al., "Effect of GLP-1 on gastric volume emptying, maximum volume ingested, and postprandial symptoms in humans," Am J Physiol Gastrointest Liver Physiol. 2002, 282:G424-G431.
EP Supplementary Partial Search Report in European Appln. No. 18881422.2, dated Jul. 5, 2021, 18 pages.
European Medicines Agency, Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s), Jul. 25, 2019, EMA/429077/2019, 2 pages, retrieved from: www.ema.europa.eu/en/documents/scientific-conclusion/saxenda-h-c-psusa-00001892-201812-epar-scientific-conclusions-grounds-variation-terms-marketing_en.pdf.
Evans et al., "Common Genetic Variants in ARNTL and NPAS2 and at Chromosome 12p13 are −e Associated with Objectively Measured Sleep Traits in the Elderly" Sleep, vol. 36, No. 3, 2013. 431-446.
Farias et al., "Set-Point Theory and Obesity," Metab. Syndr. Relat. Disorders, Apr. 2011, 9(2):85-89.
Farr et al. Longer-term liraglutide administration at the highest dose approved for obesity increases reward-related orbitofrontal cortex activation in response to food cues: Implications for plateauing weight loss in response to anti-obesity therapies. Diabetes Obes Metab. 2019;21(11):2459-2464 (11 pages).
Farr et al., "GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial," Diabetologia 2016;59:954-965.
FDA.gov [online], "Clinical Briefing Document: Endocrinologic and Metabolic Drugs Advisory Committee Meeting," NDA 22580, Feb. 22, 2012, retrieved on Feb. 2, 2021, retrieved from URLhttps://wayback.archive-it.org/7993/20170405220351/https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM292315.pdf, 200 pages.
Flegal et al., "Prevalence of Obesity and Trends in the Distribution of Body Mass Index Among US Adults, 1999-2010," JAMA, Feb. 1, 2012, 307(5):491-497.
Flint et al., "The once-daily human GLP-1 analogue liraglutide impacts appetite and energy intake in patients with type 2 diabetes after short-term treatment," Diabetes, Obesity and Metabolism 2013; 15: 958-962.
Florez et al., "TCF7L2 Polymorphisms and Progression to Diabetes in the Diabetes Prevention Program," N Engl J Med. 2006;355(3):241-250.
Fontaine et al., "Years of Life Lost Due to Obesity," JAMA, Jan. 8, 2003, 289(2):187-193.
Fothergill et al., "Persistent Metabolic Adaptation 6 Years After "The Biggest Loser" Competition," Obesity, Aug. 2016, 24(8):1612-1619.
Frandsen et al., "Liraglutide as adjunct to insulin treatment in type 1 diabetes does not interfere with glycaemic recovery or gastric emptying rate during hypoglycaemia: a randomised, placebo-controlled, double-blind, parallel-group study," Diabetes Obes Metab. 2017;19:773-782.
Gadde et al., "Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial," Lancet, Apr. 16, 2011, 377(9774):1341-1352.
Garvey et al., "Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study," Am. J. Clin. Nutrition, Feb. 2012, 95(2):297-308.
Germain et al. Specific appetite, energetic and metabolomics responses to fat overfeeding in resistant-to-bodyweight-gain constitutional thinness. Nutrition & Diabetes (2014) 4, e126. (Year: 2014).
Golzarand et al., "The bariatric surgery and weight losing: a meta-analysis in the long- and very long-term effects of laparoscopic adjustable gastric banding, laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy on weight loss in adults," Surgical Endoscopy, 2017, 31: 4331-4345.
Gonzalez-Izundegui et al., "Association of gastric emptying with postprandial appetite and satiety sensations in obesity," Obesity (Silver Spring), 2021, 29(9): 1497-1507 (Author manuscript, 20 pages).
Gostout et al., "Delayed Gastric Emptying as a Proposed Mechanism of Action During Intragastric Balloon Therapy: Results of a Prospective Controlled Study," Abstract No. O.955, Presented at Proceedings of the International Federation for the Surgery of Obesity and Metabolic Disorders 20th World Congress, Vienna, Austria, Aug. 26-29, 2015; Obes. Surgery, 2015, 25(Suppl 1):S129-S130.
Goyal et al., "Endoscopic Bariatric Therapies," Curr. Gastroenterol. Reports, Jun. 2016 18(6):26, 8 pages.
Grant et al., "Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes," Nat Genet. 2006;38(3):320-323.
Greenway et al., "Effect of naltrexone plus buprupion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial," Lancet, Aug. 21, 2010, 376(9740):595-605.
Halawi et al., "Effects of liraglutide on weight satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial," Lancet Gastroenterol. Hepatology, Sep. 25, 2017, 2(12):890-899.
Halawi et al., "Relationship of gastric emptying or accommodation with satiation, satiety and postprandial symptoms in health," Am J Physiol Gastrointest Liver Physiol. 2017, 313:G442-G447.
Hall et al., "Models Use Leptin and Calculus to Count Calories," Cell Metabolism, Jan. 7, 2009, 9(1):3-4.
Hall, "Diet Versus Exercise in "The Biggest Loser" Weight Loss Competition," Obesity, Jul. 2013, 21(5):957-959.
Harder et al., "The Effect of Liraglutide, a Long-Acting Glucagon-Like Peptide 1 Derivative, on Glycemic Control, Body Composition, and 24-h Energy Expenditure in Patients With Type 2 Diabetes," Diabetes Care 2004;27(8):1915-1921.
Harris, "Role of set-point theory in regulation of body weight," FASEB Journal, Dec. 1990, 4(15):3310-3318.
Hedjoudje et al., "Efficacy and Safety of Endoscopic Sleeve Gastroplasty: A Systematic Review and Meta-Analysis," Clinical Gastroenterology and Hepatology, 2020, 18(5):1043-1053.e4.
Hensrud DD, The Mayo Clinic Diet. Second Edition. Mayo Clinic Press, 2017. Summary only, 1 page.
Hensrud et al., "Extreme obesity: a new medical crisis in the United States," Mayo Clin. Proceedings, Oct. 1, 2006, 81(10 Suppl):S5-S10.
Hervey, "Regulation of Energy Balance," Nature, May 17, 1969, 222:629-631.
Heymsfield and Wadden, "Mechanisms, Pathophysiology, and Management of Obesity," New England Journal of Medicine 2017; 376: 254-266.
Heymsfield et al., "Mechanisms, Pathophysiology, and Management of Obesity," N Engl. J Med., (2017) 376(15):1490-1492.
Himes et al., "Stop Regain: A Pilot Psychological Intervention for Bariatric Patients Experiencing Weight Regain," Obesity Surgery, 2015, 25: 922-927.
Hollander et al., "Role of Orlistat in the Treatment of Obese Patients With Type 2 Diabetes: A 1-year randomized double-blind study," Diabetes Care, Aug. 1998 21(8):1288-1294.
Horowitz et al., "Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes," Diabetes Research and Clinical Practice 2012; 97: 258-266.
Horowitz et al., "Upper and/or lower gastrointestinal adverse events with glucagon-like peptide-1 receptor agonists: Incidence and consequences," Diabetes Obes Metab. 2017;19:672-681.
Hutchison et al., "Acute load-dependent effects of oral whey protein on gastric emptying, gut hormone release, glycemia, appetite, and energy intake in healthy men," The American Journal of Clinical Nutrition, 2015, 102: 1574-1584.
Ikegami et al., "Abstract 12631: Peripheral Gamma-aminobutyric Acid(gaba) Signaling in Brown Adipose Tissue Induces Metabolic Dysfunction in Obesity," Circulation, Nov. 10, 2015, 132(S3):A12631, 5 pages.
International Preliminary Report on Patentability for International Application No. PCT/US2023/066809 mailed Nov. 21, 2024, 10 pages.
International Search Report and Written Opinion for International Application No. PCT/US2022/030261, mailed Oct. 17, 2022, 18 pages.
International Search Report and Written Opinion for International Application No. PCT/US2023/066809 dated Sep. 29, 2023, 13 pages.
Invitation to Pay for International Application No. PCT/US2022/030261 dated Aug. 15, 2022, 3 pages.
Irving et al., "Nutrient Transporter Expression in the Jejunum in Relation to Body Mass Index in Patients Undergoing Bariatric Surgery," Nutrients, Oct. 29, 2016, 8(11):683, 12 pages.
Jalleh et al., "Acute Effects of Lixisenatide on Energy Intake in Healthy Subjects and Patients with Type 2 Diabetes: Relationship to Gastric Emptying and Intragastric Distribution," Nutrients. 2020; 12: 1962.
Jelsing et al., "Liraglutide: short-lived effect on gastric emptying—long lasting effects on body weight," Diabetes Obes Metab. 2012;14:531-538.
Jensen et al., "2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society," J. Am. Coll. Cardiology, Jul. 1, 2014, 63(25 Pt B):2985-3023.
Johannsen et al., "Metabolic Slowing with Massive Weight Loss despite Preservation of Fat-Free Mass," J. Clin. Endocrinol Metabolism, Jul. 2012, 97(7):2489-2496.
Jones et al., "Effects of lixisenatide on postprandial blood pressure, gastric emptying and glycaemia in healthy people and people with type 2 diabetes," Diabetes Obes. Metab. 2019:21 : 1158-1167.
Kadouh et al., "GLP-1 Analog Modulates Appetite, Taste Preference, Gut Hormones, and Regional Body Fat Stores in Adults with Obesity," J Clin Endocrinol Metab. 2020, 105:1552-1563.
Karra et al., "The role of peptide YY in appetite regal and obesity," J. Physiology, Jan. 2009, 587 (Pt. I): 19-25.
Katterman et al., "Mindfulness meditation as an intervention for binge eating, emotional eating, and weight loss: A systematic review," Eating Behaviors, 2014, 15: 197-204.
Keesey et al., Body Energy Homeostasis, Appetite, Nov. 2008, 51(3):442-445.
Khera et al., "Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis," JAMA, 2016;315(22):2424-2434.
Khera et al., "Effects of Weight-Loss Medications on Cardiometabolic Risk Profiles: A Systematic Review and Network Meta-analysis," Gastroenterology 2018; 154:1309-1319.
Kim et al., "Novel Testing of Human Gastric Motor and Sensory Functions: Rationale, Methods, and Potential Applications in Clinical Practice," The American Journal of Gastroenterology 2000; 95: 3365-3373.
Klok et al., The role of leptin and ghrelin in the regulation of food intake and body weight in humans: a review, Obes. Reviews, Jan. 2007, 8(1):21-34.
Kumar et al.. "Efficacy Comparison of Medications Approved for. Chronic Weight Management," Obesity, Apr. 2015, 23(Suppl 1):S4-S7.
Kuwata et al., "Effects of glucagon-like peptide-1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: A prospective, observational study," J Diabetes Investi. 2021; 12:2162-2171.
Langberg et al. Genetic Association of Adrenergic Receptor Alpha 2a with Obesity and Type 2 Diabetes. Obesity (2013) 21, 1720-1725. (Year: 2013). *
Le Bacquer et al., "TCF7L2 splice variants have distinct effects on β-cell turnover and function," Hum Mol Genet. 2011, 20(10):1906-1915.
Le Roux et al., "Three years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial," Lancet 2017;389:1399-1409.
LeBlanc, E. L. et al., "Behavioral and Pharmacotherapy Weight Loss Interventions to Prevent Obesity-Related Morbidity and Mortality in Adults Updated Evidence Report and Systematic Review for the US Preventive Services Task Force," JAMA, 2018;320(11):1172-1191.
Locke et al., "Genetic studies of body mass index yield new insights for obesity biology," Nature, Feb. 12, 2015, 518(7538):197-206.
Loos and Janssens, "Predicting Polygenic Obesity Using Genetic Information," Cell. Metab., Mar. 2017, 25(3):535-543.
Lowe et al., "Effects of Time-Restricted Eating on Weight Loss and Other Metabolic Parameters in Women and Men With Overweight and Obesity, The TREAT Randomized Clinical Trial," JAMA Intern Med. 2020;180(11):1491-1499.
Lynch et al., "Branched-chain amino acids in metabolic signalling and insulin resistance," Nat. Rev. Endocrinology, Oct. 7, 2014, 10(14.723-736.
Ma et al., "Effects of a Protein Preload on Gastric Emptying, Glycemia, and Gut Hormones After a Carbohydrate Meal in Diet-Controlled Type 2 Diabetes," Diabetes Care, 2009, 32(9): 1600-1602.
MacLean et al., "Biological Control of Appetite: A Daunting Complexity," Obesity (2017) 25, Suppl 1, S8-S16.
Marathe et al., "Acute Administration of the GLP-1 Receptor Agonist Lixisenatide Diminishes Postprandial Insulin Secretion in Healthy Subjects But Not in Type 2 Diabetes, Associated with Slowing of Gastric Emptying," Diabetes Ther. (2022) 13:1245-1249.
Maselli and Camilleri, "Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity," Adv Exp Med Biol 2020; 4: 171-192.
Maselli et al., "Effects of Liraglutide on Gastrointestinal Functions and Weight in Obesity: A Randomized Clinical and Pharmacogenomic Trial," Obesity (Silver Spring). Aug. 2022 ; 30(8): 1608-1620 (24 pages).
Mettler et al., "Motivational Improvements for Health Behavior Change from Wellness Coaching," American Journal of Health Behavior, 2014, 38(1): 83-91.
Morton et al., "A systematic review, meta-analysis and meta-regression of the effect of protein supplementation on resistance training-induced gains in muscle mass and strength in healthy adults," British Journal of Sports Medicine, 2018, 52: 376-384.
Nagai et al., "Differing effects of liraglutide on gastric emptying in Japanese patients with type 2 diabetes," Diabetes Obes Metab. 2014; 16:573-576.
Nauck et al., "Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination with Metformin, in Type 2 Diabetes: the LEAD (Liraglutide Effect and Action in Diabetes)-2 study," Diabetes Care, Jan. 2009, 32(1):84-90.
Nauck et al., "Rapid Tachyphylaxis of the Glucagon-Like Peptide 1-Induced Deceleration of Gastric Emptying in Humans," Diabetes 2011;60:1561-1565.
Newgard et al., "A Branched-Chain Amino Acid-Related Metabolic Signature that Differentiates Obese and Lean Humans and. Contributes to Insulin Resistance," Cell Metabolism Apr. 8, 2009, 9(4):311-326.
Ng et al., "Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013. a systematic: analysis for the Global Burden of Disease Study 2013," Lancet, Aug. 30, 2014, 384(9945).:766-781.
Otson et al., "Alloisoleueine Differentiates the Branched-chain Aminoacidemia of Zucker and Dietary Obese Rats," Obesity, May 2014, 22(5):1212-1215.
Papierkowski et al., "Monocarboxylic short-chain fatty acids C2-C6 in serum of obese children," Acta Paediatr. Acade. Sci. Hung., 1975, 16(3-4):277-280.
Partial Supplementary European Search Report for European Application No. 22805577.8, dated Mar. 3, 2025, 16 pages.
PCT International Preliminary Report on Patentability in International Application No. PCT/US2018/062217, dated May 26, 2020, 8 pages.
PCT International Search Report and Written Opinion in International Appin. No. PCT/US2018/062217, dated Feb. 8, 2019, 10 pages.
Pham et al., "The Effects of a Whey Protein and Guar Gum-Containing Preload on Gastric Emptying, Glycaemia, Small Intestinal Absorption and Blood Pressure in Healthy Older Subjects," Nutrients, 2019, 11: 2666, 13 pages.
Pi-Sunyer et al., "A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management," N. Engl. J. Medicine, Jul. 2, 2015, 373(1):11-22.
Rameshrad et al., "An overview of glucagon-like peptide-1 receptor agonists for the treatment of metabolic syndrome: A drug repositioning," Iran J Basic Med Sci 2020; 23:556-568.
Rauschert et al. "Metabolomic Biomarkers for Obesity in Humans: A Short Review," Ann. Nutr. Metabolisim, Oct. 2, 2014, 64(3-4):314-324.
Ravussin et al., "Early Time-Restricted Feeding Reduces Appetite and Increases Fat Oxidation But Does Not Affect Energy Expenditure in Humans," Obesity (Silver Spring), 2019, 27(8): 1244-1254.
Riebe et al., "Updating ACSM's Recommendations for Exercise Preparticipation Health Screening." Med. Sci. Sports Exercise, Nov. 2015, 47(11):2473-2479.
Roberts et al., "Tailoring pharmacotherapy to specific eating behaviours in obesity: Can recommendations for personalised therapy be made from the current data?," Acta Diabetologica, Apr. 19, 2017, 54(8):715-725.
Roberts et al., "β-Aminoisobutyric Acid Induces Browning of White Fat and Hepatic β-Oxidation and Is Inversely Correlated with Cardiometabolic Risk Factors," Cell Metabolism, Jan. 7, 2014; 19(1):96-108.
Rodriguez et al., "Obesity changes the human gut mycobiome," Sci. Reports, Oct. 12, 2015, 5:14600, 15 pages.
Rosenbaum et al., "Low Dose Leptin Administration Reverses. Effects of Sustained Weight-Reduction on Energy Expenditure and Circulating Concentrations of Thyroid Hormones," J. Clin. Endocrinol. Metabolism, May 2002, 87(5):2391-2394.
Rosenbaum et al., "Low-dose leptin reverses skeletal muscle, autonomic, and neuroendocrine adaptations to maintenance of reduced weight," J. Clin. Investigation, Dec. 2005, 115(12):3579-3586.
Royston et al., "Dichotomizing continuous predictors in multiple regression: a bad idea," Statistics in Medicine 2006; 25: 127-141.
Sachdeva et al., "Gastric Emptying of Solids and Liquids for Evaluation for Gastroparesis," Dig Dis Sci. 2011;56:1138-1146.
Sacks et al., "Comparison of Weight-Loss Diets with Different Compositions of Fat, Protein, and Carbohydrates," N Engl J Med, Feb. 26, 2009; 360(9):859-873.
Sathananthan et al., "Common Genetic Variation in GLP1R and Insulin Secretion in Response to Exogenous GLP-1 in Nondiabetic Subjects: A pilot study," Diabetes Care 2010, 33(9):2074-2076.
Saunders et al., "Pharmacotherapy for Obesity," Endocrinol. Metab. Clin. North America, Sep. 2016, 45(3):521-538.
Saxena et al., "Energy intake as a short-term biomarker for weight loss in adults with obesity receiving liraglutide: A randomized trial," Obes Sci Pract. 2021;7:281-290.
Schulte et al., "Current Considerations Regarding Food Addiction," Current Psychiatry Reports, 2015, 17: 19, 8 pages.
Secher et al., "The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss," J Clin Invest. 2014; 124(10):4473-4488.
Seynnes et al., "Early skeletal muscle hypertrophy and architectural changes in response to high-intensity resistance training," Journal of Applied Physiology, 2007, 102: 368-373.
Shu et al., "Decreased TCF7L2 protein levels in type 2 diabetes mellitus correlate with downregulation of GIP- and GLP-1 receptors and impaired beta-cell function," Hum Mol Genet. 2009, 18(13):2388-2399.
Sjostrom et al., "Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight, regain in obese patients," Lancet, Jul. 18, 1998, 352(9123):167-172.
Smith et al., "Multicenter, Placebo-Controlled Trial of Lorcaserin for Weight Management" N. Engl. J. Medicine, Jul. 15, 2010, 363(3):245-256.
Solas et al., "Precision Obesity Treatments Including Pharmacogenetic and Nutrigenetic Approaches," Trends Phamacol. Sciences, May 25, 2016, 37(7):575-593.
Speliotes et al., "Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index," Nat. Genetics, Oct. 10, 2010, 42(11):937-948.
Tan et al. Replication of 6 Obesity Genes in a Meta-Analysis of Genome-Wide Association Studies from Diverse Ancestries. PLoS One 9(5): e96149, 2014. (Year: 2014). *
Ten Kulve et al., "Endogenous GLP1 and GLP1 analogue alter CNS responses to palatable food consumption," J Endocrinol. 2016;229:1-12.
The GBD 2015 Obesity Collaborators, "Health Effects of Overweight and Obesity in 195 Countries over 25 Years," N. Engl. J. Med., 2017, 377:13-27.
Tobias et al., "Effect of Low-Fat vs. Other Diet Interventions on Long-Term Weight Change in Adults: A Systematic Review and MetaAnalysis," The Lancet Diabetes & Endocrinology, Dec. 2015, 3(12): 968-979 (Author manuscript, 21 pages).
Umapathysivam et al., "Comparative Effects of Prolonged and Intermittent Stimulation of the Glucagon-Like Peptide 1 Receptor on Gastric Emptying and Glycemia," Diabetes, Feb. 2014; 63: 785-790.
Urva et al., "The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists," Diabetes Obes Metab. 2020;22:1886-1891.
Van Can et al., "Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults," Int. J. Obesity, Jun. 2014, 38(6):784-793.
Vazquez et al., "Gastric Sensorimotor Functions and Hormone Profile in Normal Weight, Overweight, and Obese People," Gastroenterology, Dec. 2006, 131(6)1717-1724.
Vazquez-Roque et al., "Association of TCF7L2 Allelic Variations with Gastric Function, Satiation, and GLP-1 Levels," Clin Transl Sci. 2011;4:183-187.
Veldhorst et al., "Gluconeogenesis and energy expenditure after a high-protein, carbohydrate-free diet," The American Journal of Clinical Nutrition, 2008, 90: 519-526.
Vosoughi et al., "Association of glucagon-like peptide 1 analogs and agonists administered for obesity with weight loss and adverse events: A systematic review and network meta-analysis," EClinicalMedicine 2021 (42): 101213, 10 pages.
Wadden and Foster, "Behavioral Treatment of Obesity," Medical Clinics of North America, Nov. 2000, 84(2): 441-461.
Wadden et al., Weight Loss With Naltrexone SR/Bupropion SR Combination Therapy as an Adjunct to Behavior Modification: The COR-BMOD Trial, Obesity, Jan. 2011, 19(1):110-120.
Wanders et al., "Effects of dietary fibre on subjective appetite, energy intake and body weight: a systematic review of randomized controlled trials," Obesity Reviews, 2011, 12: 724-739.
Wang et al., "Gastric distention activates satiety circuitry in the human brain," Neuroimage, 2008, 39: 1824-1831.
Warrilow et al., "Dietary fat, fibre, satiation, and satiety—a systematic review of acute studies," European Journal of Clinical Nutrition, 2019, 73: 333-344.
Watanabe et al., "Serotonin Improves High Fat Diet Induced Obesity in Mice," PLoS One, Jan. 14, 2016, 11(1):e0147143, 14 pages.
Watson et al., "A whey/guar "preload" improves postprandial glycaemia and glycated haemoglobin levels in type 2 diabetes: A 12-week, single-blind, randomized, placebo-controlled trial," Diabetes, Obesity and Metabolism, 2019, 21: 930-938.
Webb and Wadden, "Intensive Lifestyle Intervention for Obesity: Principles, Practices, and Results," Gastroenterology 2017; 152: 1752-1764.
Winter et al. Evaluation of the Obesity Genes FTO and MC4R and the Type 2 Diabetes Mellitus Gene TCF7L2 for Contribution to Stroke Risk: The Mannheim-Heidelberg Stroke Study. Obes Facts 2011;4:290-296. (Year: 2011). *
Wood, "Protein Shakes Before or After a Workout for Weight Loss?", Healthfully.com, Weight Management, Oct. 17, 2013, retrieved from: https://healthfully.com/protein-shakes-before-or-after-a-workout-for-weight-loss-12683490.html, 3 pages.
Wyatt et al., "Update on Treatment Strategies for Obesity," J. Clin. Endocrinol. Metabolism, Apr. 2013, 98(4):1299-1306.
Yanovski et al. The Questionnaire on Eating and Weight Pattems-5: an updated screening instrument for binge eating disorder. Int J Eating Disord. 2015;48:259-261. (5 total pages).
Yi et al., "TCF-4 Mediates Cell Type-specific Regulation of Proglucagon Gene Expression by β-Catenin and Glycogen Synthase Kinase-3β," J Biol Chem. 2005;280(2):1457-1464.
Zhou et al. Obesity and diabetes related plasma amino acid alterations. Clinical Biochemistry 46 (2013) 1447-1452. (Year: 2013).
Zigmond et al., "The Hospital Anxiety and Depression Scale," Acta Psychiatr. Scandinavica, Jun. 1983, 67(6):361-370.
Abadi et al. Penetrance of Polygenic Obesity Susceptibility Loci across the Body Mass Index Distribution. The American Journal of Human Genetics 101, 925-938, Dec. 7, 2017. (Year: 2017). *
Abell et al., "Consensus Recommendations for Gastric Emptying Scintigraphy: A Joint Report of the American Neurogastroenterology and Motility Society and the Society of Nuclear Medicine," Journal of Nuclear Medicine Technology, 2008; 36: 44-54.
Acosta et al., "Exenatide in obesity with accelerated gastric emptying: a randomized, pharmacodynamics study," Physiol. Reports, Nov. 2015, 3(11):e12610, 10 pages.
Acosta et al., "Quantitative Gastrointestinal and Psychological Traits Associated With Obesity and Response to Weight-Loss Therapy," Gastroenterology, Mar. 1, 2015, 148(3):537-546.e4.
Acosta et al., "Recent advances in clinical practice challenges and opportunities in the management of Obesity," Gut, Apr. 2014, 63(4):687-695.
Acosta et al., "Relamorelin Relieves Constipation and Accelerates Colonic Transit in a Phase 2, Placebo-Controlled Randomized Trial," Clin. Gastroenterol. Hepatology, Dec. 2015, 13(12):2312-2319.e1.
Acosta et al., "Selection of Antiobesity Medications Based on Phenotypes Enhances Weight Loss: A Pragmatic Trial in an Obesity Clinic," Obesity (Silver Spring), 2021, 29(4): 662-671.
Acosta et al., "White-Paper AGA:. POWER—Practice Guide on Obesity and Weight Management, Education and Resources," Clin. Gastroenterol. Hepatology, May 2017, 15(5);631-649.10.
Adams et al., "Long-Term Mortality after Gastric Bypass Surgery," N. Engl. J. Medicine, Aug. 23, 2007, 357(8):753-761.
Allison et al., "Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP)," Obesity, Feb. 2012, 20(2):330-342.
Alvarez-Castro et al.,, "Ghrelin in obesity, physiological and pharmacological considerations," Mini Rev. Med. Chem., Apr. 2013; 13(4):541-552.
Apovian et al., "A Randomized, Phase 3 Trial of Naltrexone SR/Bupropion SR on Weight and. Obesity-related Risk Factors (COR-II)" Obesity, May 2013 21(5):935-943.
Apovian, C.M. et al. (2015). "Pharmacological management of obesity: an endocrine Society clinical practice guideline," J. Clin. Endocrinol. Metab. 100:342-362.
Begriche et al., "β-Aminoisobutyric Acid Prevents Diet-induced Obesity in Mice With Partial Leptin Deficiency," Obesity, Sep. 2008, 16(9):2053-2067.
Bellicha et al., "Effect of exercise training on weight loss, body composition changes, and weight maintenance in adults with overweight or obesity: An overview of 12 systematic reviews and 149 studies," Obesity Reviews, 2021, 22(Suppl 4):e13256, 13 pages.
Berkland et al., "A Worksite Wellness Intervention: Improving Happiness, Life Satisfaction, and Gratitude in Health Care Workers," Mayo Clinic Proceedings: Innovations, Quality & Outcomes, 2017, 1(3): 203-210.
Bouras et al., "SPECT imaging of the stomach: comparison with barostat and effects of sex, age, body mass index, and fundoplication," Gut 2002;51:781-786.
Brownell KD, The LEARN® Program for Weight Control. Tenth Edition. American Health Publishing Company, 2004. Summary only, 1 page.
Buchwald et al., "Weight and Type 2 Diabetes after Bariatric Surgery:. Systematic Review and Meta-analysis.," Am. J. Medicine, Mar. 2009, 122(3):248-256.e5.
Burton-Freeman, B., "Dietary fiber and energy regulation," The Journal of Nutrition, 2000, 130(2S Suppl): 272S-275S.
Bush et al., "The AUDIT Alcohol Consumption Questions (AUDIT-C): An Effective Brief Screening Test for Problem Drinking," Arch Intern Med. 1998;158:1789-1795.
Cabanac, "Regulation and the ponderostat," Int. J. Obes. Relat. Metab. Disorders, Dec. 2001, 25(Suppl 5):S7-12.
Camilleri et al., "Performance characteristics of scintigraphic measurement of gastric emptying of solids in healthy participants," Neurogastroenterol. Motility, Dec. 2012, 24(12):1076-e562.
Camilleri et al., Gastrointestinal traits: individualizing therapy for obesity with drugs and devices, Gastrointest. Endoscopy, Jan. 1, 2016, 83(1):48-56.
Chedid et al., "Allelic Variant in the Glucagon-Like Peptide 1 Receptor Gene Associated with Greater Effect of Liraglutide and Exenatide on Gastric Emptying: A Pilot Pharmacogenetics Study," Neurogastroenterol Motil. 2018;30(15):e13313 (15 pages).
Chial et al., "A nutrient drink test to assess maximum tolerated volume and postprandial symptoms: effects of gender, body mass index and age in health," Neurogastroenterol Motil. 2002; 14:249-253.
Cifuentes and Acosta, "Homeostatic regulation of food intake," Clinics and Research in Hepatology and Gastroenterology, 2022, 46(2): 101794 (Author manuscript, 18 pages).
Cifuentes et al., "Gastric Sensory and Motor Functions and Energy Intake in Health and Obesity—Therapeutic Implications," Nutrients 2021; 13: 1158, 30 pages.
Cifuentes., et al., Phenotype tailored lifestyle intervention on weight loss and cardiometabolic risk factors in adults with obesity: a single-centre, non-randomised, proof-of-concept study, EClinicalMedicine, vol. 58, No. 101923, Apr. 2023, pp. 1-11.
Clark et al., "Improvements in Health Behaviors, Eating Self-Efficacy, and Goal-Setting Skills Following Participation in Wellness Coaching," Am J Health Promot., 2016, 30(6): 458-464.
Clark et al., "Self-efficacy in weight management," Journal of Consulting and Clinical Psychology, 1991, 59(5), 739-744.
ClinicalTrials.gov [online], "Peripheral Pharmacodynamics of Phentermine-Topiramate in Obese Patients," NCT01834404, last updated Feb. 23, 2015: retrieved on Feb. 2, 2021, retrieved from URL https://clinicaltrials.gov/ct2/show/study/NCT01834404, 38 pages.
ClinicalTrials.gov, "Individualized Lifestyle Intervention for Obesity Management Based on Obesity Phenotypes," NCT04073394, Last updated Feb. 3, 2023, retrieved from https://www.clinicaltrials.gov/study/NCT04073394, 9 pages.
Connolly et al., "Valvular Heart Disease Associated with Fenflurimine-Phentermine," N. Engl. J Medicine, Aug. 28, 1997, 337(9):581-588.
Coveleskie et al. The effect of the GLP-1 analogue Exenatide on functional connectivity within an NTS-based network in women with and without obesity. Obes Sci Pract. 2017;3:434-445.
Curbelo Montañez et al., "Machine Learning Approaches for the Prediction of Obesity using Publicly Available Genetic Profiles," IEEE, 2017, pp. 2743-2750.
Dahl et al., "Oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying, in subjects with type 2 diabetes," Diabetes Obes Metab. 2021;23:1594-1603.
Dansinger et al., "Comparison of the Atkins; Ornish, Weight Watchers, and Zone Diets for Weight Loss and Heart Disease Risk Reduction: A. Randomized Trial," JAMA, Jan. 5, 2005, 293(1):43-53.
Davidson et al., "Weight Control and Risk Factor Reduction in Obese , Subjects Treated for 2 Years With Orlistat: A Randomized. Controlled Trial," JAMA, Jan. 20, 1999, 281(3):235-242.
De Luis et al. rs6923761 gene variant in glucagon-like peptide 1 receptor: Allelic frequencies and influence on cardiovascular risk factors in a multicenter study of Castilla-Leon. Clinical Nutrition 37 (2018) 2144e2148. Available online: Nov. 2, 2017. (Year: 2018). *
De Luis et al., "Evaluation of weight loss and metabolic changes in diabetic patients treated with liraglutide, effect of RS6923761 gene variant of glucagon-like peptide 1 receptor," J Diabetes Complications 2015;29:595-598.
Deane et al., "Endogenous Glucagon-Like Peptide-1 Slows Gastric Emptying in Healthy Subjects, Attenuating Postprandial Glycemia," J Clin Endocrinol Metab. 2010;95:215-221.
Delgado-Aros et al., "Effect of GLP-1 on gastric volume emptying, maximum volume ingested, and postprandial symptoms in humans," Am J Physiol Gastrointest Liver Physiol. 2002, 282:G424-G431.
EP Supplementary Partial Search Report in European Appln. No. 18881422.2, dated Jul. 5, 2021, 18 pages.
European Medicines Agency, Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s), Jul. 25, 2019, EMA/429077/2019, 2 pages, retrieved from: www.ema.europa.eu/en/documents/scientific-conclusion/saxenda-h-c-psusa-00001892-201812-epar-scientific-conclusions-grounds-variation-terms-marketing_en.pdf.
Evans et al., "Common Genetic Variants in ARNTL and NPAS2 and at Chromosome 12p13 are −e Associated with Objectively Measured Sleep Traits in the Elderly" Sleep, vol. 36, No. 3, 2013. 431-446.
Farias et al., "Set-Point Theory and Obesity," Metab. Syndr. Relat. Disorders, Apr. 2011, 9(2):85-89.
Farr et al. Longer-term liraglutide administration at the highest dose approved for obesity increases reward-related orbitofrontal cortex activation in response to food cues: Implications for plateauing weight loss in response to anti-obesity therapies. Diabetes Obes Metab. 2019;21(11):2459-2464 (11 pages).
Farr et al., "GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial," Diabetologia 2016;59:954-965.
FDA.gov [online], "Clinical Briefing Document: Endocrinologic and Metabolic Drugs Advisory Committee Meeting," NDA 22580, Feb. 22, 2012, retrieved on Feb. 2, 2021, retrieved from URLhttps://wayback.archive-it.org/7993/20170405220351/https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM292315.pdf, 200 pages.
Flegal et al., "Prevalence of Obesity and Trends in the Distribution of Body Mass Index Among US Adults, 1999-2010," JAMA, Feb. 1, 2012, 307(5):491-497.
Flint et al., "The once-daily human GLP-1 analogue liraglutide impacts appetite and energy intake in patients with type 2 diabetes after short-term treatment," Diabetes, Obesity and Metabolism 2013; 15: 958-962.
Florez et al., "TCF7L2 Polymorphisms and Progression to Diabetes in the Diabetes Prevention Program," N Engl J Med. 2006;355(3):241-250.
Fontaine et al., "Years of Life Lost Due to Obesity," JAMA, Jan. 8, 2003, 289(2):187-193.
Fothergill et al., "Persistent Metabolic Adaptation 6 Years After "The Biggest Loser" Competition," Obesity, Aug. 2016, 24(8):1612-1619.
Frandsen et al., "Liraglutide as adjunct to insulin treatment in type 1 diabetes does not interfere with glycaemic recovery or gastric emptying rate during hypoglycaemia: a randomised, placebo-controlled, double-blind, parallel-group study," Diabetes Obes Metab. 2017;19:773-782.
Gadde et al., "Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial," Lancet, Apr. 16, 2011, 377(9774):1341-1352.
Garvey et al., "Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study," Am. J. Clin. Nutrition, Feb. 2012, 95(2):297-308.
Germain et al. Specific appetite, energetic and metabolomics responses to fat overfeeding in resistant-to-bodyweight-gain constitutional thinness. Nutrition & Diabetes (2014) 4, e126. (Year: 2014).
Golzarand et al., "The bariatric surgery and weight losing: a meta-analysis in the long- and very long-term effects of laparoscopic adjustable gastric banding, laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy on weight loss in adults," Surgical Endoscopy, 2017, 31: 4331-4345.
Gonzalez-Izundegui et al., "Association of gastric emptying with postprandial appetite and satiety sensations in obesity," Obesity (Silver Spring), 2021, 29(9): 1497-1507 (Author manuscript, 20 pages).
Gostout et al., "Delayed Gastric Emptying as a Proposed Mechanism of Action During Intragastric Balloon Therapy: Results of a Prospective Controlled Study," Abstract No. O.955, Presented at Proceedings of the International Federation for the Surgery of Obesity and Metabolic Disorders 20th World Congress, Vienna, Austria, Aug. 26-29, 2015; Obes. Surgery, 2015, 25(Suppl 1):S129-S130.
Goyal et al., "Endoscopic Bariatric Therapies," Curr. Gastroenterol. Reports, Jun. 2016 18(6):26, 8 pages.
Grant et al., "Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes," Nat Genet. 2006;38(3):320-323.
Greenway et al., "Effect of naltrexone plus buprupion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial," Lancet, Aug. 21, 2010, 376(9740):595-605.
Halawi et al., "Effects of liraglutide on weight satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial," Lancet Gastroenterol. Hepatology, Sep. 25, 2017, 2(12):890-899.
Halawi et al., "Relationship of gastric emptying or accommodation with satiation, satiety and postprandial symptoms in health," Am J Physiol Gastrointest Liver Physiol. 2017, 313:G442-G447.
Hall et al., "Models Use Leptin and Calculus to Count Calories," Cell Metabolism, Jan. 7, 2009, 9(1):3-4.
Hall, "Diet Versus Exercise in "The Biggest Loser" Weight Loss Competition," Obesity, Jul. 2013, 21(5):957-959.
Harder et al., "The Effect of Liraglutide, a Long-Acting Glucagon-Like Peptide 1 Derivative, on Glycemic Control, Body Composition, and 24-h Energy Expenditure in Patients With Type 2 Diabetes," Diabetes Care 2004;27(8):1915-1921.
Harris, "Role of set-point theory in regulation of body weight," FASEB Journal, Dec. 1990, 4(15):3310-3318.
Hedjoudje et al., "Efficacy and Safety of Endoscopic Sleeve Gastroplasty: A Systematic Review and Meta-Analysis," Clinical Gastroenterology and Hepatology, 2020, 18(5):1043-1053.e4.
Hensrud DD, The Mayo Clinic Diet. Second Edition. Mayo Clinic Press, 2017. Summary only, 1 page.
Hensrud et al., "Extreme obesity: a new medical crisis in the United States," Mayo Clin. Proceedings, Oct. 1, 2006, 81(10 Suppl):S5-S10.
Hervey, "Regulation of Energy Balance," Nature, May 17, 1969, 222:629-631.
Heymsfield and Wadden, "Mechanisms, Pathophysiology, and Management of Obesity," New England Journal of Medicine 2017; 376: 254-266.
Heymsfield et al., "Mechanisms, Pathophysiology, and Management of Obesity," N Engl. J Med., (2017) 376(15):1490-1492.
Himes et al., "Stop Regain: A Pilot Psychological Intervention for Bariatric Patients Experiencing Weight Regain," Obesity Surgery, 2015, 25: 922-927.
Hollander et al., "Role of Orlistat in the Treatment of Obese Patients With Type 2 Diabetes: A 1-year randomized double-blind study," Diabetes Care, Aug. 1998 21(8):1288-1294.
Horowitz et al., "Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes," Diabetes Research and Clinical Practice 2012; 97: 258-266.
Horowitz et al., "Upper and/or lower gastrointestinal adverse events with glucagon-like peptide-1 receptor agonists: Incidence and consequences," Diabetes Obes Metab. 2017;19:672-681.
Hutchison et al., "Acute load-dependent effects of oral whey protein on gastric emptying, gut hormone release, glycemia, appetite, and energy intake in healthy men," The American Journal of Clinical Nutrition, 2015, 102: 1574-1584.
Ikegami et al., "Abstract 12631: Peripheral Gamma-aminobutyric Acid(gaba) Signaling in Brown Adipose Tissue Induces Metabolic Dysfunction in Obesity," Circulation, Nov. 10, 2015, 132(S3):A12631, 5 pages.
International Preliminary Report on Patentability for International Application No. PCT/US2023/066809 mailed Nov. 21, 2024, 10 pages.
International Search Report and Written Opinion for International Application No. PCT/US2022/030261, mailed Oct. 17, 2022, 18 pages.
International Search Report and Written Opinion for International Application No. PCT/US2023/066809 dated Sep. 29, 2023, 13 pages.
Invitation to Pay for International Application No. PCT/US2022/030261 dated Aug. 15, 2022, 3 pages.
Irving et al., "Nutrient Transporter Expression in the Jejunum in Relation to Body Mass Index in Patients Undergoing Bariatric Surgery," Nutrients, Oct. 29, 2016, 8(11):683, 12 pages.
Jalleh et al., "Acute Effects of Lixisenatide on Energy Intake in Healthy Subjects and Patients with Type 2 Diabetes: Relationship to Gastric Emptying and Intragastric Distribution," Nutrients. 2020; 12: 1962.
Jelsing et al., "Liraglutide: short-lived effect on gastric emptying—long lasting effects on body weight," Diabetes Obes Metab. 2012;14:531-538.
Jensen et al., "2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society," J. Am. Coll. Cardiology, Jul. 1, 2014, 63(25 Pt B):2985-3023.
Johannsen et al., "Metabolic Slowing with Massive Weight Loss despite Preservation of Fat-Free Mass," J. Clin. Endocrinol Metabolism, Jul. 2012, 97(7):2489-2496.
Jones et al., "Effects of lixisenatide on postprandial blood pressure, gastric emptying and glycaemia in healthy people and people with type 2 diabetes," Diabetes Obes. Metab. 2019:21 : 1158-1167.
Kadouh et al., "GLP-1 Analog Modulates Appetite, Taste Preference, Gut Hormones, and Regional Body Fat Stores in Adults with Obesity," J Clin Endocrinol Metab. 2020, 105:1552-1563.
Karra et al., "The role of peptide YY in appetite regal and obesity," J. Physiology, Jan. 2009, 587 (Pt. I): 19-25.
Katterman et al., "Mindfulness meditation as an intervention for binge eating, emotional eating, and weight loss: A systematic review," Eating Behaviors, 2014, 15: 197-204.
Keesey et al., Body Energy Homeostasis, Appetite, Nov. 2008, 51(3):442-445.
Khera et al., "Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis," JAMA, 2016;315(22):2424-2434.
Khera et al., "Effects of Weight-Loss Medications on Cardiometabolic Risk Profiles: A Systematic Review and Network Meta-analysis," Gastroenterology 2018; 154:1309-1319.
Kim et al., "Novel Testing of Human Gastric Motor and Sensory Functions: Rationale, Methods, and Potential Applications in Clinical Practice," The American Journal of Gastroenterology 2000; 95: 3365-3373.
Klok et al., The role of leptin and ghrelin in the regulation of food intake and body weight in humans: a review, Obes. Reviews, Jan. 2007, 8(1):21-34.
Kumar et al.. "Efficacy Comparison of Medications Approved for. Chronic Weight Management," Obesity, Apr. 2015, 23(Suppl 1):S4-S7.
Kuwata et al., "Effects of glucagon-like peptide-1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: A prospective, observational study," J Diabetes Investi. 2021; 12:2162-2171.
Langberg et al. Genetic Association of Adrenergic Receptor Alpha 2a with Obesity and Type 2 Diabetes. Obesity (2013) 21, 1720-1725. (Year: 2013). *
Le Bacquer et al., "TCF7L2 splice variants have distinct effects on β-cell turnover and function," Hum Mol Genet. 2011, 20(10):1906-1915.
Le Roux et al., "Three years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial," Lancet 2017;389:1399-1409.
LeBlanc, E. L. et al., "Behavioral and Pharmacotherapy Weight Loss Interventions to Prevent Obesity-Related Morbidity and Mortality in Adults Updated Evidence Report and Systematic Review for the US Preventive Services Task Force," JAMA, 2018;320(11):1172-1191.
Locke et al., "Genetic studies of body mass index yield new insights for obesity biology," Nature, Feb. 12, 2015, 518(7538):197-206.
Loos and Janssens, "Predicting Polygenic Obesity Using Genetic Information," Cell. Metab., Mar. 2017, 25(3):535-543.
Lowe et al., "Effects of Time-Restricted Eating on Weight Loss and Other Metabolic Parameters in Women and Men With Overweight and Obesity, The TREAT Randomized Clinical Trial," JAMA Intern Med. 2020;180(11):1491-1499.
Lynch et al., "Branched-chain amino acids in metabolic signalling and insulin resistance," Nat. Rev. Endocrinology, Oct. 7, 2014, 10(14.723-736.
Ma et al., "Effects of a Protein Preload on Gastric Emptying, Glycemia, and Gut Hormones After a Carbohydrate Meal in Diet-Controlled Type 2 Diabetes," Diabetes Care, 2009, 32(9): 1600-1602.
MacLean et al., "Biological Control of Appetite: A Daunting Complexity," Obesity (2017) 25, Suppl 1, S8-S16.
Marathe et al., "Acute Administration of the GLP-1 Receptor Agonist Lixisenatide Diminishes Postprandial Insulin Secretion in Healthy Subjects But Not in Type 2 Diabetes, Associated with Slowing of Gastric Emptying," Diabetes Ther. (2022) 13:1245-1249.
Maselli and Camilleri, "Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity," Adv Exp Med Biol 2020; 4: 171-192.
Maselli et al., "Effects of Liraglutide on Gastrointestinal Functions and Weight in Obesity: A Randomized Clinical and Pharmacogenomic Trial," Obesity (Silver Spring). Aug. 2022 ; 30(8): 1608-1620 (24 pages).
Mettler et al., "Motivational Improvements for Health Behavior Change from Wellness Coaching," American Journal of Health Behavior, 2014, 38(1): 83-91.
Morton et al., "A systematic review, meta-analysis and meta-regression of the effect of protein supplementation on resistance training-induced gains in muscle mass and strength in healthy adults," British Journal of Sports Medicine, 2018, 52: 376-384.
Nagai et al., "Differing effects of liraglutide on gastric emptying in Japanese patients with type 2 diabetes," Diabetes Obes Metab. 2014; 16:573-576.
Nauck et al., "Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination with Metformin, in Type 2 Diabetes: the LEAD (Liraglutide Effect and Action in Diabetes)-2 study," Diabetes Care, Jan. 2009, 32(1):84-90.
Nauck et al., "Rapid Tachyphylaxis of the Glucagon-Like Peptide 1-Induced Deceleration of Gastric Emptying in Humans," Diabetes 2011;60:1561-1565.
Newgard et al., "A Branched-Chain Amino Acid-Related Metabolic Signature that Differentiates Obese and Lean Humans and. Contributes to Insulin Resistance," Cell Metabolism Apr. 8, 2009, 9(4):311-326.
Ng et al., "Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013. a systematic: analysis for the Global Burden of Disease Study 2013," Lancet, Aug. 30, 2014, 384(9945).:766-781.
Otson et al., "Alloisoleueine Differentiates the Branched-chain Aminoacidemia of Zucker and Dietary Obese Rats," Obesity, May 2014, 22(5):1212-1215.
Papierkowski et al., "Monocarboxylic short-chain fatty acids C2-C6 in serum of obese children," Acta Paediatr. Acade. Sci. Hung., 1975, 16(3-4):277-280.
Partial Supplementary European Search Report for European Application No. 22805577.8, dated Mar. 3, 2025, 16 pages.
PCT International Preliminary Report on Patentability in International Application No. PCT/US2018/062217, dated May 26, 2020, 8 pages.
PCT International Search Report and Written Opinion in International Appin. No. PCT/US2018/062217, dated Feb. 8, 2019, 10 pages.
Pham et al., "The Effects of a Whey Protein and Guar Gum-Containing Preload on Gastric Emptying, Glycaemia, Small Intestinal Absorption and Blood Pressure in Healthy Older Subjects," Nutrients, 2019, 11: 2666, 13 pages.
Pi-Sunyer et al., "A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management," N. Engl. J. Medicine, Jul. 2, 2015, 373(1):11-22.
Rameshrad et al., "An overview of glucagon-like peptide-1 receptor agonists for the treatment of metabolic syndrome: A drug repositioning," Iran J Basic Med Sci 2020; 23:556-568.
Rauschert et al. "Metabolomic Biomarkers for Obesity in Humans: A Short Review," Ann. Nutr. Metabolisim, Oct. 2, 2014, 64(3-4):314-324.
Ravussin et al., "Early Time-Restricted Feeding Reduces Appetite and Increases Fat Oxidation But Does Not Affect Energy Expenditure in Humans," Obesity (Silver Spring), 2019, 27(8): 1244-1254.
Riebe et al., "Updating ACSM's Recommendations for Exercise Preparticipation Health Screening." Med. Sci. Sports Exercise, Nov. 2015, 47(11):2473-2479.
Roberts et al., "Tailoring pharmacotherapy to specific eating behaviours in obesity: Can recommendations for personalised therapy be made from the current data?," Acta Diabetologica, Apr. 19, 2017, 54(8):715-725.
Roberts et al., "β-Aminoisobutyric Acid Induces Browning of White Fat and Hepatic β-Oxidation and Is Inversely Correlated with Cardiometabolic Risk Factors," Cell Metabolism, Jan. 7, 2014; 19(1):96-108.
Rodriguez et al., "Obesity changes the human gut mycobiome," Sci. Reports, Oct. 12, 2015, 5:14600, 15 pages.
Rosenbaum et al., "Low Dose Leptin Administration Reverses. Effects of Sustained Weight-Reduction on Energy Expenditure and Circulating Concentrations of Thyroid Hormones," J. Clin. Endocrinol. Metabolism, May 2002, 87(5):2391-2394.
Rosenbaum et al., "Low-dose leptin reverses skeletal muscle, autonomic, and neuroendocrine adaptations to maintenance of reduced weight," J. Clin. Investigation, Dec. 2005, 115(12):3579-3586.
Royston et al., "Dichotomizing continuous predictors in multiple regression: a bad idea," Statistics in Medicine 2006; 25: 127-141.
Sachdeva et al., "Gastric Emptying of Solids and Liquids for Evaluation for Gastroparesis," Dig Dis Sci. 2011;56:1138-1146.
Sacks et al., "Comparison of Weight-Loss Diets with Different Compositions of Fat, Protein, and Carbohydrates," N Engl J Med, Feb. 26, 2009; 360(9):859-873.
Sathananthan et al., "Common Genetic Variation in GLP1R and Insulin Secretion in Response to Exogenous GLP-1 in Nondiabetic Subjects: A pilot study," Diabetes Care 2010, 33(9):2074-2076.
Saunders et al., "Pharmacotherapy for Obesity," Endocrinol. Metab. Clin. North America, Sep. 2016, 45(3):521-538.
Saxena et al., "Energy intake as a short-term biomarker for weight loss in adults with obesity receiving liraglutide: A randomized trial," Obes Sci Pract. 2021;7:281-290.
Schulte et al., "Current Considerations Regarding Food Addiction," Current Psychiatry Reports, 2015, 17: 19, 8 pages.
Secher et al., "The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss," J Clin Invest. 2014; 124(10):4473-4488.
Seynnes et al., "Early skeletal muscle hypertrophy and architectural changes in response to high-intensity resistance training," Journal of Applied Physiology, 2007, 102: 368-373.
Shu et al., "Decreased TCF7L2 protein levels in type 2 diabetes mellitus correlate with downregulation of GIP- and GLP-1 receptors and impaired beta-cell function," Hum Mol Genet. 2009, 18(13):2388-2399.
Sjostrom et al., "Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight, regain in obese patients," Lancet, Jul. 18, 1998, 352(9123):167-172.
Smith et al., "Multicenter, Placebo-Controlled Trial of Lorcaserin for Weight Management" N. Engl. J. Medicine, Jul. 15, 2010, 363(3):245-256.
Solas et al., "Precision Obesity Treatments Including Pharmacogenetic and Nutrigenetic Approaches," Trends Phamacol. Sciences, May 25, 2016, 37(7):575-593.
Speliotes et al., "Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index," Nat. Genetics, Oct. 10, 2010, 42(11):937-948.
Tan et al. Replication of 6 Obesity Genes in a Meta-Analysis of Genome-Wide Association Studies from Diverse Ancestries. PLoS One 9(5): e96149, 2014. (Year: 2014). *
Ten Kulve et al., "Endogenous GLP1 and GLP1 analogue alter CNS responses to palatable food consumption," J Endocrinol. 2016;229:1-12.
The GBD 2015 Obesity Collaborators, "Health Effects of Overweight and Obesity in 195 Countries over 25 Years," N. Engl. J. Med., 2017, 377:13-27.
Tobias et al., "Effect of Low-Fat vs. Other Diet Interventions on Long-Term Weight Change in Adults: A Systematic Review and MetaAnalysis," The Lancet Diabetes & Endocrinology, Dec. 2015, 3(12): 968-979 (Author manuscript, 21 pages).
Umapathysivam et al., "Comparative Effects of Prolonged and Intermittent Stimulation of the Glucagon-Like Peptide 1 Receptor on Gastric Emptying and Glycemia," Diabetes, Feb. 2014; 63: 785-790.
Urva et al., "The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists," Diabetes Obes Metab. 2020;22:1886-1891.
Van Can et al., "Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults," Int. J. Obesity, Jun. 2014, 38(6):784-793.
Vazquez et al., "Gastric Sensorimotor Functions and Hormone Profile in Normal Weight, Overweight, and Obese People," Gastroenterology, Dec. 2006, 131(6)1717-1724.
Vazquez-Roque et al., "Association of TCF7L2 Allelic Variations with Gastric Function, Satiation, and GLP-1 Levels," Clin Transl Sci. 2011;4:183-187.
Veldhorst et al., "Gluconeogenesis and energy expenditure after a high-protein, carbohydrate-free diet," The American Journal of Clinical Nutrition, 2008, 90: 519-526.
Vosoughi et al., "Association of glucagon-like peptide 1 analogs and agonists administered for obesity with weight loss and adverse events: A systematic review and network meta-analysis," EClinicalMedicine 2021 (42): 101213, 10 pages.
Wadden and Foster, "Behavioral Treatment of Obesity," Medical Clinics of North America, Nov. 2000, 84(2): 441-461.
Wadden et al., Weight Loss With Naltrexone SR/Bupropion SR Combination Therapy as an Adjunct to Behavior Modification: The COR-BMOD Trial, Obesity, Jan. 2011, 19(1):110-120.
Wanders et al., "Effects of dietary fibre on subjective appetite, energy intake and body weight: a systematic review of randomized controlled trials," Obesity Reviews, 2011, 12: 724-739.
Wang et al., "Gastric distention activates satiety circuitry in the human brain," Neuroimage, 2008, 39: 1824-1831.
Warrilow et al., "Dietary fat, fibre, satiation, and satiety—a systematic review of acute studies," European Journal of Clinical Nutrition, 2019, 73: 333-344.
Watanabe et al., "Serotonin Improves High Fat Diet Induced Obesity in Mice," PLoS One, Jan. 14, 2016, 11(1):e0147143, 14 pages.
Watson et al., "A whey/guar "preload" improves postprandial glycaemia and glycated haemoglobin levels in type 2 diabetes: A 12-week, single-blind, randomized, placebo-controlled trial," Diabetes, Obesity and Metabolism, 2019, 21: 930-938.
Webb and Wadden, "Intensive Lifestyle Intervention for Obesity: Principles, Practices, and Results," Gastroenterology 2017; 152: 1752-1764.
Winter et al. Evaluation of the Obesity Genes FTO and MC4R and the Type 2 Diabetes Mellitus Gene TCF7L2 for Contribution to Stroke Risk: The Mannheim-Heidelberg Stroke Study. Obes Facts 2011;4:290-296. (Year: 2011). *
Wood, "Protein Shakes Before or After a Workout for Weight Loss?", Healthfully.com, Weight Management, Oct. 17, 2013, retrieved from: https://healthfully.com/protein-shakes-before-or-after-a-workout-for-weight-loss-12683490.html, 3 pages.
Wyatt et al., "Update on Treatment Strategies for Obesity," J. Clin. Endocrinol. Metabolism, Apr. 2013, 98(4):1299-1306.
Yanovski et al. The Questionnaire on Eating and Weight Pattems-5: an updated screening instrument for binge eating disorder. Int J Eating Disord. 2015;48:259-261. (5 total pages).
Yi et al., "TCF-4 Mediates Cell Type-specific Regulation of Proglucagon Gene Expression by β-Catenin and Glycogen Synthase Kinase-3β," J Biol Chem. 2005;280(2):1457-1464.
Zhou et al. Obesity and diabetes related plasma amino acid alterations. Clinical Biochemistry 46 (2013) 1447-1452. (Year: 2013).
Zigmond et al., "The Hospital Anxiety and Depression Scale," Acta Psychiatr. Scandinavica, Jun. 1983, 67(6):361-370.

Also Published As

Publication number Publication date
US20230358765A1 (en) 2023-11-09
US20210072259A1 (en) 2021-03-11
US11740247B2 (en) 2023-08-29
EP3713478A1 (en) 2020-09-30
CA3080932A1 (en) 2019-05-31
AU2025203077A1 (en) 2025-05-22
WO2019104146A1 (en) 2019-05-31
EP3713478A4 (en) 2021-11-03
AU2018371776A1 (en) 2020-05-28

Similar Documents

Publication Publication Date Title
US12474353B2 (en) Methods and materials for assessing and treating obesity
Zhang et al. Metformin triggers a kidney GDF15-dependent area postrema axis to regulate food intake and body weight
Almenning et al. Effects of high intensity interval training and strength training on metabolic, cardiovascular and hormonal outcomes in women with polycystic ovary syndrome: a pilot study
Federico et al. Gastrointestinal hormones, intestinal microbiota and metabolic homeostasis in obese patients: effect of bariatric surgery
Irwin et al. Randomized controlled trial of aerobic exercise on insulin and insulin-like growth factors in breast cancer survivors: the Yale Exercise and Survivorship study
Bradley et al. Gastric bypass and banding equally improve insulin sensitivity and β cell function
Pugh et al. Acute molecular responses to concurrent resistance and high‐intensity interval exercise in untrained skeletal muscle
US20240252593A1 (en) Assessing and treating obesity
Bandera et al. The Women’s Circle of Health Follow-Up Study: a population-based longitudinal study of Black breast cancer survivors in New Jersey
Harris et al. Sleeve gastrectomy enhances glucose utilization and remodels adipose tissue independent of weight loss
Deng et al. Exercise training reduces the inflammatory response and promotes intestinal mucosa-associated immunity in lynch syndrome
Sala et al. The SURMetaGIT study: Design and rationale for a prospective pan-omics examination of the gastrointestinal response to Roux-en-Y gastric bypass surgery
EP4522269A1 (en) Individualized lifestyle intervention for obesity management based on obesity phenotypes
Jorsal et al. Gut mucosal gene expression and metabolic changes after Roux‐en‐Y gastric bypass surgery
Bessell et al. How to provide a structured clinical assessment of a patient with overweight or obesity
Haqq et al. The Study of the Effects of Diet on Metabolism and Nutrition (STEDMAN) weight loss project: Rationale and design
Mendes et al. Obesity and asthma: implementing a treatable trait care model
Di Vincenzo et al. European Association for the study of obesity position statement on the diagnosis and management of obesity in older adults
Powell-Brett et al. Comprehensive, long-term evaluation of pancreatic exocrine insufficiency after pancreatoduodenectomy
Chaker et al. Characterizing Genetic, Epigenetic, Nutritional, and Clinico‐Biochemical Profile of Women With Polycystic Ovary Syndrome: A Case–Control Study
D’alonzo et al. WISER Survivor Trial: Combined effect of exercise and weight loss interventions on insulin and insulin resistance in breast cancer survivors. Nutrients. 2021; 13 (9): 3108. PMID: 34578984
IL322977A (en) Methods for predicting response to pharmacological agents in patients with obesity
Miras et al. Diabetes Care Publish Ahead of Print, published online November, 6, 2020
Zeleznik et al. Circulating amino acids, amino acid metabolites, dipeptides, and other cationic metabolites and risk of breast cancer
WO2026064656A1 (en) Methods for predicting weight gain in patients

Legal Events

Date Code Title Description
AS Assignment

Owner name: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH, MINNESOTA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ACOSTA, ANDRES J.;CAMILLERI, MICHAEL L.;SIGNING DATES FROM 20181203 TO 20181213;REEL/FRAME:064229/0552

FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

STPP Information on status: patent application and granting procedure in general

Free format text: APPLICATION UNDERGOING PREEXAM PROCESSING

FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: SMAL); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

STPP Information on status: patent application and granting procedure in general

Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED

STCF Information on status: patent grant

Free format text: PATENTED CASE